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1. INTRODUCTION 
1.1 Coronary Heart Disease: Where Do We Stand 
 
Over the past two decades, significant progress has been achieved in combating coronary 
heart disease (CHD), both in prevention and treatment. In the UK, death rates from CHD for 
people under 65 years old has fallen by 45% in the last decade(1). However, CHD continues 
to be the most common cause of premature death in the UK (1). CHD manifests in a spectrum 
of clinical presentations ranging from stable angina, acute myocardial infarction (AMI), heart 
failure (HF), arrhythmias and sudden cardiac death (SCD). The location, extent, and the 
nature of the CHD determine the clinical presentation in these patient groups. These factors 
also determine the definitive treatment the clinicians provide, which are tailored 
individually. Patients with stable angina can be treated pharmacologically to control 
symptoms. For more unstable presentations, myocardial revascularisation remains the main 
therapeutic option. Further, with the progression of CHD, many stable angina patients on 
medication will eventually require myocardial revascularisation. Therefore, myocardial 
revascularisation has occupied a prominent part in the treatment of cardiac patients. 
‘Myocardial revascularisation’, which refers to the restoration of blood supply to the 
ischaemic myocardium, can be achieved by three main methods: 
• Percutaneous Coronary Intervention (PCI) 
• Coronary artery bypass grafting (CABG) 
• Thrombolytic therapy (applicable for patients with acute myocardial infarctions, 
where primary percutaneous intervention facilities are not available). 
Coronary atherosclerotic plaque status and its progression determines the clinical 
presentation and subsequent strategy of myocardial revascularisation. Atherosclerotic 
plaque obliterating > 50% of the lumen is considered significant stenosis and likely 
jeopardises the myocardial flow therefore necessitating one or the other form of 
revascularisation. These lesions are treatable with either PCI or CABG. A significant lesion in 
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more than two epicardial coronary arteries, or the involvement of Left main stem of the 
coronary circulation is dealt with CABG. Lesions involving up to two coronary arteries, and 
with favaourable lesion anatomy are dealt with PCI. In acute plaque rupture with platelet 
plugging and complete coronary acute obliteration (STEMI), an emergency PCI to open the 
artery is performed and is called primary PCI. Alternately, a strategy to pharmacologically 
thrombolyse the acute thrombosis is used in few geographical areas where primary PCI is 
unavailable. 
Percutaneous Coronary Intervention (PCI) is an interventional procedure whereby the 
diseased narrow coronary arteries are opened percutaneously through the usage of 
catheters and balloons. In most cases, an intra-coronary stent is deployed at the site of the 
balloon angioplasty which maintains the lumen patency. PCI has become the predominant 
procedure for coronary revascularisation in patients with both stable and unstable CAD. 
Since the first description of coronary angioplasty by Andreas Grüntzig in 1977, the 
procedure has been modified extensively. The technical advances coupled with the use of 
coronary stents and adjuvant drug therapies have resulted in high procedural success rates 
and low re-stenosis rates. Older patients are now being treated and more complex multiple 
coronary lesions deemed appropriate for PCI.  
Coronary artery bypass graft (CABG) surgery is the surgical method of coronary 
revascularisation, whereby vessels from another part of the body are harvested and grafted 
(proximal to and distal to the diseased coronary artery) to restore the blood supply to the 
ischaemic myocardium. CABG requires open thoracotomy and is done under general 
anesthesia. Over the last 2 decades a significant proportion of patients previously deemed 
appropriate for CABG are increasingly revascularised using PCI. However, CABG remains a 
predominant coronary revascularisation procedure in patients with more severe and 
complex coronary disease who are unsuitable for PCI. 
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1.2 Ischaemia Reperfusion Injury  
1.2.1 Ischaemic Injury 
 
Prolonged deprivation of blood supply to the myocardium results in ischaemic injury. Typical 
ischaemic insults in a clinical setting happen during an acute myocardial infarction, during 
percutaneous coronary interventions, and during cardiac surgery. The quantity of ischaemic 
damage sustained by the myocardial tissue depends on the duration of ischaemia, the area of 
myocardium at risk, and the presence of collateral blood supply to the affected myocardium. 
At a cellular level, oxygen and substrate deprivation during ischaemia results in reduced 
oxidative phosphorylation and consequently reduced adenosine tri-phosphate (ATP) levels. 
Lack of ATP affects cell membrane ion channels leading to sodium (Na+) and water 
accumulation and loss of potassium (K+) from the cells, which result in progressive cellular 
swelling. The activation of anaerobic glycolytic pathways to compensate for the lack of 
energy generation through the respiratory chain results in intracellular acidosis due to 
lactate accumulation. This results in activation of sodium-hydrogen (Na+H+) exchanger 
resulting in further cellular Na+ accumulation. In addition, the accumulation of fatty acid 
metabolites through lipolysis leads to progressive impairment of cell membrane structure 
and function(2). Sodium-Calcium exchanger (Na+/Ca2+) is one of the most important cellular 
mechanisms for removing Ca2+ and removes one calcium ion in exchange for the import of 
three Na+ ions. In response to high intracellular Na+ it acts in reverse to maintain sodium 
homeostasis but results in increased intracellular Ca2+ accumulation. The Ca2+ entry into the 
cell also happens through direct Ca2+ channels and through the release of Ca2+ from cellular 
sarcoplasmic reticulum during ischaemic insult(3). The transition of reversible injury to 
irreversible injury begins with unregulated Ca2+ accumulation, which also is characterised by 
the development of severe defects in membrane permeability (4). The mitochondrial matrix 
Ca2+ levels also increase as the Ca2+ uniporter in the mitochondrial membrane acts as a 
channel through which extra-mitochondrial intracellular Ca2+ enters into the mitochondrial 
matrix. This leads to Ca2+ overload with loss of electrical potential difference across the 
membrane leading to mitochondrial damage (5). The classical necrotic cell death ensues with 
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swelling of cell organelles and consequential extrusion of all cellular contents into the 
extracellular matrix due to rupture of the plasma cell membranes. 
In clinical settings, a purely ischaemic injury leading to necrosis of myocardial cell 
(infarction) can happen during an untreated myocardial infarction or a silent myocardial 
infarction. During elective coronary interventions in patients, peri-procedural micro-
embolism of the atherosclerotic plaque debris is another instance where predominantly 
necrotic myocardial cell death happens. However, in most other clinical settings, the 
ischaemic myocardium is replenished with its blood supply by therapeutic or spontaneous 
revascularisation. This ‘reperfusion’, of course limits further ischaemic damage to the cell, 
however it also initiates a cascade of cellular events which lead to myocardial damage 
termed ‘reperfusion injury’. This phenomenon will be discussed in more detail in section 1.2. 
 
Apart from necrotic cell death, there are two other modes through which cell death can occur 
due to ischaemia reperfusion injury; ‘apoptosis’ and ‘autophagy’. Apoptosis can be initiated 
by the release of cytochrome c from the damaged mitochondria (mitochondria initiated) or 
through ligation of a death receptor that transmit apoptotic signals within the cell. Both these 
apoptotic routes result in the activation of cytosol caspases. Cell death through this 
mechanism is mainly through cell shrinkage, condensation, margination of the chromatin, 
and budding of the plasma membrane (6). Ischaemia can also trigger a third method of cell 
death through autophagy, an intracellular phenomenon where the cell digests its own 
constituents. Knowledge of the exact mechanism of this type of cell death is still limited, but it 
involves proteolytic lysozymal enzyme activation in response to lactate and protons 
accumulation in the cell.  Although the mechanisms of all three types of cell death are thought 
to be mutually exclusive, in practice considerable overlap exists between them, and 
individual dying cells may exhibit features of more than one mechanism over time (6). 
 
1.2.2 Reperfusion Injury 
Reperfusion of ischaemic myocardium contributes is necessary to prevent further ischaemic 
damage of the cells experiencing absolute myocardial ischaemia. However, on sudden 
reperfusion, the myocardial cells that have experienced varying degrees of ischaemic damage 
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initiate a cascade of cellular events, which can actually lead to further cellular damage and 
death. This phenomenon of myocardial cell injury and death, due to the sudden restoration of 
perfusion in an ischaemic myocardium is known as ‘‘lethal reperfusion injury’.’ Lethal 
reperfusion injury contributes to the final infarction size of the myocardium.  Myocardial 
reperfusion can also lead to other clinical manifestations other than lethal reperfusion injury, 
namely myocardial stunning and reperfusion arrhythmias.  
For lethal reperfusion injury to occur, ischaemia has to set the stage without producing 
irreversible injury itself. Therefore the corollary is that, ischaemic alterations of cellular 
conditions are necessary prerequisites for lethal reperfusion injury, but not in themselves 
sufficient causes for cell death (7). Unfortunately, in the setting of ischaemia-reperfusion, it is 
technically impossible to evaluate manifestation of irreversible injury in the same piece of 
myocardium both before and after reperfusion. It is also not possible to determine whether 
cell death is caused entirely by the ischaemic history or by reperfusion from analysis of 
developing damage in the reperfused myocardium alone (7). The only indirect way of 
establishing this is by studying whether modification of the conditions of reperfusion can 
prevent cell death that may otherwise occur in ischaemic-reperfused myocardium. It is now 
well established that some modifications to the reperfusion conditions do indeed provide 
protection.  
The cellular mechanisms involved in reperfusion injury have been well elucidated over the 
years by many researchers and are reviewed in detail by Yellon and Hausenloy (8) and Piper 
et al. (7). Current proposed mechanisms of reperfusion injury involve: a) abrupt intracellular 
calcium overload leading to myocyte hyper-contracture b) oxidative stress c) rapid 
restoration of physiological pH from acidotic milieu and d) activation of inflammatory 
cascades, all of which would aid in reperfusion induced myocardial necrosis or apoptotic 
death.  
Cardiac myocytes consume large quantities of energy. To accommodate this requirement, 
these cells host a high density of mitochondria. The mitochondrial permeability transition 
pore (mPTP) has been the centre of a growing amount of attention for its role in the 
mediation of reperfusion injury. The inner mitochondrial membrane, which is responsible 
for maintaining mitochondrial transmembrane potential, is normally impermeable to ions 
and proteins. Dissipation of the electrical potential across this membrane is termed 
12 
 
‘‘permeability transition”, a process thought to be mediated through the mPTP. Although the 
constituent protein components of the pore remain unknown, formation of the pore creates a 
nonselective channel between the inner membrane of the mitochondrion and the 
sarcoplasm. This results in loss of the electrochemical gradient, the release of reactive oxygen 
species (ROS), and apoptosome formation. Calcium overload, rapid normalization of pH and 
oxidative stress are all known to be triggers of mPTP. The non-specific highly permeable 
mPTP leads to uncoupling of oxidative phosphorylation and consequent ATP depletion, 
mitochondrial swelling and loss of cellular integrity (5, 9). Also, pro-apoptotic pathway 
activation by the release of cytochrome c from the inner mitochondrial membrane also 
contributes to cell death. With its central role in reperfusion injury, the inhibition of mPTP 
has emerged as a prime target in inhibiting myocardial reperfusion injury. 
In clinical settings, it is not possible to sustain lethal reperfusion injury without ischaemic 
injury. Consequently most cases of myocardial reperfusion injury would also have varying 
degrees of myocardial ischaemic injury. Some classical ischaemia-reperfusion injury 
situations encountered in cardiac care include acute ST elevation myocardial infarction 
(STEMI) subjected to primary percutaneous intervention or thrombolysis and, in almost all 
cardiac surgeries, requiring cardioplegic arrest.  
Over the years, the major priority in the management of acute MI has always been the early 
restoration of blood supply. This led to the rapid development of more advanced medical and 
interventional techniques for rapid restoration of reperfusion to limit the ischaemic 
myocardial injury. In cardiac surgery settings too, the emphasis has been in reducing the 
ischaemic time of the cardioplegic heart with improvement in both surgical techniques and 
instrumentation to limit ischaemic injury to the heart. However, a seminal paper by Murry et 
al. (10) provided scientists with an additional tool to further reduce infarct size by limiting 
myocardial ischaemia-reperfusion injury and heralded the era of ischaemic preconditioning. 
1.3 Ischaemic Preconditioning 
Although the pathogenesis of ischaemia-reperfusion injury was well understood in early 
years it was not until 1986 when canine experiments by Murry et al. (10) heralded the 
concept of ‘‘Ischaemic Preconditioning’’ - a phenomenon which is now understood to involve 
a wide range of cellular mechanisms and pathways. Using dog models, Murry et al. (10) 
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showed that by subjecting the hearts to four cycles of 5 minute regional ischaemia followed 
by 5 minute reperfusion and subjecting the same myocardium to 40 minute sustained 
ischaemia, the final infarct size was reduced by 75% when compared to control hearts.(10) 
This endogenous protective phenomenon, where brief episodes of sub-lethal ischaemia to an 
organ render it resistant to prolonged lethal ischaemic insult, is known as Ischaemic 
Preconditioning (IPC). Over the last 2 decades, significant progress has been achieved in 
elucidating the precise mechanism of this cardioprotective phenomenon and IPC has been 
shown to occur in virtually all animal species tested, including humans, and in most of the 
tissues including kidney (11), brain (12), lung (13), skeletal muscle (14), and liver (15). 
 
The cardioprotection conferred by IPC of the heart reveals two distinct components – ‘Classic 
preconditioning’ and ‘Delayed preconditioning’. The classic preconditioning phase is induced 
immediately after the sub-lethal ischaemic stimulus and lasts for 2 to 4 hours (16, 17). A 
second phase of ‘delayed preconditioning’ sets in about 24 hours after the initial 
preconditioning stimulus and lasts up to three days (18, 19). Delayed preconditioning is also 
called the ‘second window of preconditioning (SWOP)’ or ‘late preconditioning’. 
 
1.3.1 Mechanism of Ischaemic Preconditioning in Myocardium. 
 
Although it has been widely believed that receptor mediation plays significant roles in 
preconditioning, there are sufficient uncertainties in the mechanism of IPC to conclude that 
IPC is largely receptor mediated. Receptor activation during IPC activates complex signaling 
cascades, which during the lethal ischaemia converge on one or more end-effectors to 
mediate the protection. Identification of the triggers, transducers and end effectors in the 
cardiac myocyte that are activated in IPC has been the major focus of research in the last two 
decades. 
An important part in the preconditioning process is the cell’s innate memory to the 
preconditioning stimulus, rendering the cell in a preconditioned state during this memory 
period. As discussed above, this memory period appears to be 2-4 hours in classic IPC and up 
to 72 hours after the delayed preconditioning has set in. The memory information in classic 
preconditioning is thought to occur as a reversible post-translational modification of some 
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pre-existing protein (such as a phosphorylation or translocation), but the site of that 
modification is unknown (20). In delayed preconditioning, an additional mechanism of new 
protein synthesis is also described. As described by Yellon et al. (20) in their review, the 
mechanism of preconditioning is probably best described in terms of triggers, mediators, 
memory, and end effectors. (20) 
 
1.3.2 Mediators of ‘Ischaemic Preconditioning’ - Trigger Mechanism  
The cell surface receptors, which, when stimulated by ischaemia act as trigger mechanism in 
the preconditioning process. Three main groups of cell surface receptors – Gi protein-coupled 
receptors (GPCR), growth factor receptors and other ligand specific receptors are thought to 
be involved in the preconditioning process. Although receptor mediated trigger largely 
accounts for IPC, there are also non-receptor mediated preconditioning triggers thought to 
be involved when the stimulus is non-ischaemic (i.e. volatile anaesthetics, Statins, metformin 
and mechanical stimuli like heat and stretch) (21). GPCRs on myocardial cell surfaces could 
be stimulated by their respective ligands, and many of the activated GPCRs can trigger a 
preconditioned state by activating tyrosine kinase. Adenosine A1 GPCR was the first GPCR to 
be shown to play a role in ischaemic preconditioning (22), followed by  bradykinin and 
opioid receptor ligands with a role in IPC (23, 24). Subsequently other GPCR ligands like 
urocortin, adrenomedullin and glucagon-like peptide-1 (GLP-1) were found to be associated 
with IPC. Growth factor receptor ligands associated with IPC include insulin, transforming 
growth factor (TGF)- β, insulin like growth factor (IGF)-1, corticotrophin 1, fibroblast growth 
factor (FGF)-2, granulocyte colony stimulating factor (G-CSF), erythropoietin and 
adipocytokines (visfatin, apelin, leptin) (21).  
The third class of receptors involved in preconditioning are other ligand specific receptors 
like oestrogen receptor and guanyl cyclase receptor, which bind atrial natriuretic 
peptide(ANP) (21). These characterisations aid in targeting these receptors with 
pharmacological agents and, hence, mimic the effect of preconditioning.  
 
 
 
 
15 
 
1.3.3 Mediators of Ischaemic Preconditioning- Signal Transduction Pathways 
 
At the sub-cellular level, many ‘protein kinases’ which get activated through the above 
mentioned trigger receptors act as mediators of signal transduction. While adenosine 
receptors directly activate protein kinase C (PKC), opioid and bradykinin receptors activate 
phosphoinositide 3-kinase (PI3K), which in turn activates serine/threonine kinase (Akt) 
(25). Subsequent downstream activation, in order include - activation of nitric oxide 
synthase (NOS) and nitric oxide (NO) formation, guanylate cyclase activation, protein kinase 
G (PKG) activation, and finally protein kinase C (PKC) activation (25). It is thought that 
activated PKC is the molecule that helps the cell ‘remember’ it has been preconditioned long 
after the trigger has ceased. Activation of PKC appears to need reactive oxygen species (ROS), 
which in turn is thought to be released through the opening of inner mitochondrial ATP-
dependent potassium channels (mitoKATP). PKG appears to be the key mediator transmitting 
signals from the cytosol to the inner mitochondria; the exact mechanism is still not clear but 
appears to involve ɛ-PKC (26). The opening of mitoKATP channels results in an influx of 
potassium that causes swelling of the mitochondria, which is thought to lead to the 
production of ROS, although the exact mechanism is still unclear (25).  The production of ROS 
happens when there is reperfusion after a sub-lethal ischaemic stimulus. ROS acting as a 
second messenger at reperfusion in a PKC dependent mechanism are responsible for the 
generation of pro-survival kinases (Akt and ERK1/2). This Reversible Ischaemic Salvage 
Kinase (RISK) pathway confers cardioprotection at reperfusion by resisting the 
mitochondrial permeability pore (mPTP) opening (21). This confers antinecrotic, anti-
apoptotic and anti-autophagic effects resulting in reduced cell death (27). It is important to 
realise that ROS production is not only associated with reperfusion injury after lethal 
ischaemic insult but also in the preconditioning cascade, which is actually cardioprotective. 
 
1.3.4 Mediators of Ischaemic Preconditioning - End Effectors 
 
 The possible end-effector, on which many of the preconditioning pathways appear to 
converge, is the mitochondrial permeability transition pore (mPTP). As mPTP opening is the 
key phenomenon leading to cell death, inhibition of this pore opening by preconditioning 
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during reperfusion confers a large part of cardioprotection. The other end effectors that are 
thought to be involved in the preconditioning mechanism involve ‘gap junctions’ and 
‘sodium/hydrogen (Na+/H+) exchanger’. Preconditioning inhibits the Na+/H+ exchanger 
aiding cell resistance to osmotic swelling. Inhibition of the Na+/H+ exchanger would also 
prevent Na+/Ca2+ exchanger opening during reperfusion, hence, preventing Ca2+ influx 
related injury. 
The gap junction plays a role not only in electrical coupling of cardiomyocytes but also in 
intercellular transport of biologically active substances. Furthermore, the gap junction 
participates in decision making on cell survival versus cell death in various types of cells, and 
may mediate part of reperfusion injury in the heart (28). Lethal ischaemia suppresses both 
electrical and chemical gap junction communication (GJC). IPC delays electrical GJC 
suppression by ischaemia, conferring cardioprotective effect against ischaemia reperfusion 
injury (29).  
1.4 Ischaemic Postconditioning 
In clinical practice, IPC poses a major limitation in its applicability, as it is not possible to 
predict the onset of index ischaemia. This applies to most clinical situations encountered 
involving ischaemia reperfusion injury, like acute myocardial infarction (AMI). However, in 
situations where the index ischaemia can be predicted, as in cardiac surgery, IPC potentially 
could be evaluated. IPC, by definition has to be induced before the lethal ischaemic insult.  
Zhao et al. (30) in 2003, described a new phenomenon in their canine model, where rapid 
interruption of blood flow in the early phase of reperfusion after lethal ischaemia conferred a 
similar degree of protection as provided by IPC. This phenomenon of cardioprotection 
induced by interrupted perfusion of the already ischaemic tissue before continuous 
reperfusion is called Ischaemic post conditioning (IPostC).  
In fact, Hausenloy et al. (31) in 2004, had demonstrated that IPC actually exerts its protection 
early in reperfusion following the lethal ischaemia,  and gave a physiological basis as to why 
IPostC should work. The therapeutic time frame for IPostC is very discrete, within initial 
minutes of reperfusion. In animal models, a delay in postconditioning of more than one 
minute into reperfusion has failed to show cardioprotection (32). The mechanisms through 
which IPostC confers cardioprotection appear to be through similar mechanisms seen in IPC. 
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There are studies implicating the RISK pathway (Erk1/2 and PI3 Akt) in postconditioning. 
Similarly, many studies have shown the involvement of ROS, PKC, nitric oxide, mito-KATP and 
inhibition of mPTP (33).  Certainly, the involvement of similar mediators and molecules in 
both IPC and IPostC indicate that they evidently have very different roles by virtue of the 
timing and the compartment in which their effects are exerted. 
Cardioprotection from IPostC is, therefore, applicable in human settings as it can be applied 
after the onset of index ischaemia. Indeed, this new concept was soon applied in a  clinical 
setting in a pilot study by Laskey et al (34). They showed improved ST segment shift 
response and Doppler-derived distal coronary velocity data in acute MI patients subjected to 
IPostC undergoing primary PCI. Later, Staat et al (35), in similar classes of patients showed 
significant reduction in cardiac enzyme (total CK) release in patients subjected to IPostC. 
IPostC was induced through brief inflations of angioplasty balloon in the affected artery after 
reperfusion. The IPostC stimulus in this study was provided within 1 minute of coronary 
reflow and included inflation of angioplasty balloon for 1 minute followed by 1 minute 
reperfusion for 4 cycles.  
The potential limitations in applicability of IPostC in routine practice in patients with acute 
MI surrounds the fact that it can only be applied to patients undergoing primary PCI and not 
thrombolysis. In addition, when thromboaspiration catheters are used in primary PCI, the 
utility of IpostC, and possible interference with IpostC, is uncertain (36). Certainly, 
pharmacological post-conditioning triggers would be much more applicable in all these 
settings, and consequently the search of pharmacological postconditioning agents continues. 
In this context, Ovize et al. (37) in their pilot study involving 58 patients showed that the 
drug Cyclosporin-A, used as a pharmacological postconditioning substance, reduces the final 
myocardial infarct size in patients undergoing primary PCI . 
  
1.5 Remote Ischaemic Preconditioning 
 
Seven years after the discovery of phenomenon of Ischaemic Preconditioning by Murry et al. 
(38), an intriguing discovery was made by Przyklenk et al. (39) in 1993 of a phenomenon in 
their canine model. They showed that prior induction of brief episodes of sub-lethal 
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ischaemia followed by reperfusion in circumflex artery territory, protected the myocardium 
supplied by left anterior descending artery (LAD) through reduction in the infarct size when 
LAD was occluded and reperfused (40). The initial explanation for this phenomenon was that 
a diffusion factor, which generates in the preconditioned tissue, would diffuse into remote 
tissue and provide protection. In addition, the possibility of stretch induced cardioprotective 
signaling was put forward as another explanation, but later studies have failed to identify 
such a local diffusion factor. The intra-cardiac protection of was later extended to other 
organs.  A number of studies have identified the cardioprotective effect from preconditioning 
distant organs after an ischaemic insult, and also protection of other organs from ischaemic 
insult. This intriguing phenomenon, of distant organ protection from lethal ischaemic insult 
when a different remote organ is preconditioned prior the onset of lethal ischaemia is called 
Remote Ischaemic Preconditioning (RIPC) 
 
Inter Organ Remote Preconditioning  
McClanahan et al. (41) in their in-vivo rabbit model, were the first to demonstrate that a 10 
minute left renal artery occlusion was as effective as a 5 minute brief coronary artery 
occlusion (classic IPC) in reducing infarct size. A study by Gho et al. (42) on rat models in 
1996, was pivotal in further understanding of the remote preconditioning mechanism. In 
their study, they assessed the cardioprotective effect by inducing transient sub-lethal 
ischaemic stimulus to the small intestine and kidneys.  They also showed that transient 
mesenteric artery occlusion of 15 minutes followed by 10 minutes reperfusion, before 60 
minutes of coronary artery occlusion and 180 minutes of reperfusion, provides a similar 
reduction in infarct size as 15 minutes of classic myocardial preconditioning (IPC). In their 
renal model, the protection was conferred only in presence of hypothermia, but this was not 
necessary in mesenteric artery conferred protection. Further, they showed that the 
cardioprotective effect of mesenteric artery preconditioning is lost by administering 
hexamethonium - a ganglion blocker. In addition, they showed that cardioprotection is lost if 
the mesenteric artery occlusion was not followed by reperfusion. The results of this study 
provided the first mechanical insights into this intriguing phenomenon. An involvement of a 
humoral factor was suggested due to the fact that reperfusion was mandatory to confer 
distant protection. Meanwhile the attenuation of the cardioprotection by hexamethonium 
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also suggested the involvement of neural pathways in this phenomenon. Subsequent to these 
studies, more animal studies have shown cardioprotection by brief sub-lethal ischaemic 
exposure of renal, mesenteric, hind limb and carotid arteries (43). These studies are 
reviewed in detail by Hausenloy et al. Many of these studies have also contributed 
mechanistic insights into the RIPC phenomenon.  
 
1.5.1 Mechanisms Underlying RIPC  
Although several mechanisms are proposed to be involved in mechanistic pathways and 
signal transduction cascades, the exact nature of this remote organ protection phenomenon 
remains largely unclear. What is known so far, is that the cardioprotection mechanisms in the 
heart from RIPC have a lot similarity to the cardioprotection mechanisms through classic 
ischaemic preconditioning. Nevertheless, what heralds these protective signaling cascades at 
the outset in a remote organ and how this entity reaches the remote organ are still under 
research. The mechanisms known may be subdivided into: a) remote organ (preconditioned 
organ) responses to RIPC stimulus, b) cardioprotective message relay mechanisms conveyed 
from remote organ to heart, c) myocardial protective response to the relayed message from 
the remote organ. 
Remote organ ischaemic responses involve release of endogenous autocoids and factors, 
which are responsible somehow for triggering cardioprotection involving signal relay 
mechanisms (44). Since the discovery of RIPC, the emphasis has been on the study of the role 
of relay mechanisms between the remote organ and the heart. Two major relay mechanisms 
have been postulated with evidence supporting both mechanisms. The first mechanism 
postulated, is the presence of a humoral factor released in the remote tissue, which is then 
transported to the heart. The second mechanism postulated, is the presence of a neural 
pathway between the remote organ and the myocardium, which acts as a signal relay 
medium. 
 
1.5.1.1 Humoral Mechanism 
The possibility of a potential humoral factor responsible in RIPC was first conceived with the 
identification that a period of reperfusion was mandatory in the remote organ to produce 
cardioprotection in rat experiments (42). The demonstration by Dickson et al. (45) that 
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blood taken from a rabbit, with simultaneous preconditioning of heart and kidneys, if 
transfused to an untreated rabbit would reduce infarct size in the untreated rabbit was 
further evidence for this mechanism. They also showed that coronary effluent from a 
preconditioned rabbit heart was also capable of reducing infarct size and improving LV 
function in the untreated rabbit heart (46). One must note that these experiments had 
preconditioned hearts and not just preconditioned remote organ, and therefore it does not 
give a firm basis of the humoral factor coming from a distal organ, but rather a role in the 
heart only. However, a pig model study by Konstantinov et al. (47) in 2005, that showed RIPC 
of the limb in pigs reduced infarct size in their transplanted hearts, strongly supports the role 
of humoral factor as the only possible way the signal relay could be possible. Recently 
Shimizu et al. (48) in their Langendorff heart model, have shown that this likely humoral 
factor is less than 15 kDa and is hydrophobic. Previously, Serejo et al. (49) in their rat model 
involving coronary effluent, had identified that this factor was larger than 3.5 kDa, and 
confers cardioprotection by activation of PKC. Therefore, it appears that this unknown 
humoral relay factor is between 3.5 to 15 kDa. Numerous studies have evaluated various 
endogenous autocoids and factors that are released in the remote organ. Some of these 
substances travel to the heart and exert their effect directly to the myocardium, and some 
also activate afferent neural pathways within the remote preconditioned organ to confer 
cardioprotection. 
The endogenous substances implicated in this mediation include opioids, endocannabinoids 
and other receptor ligands. Patel et al (50) have shown that non-specific opioid receptor 
antagonist Naloxone, abolishes the cardioprotective effect of RIPC in intact rat model studies. 
Both δ1 and κ opioid receptors have been implicated in RIPC, however, there is  some 
conflicting evidence regarding δ1 receptor involvement (51, 52). Opioids are thought to be 
transported and directly act on myocardium as cardioprotective substances. The 
endocannabinoid receptor CB2 has also been implicated in RIPC mediation. A recent rat 
model experiment has shown that CB2 blocker prevented the cardioprotective effect of 
intestinal ischaemia in infarct limitation (53). Endocannabinoids are also thought to be 
directly acting on the myocardium through CB2 receptors. Other receptor ligands which have 
been implicated include angiotensin receptor ligands and noradrenaline (54, 55).  
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1.5.1.2 Neural Mechanism  
As discussed earlier, the first mechanistic insight of possible neural mechanism was shown 
by Gho et al. (42) in their rat model, where ganglion blocker, hexamethonium, abolished 
cardioprotective effect. Later, this effect was reproduced by many researchers using 
hexamethonium. Ding et al. (56) in their rabbit model of renal RIPC showed that sectioning 
renal nerve abolished cardioprotective effect. Also, they implicated the role of adenosine in 
activating renal afferents, showing that an adenosine blocker also abolished 
cardioprotection, and also decreased the renal afferent nerve discharge rates. The role of 
adenosine in RIPC was first implicated in 1998 in our own laboratory. We showed 
abolishment of the cardioprotective effect in rabbits treated with the adenosine receptor 
antagonist 8-sulphophenyltheophylline (8-SPT), prior to renal remote preconditioning (57). 
Further evidence of adenosine’s role in a neural relay mechanism in RIPC was also shown by 
Liem et al. (58) involving mesenteric afferents. Dong et al. (59) in their rat hind limb remote 
ischaemic model, showed that severing femoral nerve abolished the myocardial protection of 
reducing infarct size conferred by limb RIPC, and further femoral artery adenosine injection 
decreased the infarct size. This has strengthened the necessity of neural integrity and 
adenosine’s role in RIPC relay mechanism. 
Bradykinin and Calcitonin gene related peptide (CGRP) are the two other endogenous 
substances implicated in neural pathway of RIPC, in which they act to stimulate the afferent 
nerve fibres from the remote organ. The role of bradykinin in RIPC was shown in an 
experiment involving mesenteric artery occlusion in male rats by Schoemaker et al. (60). 
They showed that bradykin B2 receptor blocker HOE140 abolished the myocardial 
protective effect. In addition, they showed that intra-mesentric bradykinin injection was also 
cardioprotective, and this effect was blocked by hexamethonium, suggesting that bradykinin 
acted through neural afferent stimulation. Wolfrum et al. (61) further showed that 
myocardial PKC-ɛ activation which happened with intestinal ischaemia was suppressed by 
B2 blocker HOE140 in a similar model, implicating bradykinins role prior to PKC activation. 
The role of the neurotransmitter, CGRP, which is released from capsaicin-sensitive nerve 
terminals, is implicated in few experimental studies for its potential role in RIPC relay 
mechanism. Tang et al. (62) in their rabbit intestinal remote ischaemia model showed that 
pre-administration of capsaicin which prevents CGRP release, abrogates the cardioprotective 
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infarct reduction. Xiao et al. (63) reproduced similar effects in rat intestine models, and also 
showed that the abrogation of cardioprotective effect occurred with both capsaicin and L-
nitroarginine methyl ester (L-NAME), an inhibitor of NO synthetase, suggesting that CGRP 
effect acts via nitric oxide pathway. Wolfrum et al. (64) showed in their intestinal remote 
preconditioning model, that CGRP release was associated with RIPC cardioprotection and 
appeared to act via PKC-ɛ. 
 
1.5.2 Cardioprotection from Skeletal Muscle Ischaemia 
Skeletal muscle remote preconditioning is of particular interest in this discussion as our 
studies (to be discussed in detailed in chapters 3 and 4) are based on this form of RIPC. 
Cardioprotection from skeletal muscle ischaemia was first shown by Birnbaum et al. (65)  in 
their rabbit studies, involving partial occlusion of femoral artery blood flow. Instead of total 
occlusion, they used 30 minutes of partial occlusion of femoral artery blood flow to 55-60%. 
However, they induced demand-supply imbalance by rapidly pacing the gastrocnemius 
muscle. This maintained continuous perfusion yet providing ischaemia and allowed for 
facilitated transport of any humoral factors or mediators out of ischaemic zone. They showed 
reduction of 65% infarct size in this model. Subsequently, Oxman et al. (54) in their rat model 
with in vivo hind limb ischaemia, showed reduction in reperfusion arrhythmias in isolated 
Langendorff perfused hearts of rats, which underwent prior hind limb preconditioning. They 
also showed that this effect was due to increased release of norepinephrine in the perfused 
hearts, and postulated that norepinephrine was one of the humoral factors responsible for 
RIPC. Weinbrenner et al. (66) in their rat model of limb ischaemia by infra renal aortic 
occlusion, showed that reduction in myocardial infarct size was proportional to the duration 
of remote ischaemia, with 15 minutes of occlusion proving to be as protective as classic 
preconditioning with a reduction of infarct size to 18% compared to the control hearts which 
had infarct size of 52%. Ten minute and 5 minute remote ischaemic stimulus reduced infarct 
sizes to 37% and 42% respectively. They also showed that this protective effect was PKC 
dependent by showing the blockage of protection using chelerythrine, a selective PK C-
inhibitor. In their experiment, hexamethonium did not block the protective effect, and this 
led them to conclude that the neural mechanism is unlikely to be involved in the signaling 
mechanism of RIPC.  
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The cardioprotective effect of skeletal muscle RIPC was also shown by Kharbanda et al. (67) 
in their pig model, where 4 cycles of 5-minute ischaemia followed by 5-minute reperfusion 
reduced experimentally induced myocardial infarction size. This study also showed that 
reduction of ejection fraction, which occurred during experimental myocardial infarction, 
was reduced in remote preconditioned pigs compared to controls. The same group also 
demonstrated the cardioprotective effect of lower limb RIPC in pigs undergoing 
cardiopulmonary bypass (CPB) with 2 hour cardioplegic arrest. They showed that 4 cycles of 
5-minute lower limb ischaemia could reduce myocardial injury (Troponin release), lactate 
concentration (suggestive of tissue hypoxia), and acute lung injury (pulmonary resistance) 
(68). These benefits in systemic protection, not necessarily restricted to cardioprotection, in 
this study, was a vital signal of its wide beneficial effect to be found in clinical studies.  
In view of its simplicity and noninvasiveness, transient limb ischaemia for providing RIPC is 
very attractive in human subjects. MacAllister’s group was the first to characterise a transient 
limb ischaemia model in normal human volunteers (67). In their clinical study, Kharbanda et 
al. (67) induced transient limb ischaemia by applying a blood pressure cuff to the upper arm 
and inflating it to 200mmHg. Transient ischaemia was given for 5 minutes by cuff inflation, 
followed by reperfusion for 5 minutes through cuff deflation, a cycle repeated 3 times in the 
treatment group. They showed that the endothelial dysfunction for a 20 minute sustained 
ischaemia in the contra lateral arm was much lesser in remote preconditioned groups, as 
compared to controls. This was assessed through venous plethysmography for flow-response 
to acetylcholine, 15 minutes after sustained ischaemia. Loukogeorgakis et al. (69) 
characterised the time course of this remote preconditioning effect on endothelial protection 
of human volunteers. They showed that the endothelial protective effect measured by flow 
mediated dilatation response occurred immediately, however did not occur at 4 hours. The 
protection reappeared at 24 and 48 hours. This is an important study demonstrating in 
humans, the early and late phases of RIPC as seen in animal models. They also demonstrated 
that this protection was blocked by injection of trimetaphan (an autonomic ganglion locker), 
suggesting the role of neural mechanism in human RIPC.  
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1.5.3 Post Signal Relay Cardioprotective Mechanisms  
Once the cardioprotective signal reaches the myocardium from the remote organ, 
intracellular signal transduction mechanisms are recruited within the cardiomyocytes, which 
are similar to those that participate in IPC and IPostC. These include G-protein cell surface 
receptors with their ligands such as adenosine, bradykinin, opioids, angiotensin and 
endocannabinoids (70). The binding of these cell surface receptors would then activate 
intracellular kinases, reactive oxygen species (ROS), nitric oxide, and mitochondrial KATP 
channel, which act as mediators of cardioprotection in the same way as described in IPC 
mechanism. It probably is better to highlight the commonalities between myocardial 
signaling response to IPC and RIPC involving the above mediators. 
 
1.5.3.1 K ATP Channel  
Several studies have linked the opening of KATP channels in cardioprotection from remote 
ischaemic preconditioning. Treatment with KATP blockers like glibenclamide or 5-
hydroxydecanate abrogated the remote preconditioning cardioprotection in these animal 
models (47, 57). Also, in a similar study Kristiansen et al. (71) have shown that this KATP 
channel appears to be mitochondrial, and not sarcolemmal KATP channel, in their rat model 
experiment. In the setting of IPC, mitochondrial KATP channel opening leads to mitochondrial 
ROS generation, which then mediates cardioprotection by either activating survival kinases 
or by inhibiting mPTP. This was discussed in earlier section. Whether this is also the case in 
RIPC is still not known.  
 
1.5.3.2 Nitric Oxide  
Nitric oxide (NO) generated through nitric oxide synthase (NOS), is an important mediator in 
the cardioprotective signaling cascade of IPC. In RIPC studies, there are conflicting data in its 
exact role in early RIPC, however, there appears to be a significant role of NO in delayed RIPC. 
In rat intestinal ischaemia model, Xiao et al. (63) had shown that delayed RIPC 
cardioprotection is abolished by nitric oxidase synthase inhibitor L-NAME. However, a 
similar experiment by Petrishchev et al. (72) involving early RIPC showed that nitric oxide 
blocker N omega-nitro-L-arginine (L-NNA) did not abrogate myocardial protection from 
RIPC. Shahid et al. (73) in their recent study in rat models have shown that cardioprotection 
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from RIPC is mediated by NO, and have also shown that NO is working upstream and acts via 
activation of mito-KATP channels, which subsequently increases the production of ROS. An 
experiment by Chen et al. (74) on Wistar rats also implicated the role of NO in early RIPC, as 
L-NAME did abolish the cardioprotective effect of RIPC in their model. Tokuno et al. (75) in 
their brain ischaemia model evaluating delayed RIPC cardioprotective effects, also implicated 
the NO role by showing abolished protection in iNOS knockout mice. When all studies are 
taken into account, it appears that NO plays a major role in signal transduction in both early 
and delayed RIPC. 
 
1.5.3.3 PKC-epsilon (ɛ) 
The role of PKC-ɛ in RIPC is implicated in many studies, which have shown that non-specific 
PKC blocker-chelerythrine abolishes the cardioprotection from RIPC stimulus (61, 66). It was 
also shown that the previously described mediators, bradykinin B2 receptor and CGRP 
cardioprotect via PKC-ɛ activation (61, 64). PKC-ɛ role in IPC is well recognised for opening 
KATP channels and subsequent ROS production, which leads to mitochondrial swelling (as 
discussed earlier). A similar role of PKC-ɛ in RIPC is suspected, however, this needs to be 
shown. 
1.5.3.4 Reactive Oxygen Species (ROS) 
ROS generation in a PKC-dependent manner and its role in activation pro-survival kinases 
(Akt and ERK1/2) in the IPC setting were discussed earlier. ROS involvement in RIPC 
cardioprotection was shown by Weinberenner et al. (52), in their rat model. They showed 
that the cardioprotection from RIPC was lost by administration of free radical scavenger. 
Whether ROS serves similar function of RISK pathway activation, and if it is involved in mPTP 
inhibition as in IPC is still not known. 
1.5.3.5 RISK Pathway And Mitochondrial Permeability Transistion Pore (mPTP) 
The RISK pathway refers to a group of pro-survival kinases which act downstream to PKC 
and they get activated at the time of reperfusion in the setting of IPC. The RISK pathway 
confers cardioprotection by inhibiting mPTP opening, anti-apoptotic signaling and anti-
autophagy properties (21). The main components of the RISK pathway include Akt, ERK ½, 
PKG, p70s6K, and GSK-3β (21). There are also other kinases, which are thought to be pro-
survival, however, it is not still very clear if they are truly protective or not. These kinases 
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include MAPK, P38 and JNK (21). RISK pathway activation is the final common pathway 
recruited in both IPC and IPostC (76), and therefore it is likely that RISK plays an important 
role in RIPC as well. One study has shown the increased phosphorylation of ERK1/2 in RIPC 
(77) setting and also have shown that an ERK1/2 antagonist would abrogate the 
cardioprotective effect of RIPC. This requires more studies to firmly establish the role of RISK 
in RIPC. 
 
1.5.3.6 Mitochondrial Permeability Transition Pore -mPTP 
The mitochondrial permeability transition pore (mPTP) has been the center of a growing 
amount of attention for its role in the mediation of reperfusion injury. The mPTP is a non-
specific high conductance channel in the inner mitochondrial membrane, the formation of 
which leads to high permeability states with subsequent cell death (76). The inhibition of the 
mPTP by IPC and IPostC is well established, and the relevant mechanisms and studies are 
reviewed by Hausenloy et al. (76). The mPTP as an end effector in RIPC is however still not 
very firmly established. Zhang et al. (51) in their remote ischaemia model, have shown that 
the cardioprotective effect of RIPC was blocked by both κ-opioid receptor blocker and mPTP 
opener, indirectly suggesting the role of mPTP in RIPC cardioprotection. Further studies are 
needed to clarify mPTP inhibition in the setting of RIPC. 
1.6 Clinical Application of Remote Ischaemic Preconditioning 
The cardioprotective effect of RIPC seen in animal models of myocardial ischaemic 
reperfusion injury certainly is of huge interest for its applicability in human clinical settings, 
involving ischaemia reperfusion injury. As discussed earlier, MacAllister’s group in 2002 (67) 
demonstrated its applicability in human volunteers, with beneficial effect on vascular 
endothelium to a prolonged ischaemic injury through remote preconditioning the contra-
lateral arm. This meant that in clinical situations involving potential ischaemia reperfusion 
injury, this non-invasive intervention could be promising. Consequently, many settings 
exposed to IR injury involving various organs are being evaluated in clinical trials for the 
beneficial effect from RIPC. Cardiac surgery settings and myocardial revascularisation 
settings (surgical and percutaneous) have been evaluated in randomised trials so far, and 
many trials are underway in other non-cardiac settings involving IR injury. The first of the 
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studies which showed benefit of RIPC in clinical settings was done in the paediatric patient 
group undergoing corrective cardiac surgery (78). Subsequently, our institute in a 
randomised controlled trial involving 57 adult patients undergoing cardiac bypass surgery, 
showed a 43% reduction in peri-operative troponin-T release in remote limb preconditioned 
patients (79).  Ali et al. (80) have shown a reduction in both myocardial injury and renal 
injury in the remote limb preconditioned patients undergoing elective abdominal aortic 
aneurysm repair.  
1.7 Cardiac Revascularisation Associated Myocardial Injury 
  
Both forms of revascularisations (PCI and CABG) are vital for treating coronary artery 
disease. However, both these forms of revascularisation can have a deleterious effect on the 
myocardium while its vascular supply is re-established. The mechanisms of this particular 
type of injury are different in settings of PCI and CABG. Consequently, the myocardial injury 
sustained during PCI (Peri-procedural myocardial injury) and during CABG (Peri-operative 
myocardial injury), will be discussed separately in detail. 
1.8 Peri-Procedural Myocardial Injury During PCI  
 
Although medical therapy can be used for prognostic and symptomatic benefit, coronary 
revascularisation, by either coronary artery bypass graft (CABG) surgery or percutaneous 
coronary intervention (PCI), remain important approaches for the treatment of occlusive 
CAD. In Europe, the number of PCI’s increased from 184 000 to 885 000 during the period 
1992 to 2004, with a projected increase to 1.5 million procedures by 2010 (81). In the USA, 
1.3 million PCI procedures were performed in 2006 (82). Changing patient demographics, 
mainly linked to increased life expectancy, have resulted in the increased prevalence and 
complexity of CAD affecting an older age group. 
 
Since the first description of coronary angioplasty by Andreas Grüntzig in 1977, the 
procedure has been extensively modified. The technical advances coupled with the use of 
coronary stents and adjuvant drug therapy, have resulted in high procedural success rates 
and low re-stenosis rates. Older patients are now being treated, and more complex multiple 
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coronary lesions deemed appropriate for PCI. PCI improves symptoms in patients with stable 
CHD, but does not improve clinical outcomes (83). About one third of all elective PCI 
procedures are associated with significant myocardial injury (termed peri-procedural 
myocardial injury, PMI), which has been associated with increased subsequent mortality 
(84). This underscores the importance of risk stratifying prior to the procedure to identify 
the patient group most likely to develop PMI. If PMI incidence can be reduced, clinical 
outcomes would be expected to improve. In this section, we review the underlying etiological 
factors resulting in PMI, the methods available for its detection and quantification, its 
prognostic significance, and the treatment strategies currently available and emerging 
designed to reduce this injury.   
 
1.8.1 Incidence And Prognostic Significance Of Peri-Procedural Myocardial Injury 
 
Cardiac biomarkers have been extensively used in the last two decades to establish the 
incidence and the prognostic implication of PMI. For the most part, these studies have 
focused on patients with stable CAD undergoing planned PCI, although patients with 
unstable CAD undergoing urgent PCI have also been included in some studies. The choice of 
cardiac enzyme assay, the proportional increase in the enzyme level, the criteria of enzyme 
cut-off value used to define PMI, and the timing and frequency of blood analysis can all affect 
the incidence of the PMI in studies evaluating cardiac biomarkers.  
 
1.8.1.1 CK-MB 
Although controversies regarding the prognostic significance of individual cardiac 
biomarkers persist, CK-MB elevation is widely accepted as a biomarker with prognostic 
significance when raised post-PCI. Elevation of CK-MB above the normal levels occurs in 
about 30% of patients undergoing elective PCI (84). More than 60 studies in the last two 
decades have assessed the prognostic significance of elevations in total CK and/or CK-MB 
fraction following PCI. Most meta-analyses that have analysed the majority of the prospective 
randomised studies, and few PCI registry studies (85-89) have inferred the proportionate 
increase in the early and late mortality with increased CK-MB release peri-procedurally (84, 
90, 91).  
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1.8.1.2 TROPONINS 
 
Troponins (Troponin I and Troponin T) are more sensitive and more specific markers of 
cardiac injury than CK-MB (92, 93). Troponin increases following PCI had originally thought 
to carry less prognostic importance than CK-MB elevations, although recent studies and 
meta-analyses have shown that Troponin elevations post-PCI are prognostically significant. 
Nienhuis et al. (94) in their meta-analysis of 15,581 patients from 20 studies over a 19 year 
period, reported the incidence of Troponin release post-PCI in elective PCI to be  33.0%, and 
increased mortality was significantly associated with Troponin elevation after PCI (4.4% vs. 
3.3%, P = 0.001; OR 1.35). New generation high sensitive troponins (hsTrop), which have 
only recently become available, deserve attention at this stage. Although, studies looking at 
hsTrop elevation in the context of PCI are limited, there are a few studies looking at the 
incidence of this biomarker elevation in suspected ACS. In one study involving geriatric 
group of patients, high sensitive troponins were elevated in 76% of suspected ACS patients, 
but two thirds of these patients had no coronary disease in the angiography (95). A similar 
study involving 1026 patients comparing conventional troponin and high sensitive troponin 
assays reported higher diagnostic accuracy for detecting MI, but 51% were false positives 
(96). The cut-off value to define myocardial infarction in the context of PCI, therefore, is felt 
by many researchers to need re-assessment when using this biomarker 
1.8.1.3 New Definition Of Peri-Procedural MI During PCI  
The Joint ESC/ACCF/AHA/WHF Task Force Universal definition of Myocardial Infarction 
2007(97) recently defined peri-procedural myocardial injury during PCI as an elevation of 
serum biomarkers (preferably cardiac Troponins) above the 99th percentile upper reference 
limit (URL) after PCI, assuming a normal baseline Troponin value. According to these 
published guidelines, an elevation in serum cardiac enzyme to more than three times the 
99th percentile URL has been defined as a Type 4a PCI-related myocardial infarction. 
Applying the new definition of peri-procedural MI to the existing studies, Testa et al. (98) in 
their recent meta-analysis of 15 studies incorporating 7578 patients, observed that 15% of 
patients met the new criteria for peri-procedural myocardial infarction, and these patients 
are at high risk of further adverse events both during the hospital stay and at 18 months. 
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Based on the above findings, it appears that a routine Troponin assessment post-PCI may 
allow the identification of patients at risk of developing immediate and longer-term adverse 
events. However, the threshold level of troponin raise used to define periprocedural MI has 
generated lot of debate recently. A recent prospective study by Banning et al in which thirty 
two patients undergoing multivessel PCI and  late gadolinium enhancement (LGE) cardiac 
magnetic resonance (CMR) had cardiac troponin I, CK-MB, and inflammatory markers (C-
reactive protein, serum amyloid A, myeloperoxidase, tumor necrosis factor alpha) measured 
at baseline, 1 h, 6 h, 12 h, and 24 h after the procedure.(99) Three “periprocedural injury” 
groups were defined with the universal definition: G1: no injury (biomarker <99th 
percentile); G2: periprocedural necrosis (1 to 3 × 99th percentile); G3: myocardial infarction 
(MI) type 4a (>3 × 99th percentile). Differences in inflammatory profiles were analyzed. With 
CK-MB there were 17, 10, and 5 patients in groups 1, 2, and 3, respectively. Patients with CK-
MB–defined MI type 4a closely approximated patients with new CMR-LGE injury. Groups 
defined with CK-MB showed progressively increasing percentage change in C-reactive 
protein and serum amyloid A, reflecting increasing inflammatory response (p < 0.05). Using 
cardiac troponin I resulted in 26 patients defined as MI type 4a, but only a small minority had 
evidence of abnormality on CMR-LGE, and only 3 patients were defined as necrosis. No 
differences in inflammatory response were evident when groups were defined with 
troponin. The study concluded that Measuring CK-MB is more clinically relevant for 
diagnosing MI type 4a, when applying the universal definition. Current troponin thresholds 
are oversensitive with the arbitrary limit of 3 × 99th percentile failing to discriminate 
between periprocedural necrosis and MI type 4a. Therefore the meaningfulness of using 
troponins as a sole outcome measure in the research might be a pitfall in itself.   
 
 
1.8.1.4 ECG Changes 
 
Although a 12-lead surface ECG is continuously recorded during the cardiac catheterisation 
procedure, the sensitivity of the ECG for detecting ischaemia during PCI has been 
disappointing. Unipolar intra coronary ECG recording appears to be more sensitive and 
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reliable in detection of ischaemia during PCI (100, 101). However, intra-coronary ECG has 
not been generally adopted during PCI, its role being relegated to historical interest only. 
 
1.8.1.5 Cardiac MRI 
 
Non-invasive imaging of the heart by cardiac magnetic resonance (CMR) imaging can be used 
to detect the location of the PMI and quantify its extent. The presence and extent of increased 
signal intensity on late gadolinium enhancement CMR can be used to image myocardial 
injury directly following PCI, with minimal inter-observer and intra-observer variability 
(102-104). In a prospective study involving 50 patients, Selvanayagam and co-workers (105) 
showed a very strong correlation with CMR defined new myocardial infarction and elevated 
Troponins post-PCI, thereby validating Troponin release post-PCI as a marker of myocardial 
necrosis.  
 
1.8.2 Mechanisms of Myocardial Injury During PCI 
 
The most common mechanisms of myocardial injury during PCI are distal embolisation and 
side-branch occlusion (SBO). Other significant causes include dissection, thrombus, no 
reflow/slow flow, or coronary perforation. Herrmann J  in his review on PMI in 2005 (106), 
classified PMI into two types. Type 1 (Proximal type), which is in proximity to the target 
lesion of PCI and may be due to side-branch occlusion, and Type 2 (distal type) that is in the 
perfusion territory of the treated coronary artery, and mainly due to structural and 
functional microvascular obstruction (106). Fifty to 75% of all PMI is Type 2 (the distal type) 
(106).  
 
1.8.2.1 Type 1 or Proximal Type of PMI 
 
Proximal type of PMI is most often seen adjacent to the treated arterial segment. This type of 
myocardial injury is mainly attributed to side-branch occlusion (SBO), which can happen 
during balloon inflation or with stent insertion. Side-branches are within the vicinity of the 
angioplasty site in over 50% of cases and, although many are unaffected, a considerable 
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proportion are compromised by the procedure (107). Occlusion of a side-branch has been 
reported in up to 19% of cases in which a stent was placed across a major side-branch 
(>1mm) (108). Most occlusions occur after post-stent dilation performed with high-pressure 
inflations (108).  
Side-branches originating from within the lesion of the native coronary artery are at a higher 
risk of occlusion during PCI and, if ostial disease is present in the branch vessel, there is a 
five- to ten-fold increase in the possibility of side-branch compromise (108-111). Other 
influencing factors include the branch relationship to parent vessel lesion, branch vessel size, 
and balloon to artery ratio (108-111). The proposed mechanisms of SBO include snow 
plough effect (plaque shift), thrombus formation, dissection of the dilated artery involving 
the take-off of the side-branch, side-branch spasm and plaque embolisation (109, 110, 112).  
 
1.8.2.2 Type 2 or Distal Type of PMI 
 
This type of myocardial injury is seen in the distal perfusion territory of the treated 
epicardial artery and accounts for 50 to 75% of PMI (106). The atherosclerotic plaque 
disruption and local vessel trauma are the predominant cause in the distal injury and possess 
occlusion potential of both epicardial vessels and myocardial microvascular levels (106). The 
potential mechanisms through which this disrupted plaque and local trauma leads to distal 
perfusion territory insult include:  
a. Distal embolism of atheromatous debris and thrombotic debris. 
b. Platelet activation and thrombosis, leading to micro-vascular plugging of platelets and 
neutrophils. 
c. Neuro-hormonal activation and modulation of vascular and myocardial functions. 
d. Oxidative stress and inflammation 
 
1.8.2.2.1 Distal Embolism of Atheromatous Debris and Thrombotic Elements 
 
Distal embolisation as a result of plaque denudation during percutaneous trans-luminal 
angioplasty (PTCA), was first described in the 1980s (113). Recent developments in 
intravascular ultrasound (IVUS) techniques have contributed to the understanding of 
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atherosclerotic plaque morphology and its components (114). Compared to balloon 
angioplasty, in which the lumen expansion is predominantly due to plaque redistribution and 
plaque dissection, lumen enlargement after stenting involves a combination of plaque 
redistribution, plaque extrusion, vessel expansion, plaque compression, and plaque 
embolisation (115, 116).  
Using filter devices distal to the lesion, studies have identified that the embolisation of plaque 
fragments frequently occurs during PCI (117, 118). The atherosclerotic plaque burden in the 
lesion before intervention is correlated with increased PMI as evidenced by subsequent 
cardiac enzyme elevation (119). The development of IVUS Virtual histology (VH) has 
enabled, in vivo identification of the histopathological characteristics of plaques, and the 
usage of Doppler wire and evaluating high intensity signals (HITS) enables direct detection of 
small embolic particles which could not be detected with conventional angiography (120). 
Using these techniques, Kawamoto et al. (120) have shown the impact of distal emboli and 
plaque characteristics on coronary microcirculation, as assessed by Coronary Flow Velocity 
Reserve (CFVR) during PCI, in a study involving 44 patients with stable angina. Patients in 
the highest tertile of HITS had a significantly larger necrotic core area compared with 
patients in lower tertiles. In addition, there was a small but significant negative correlation 
between HITS and CFVR after PCI.  
Atherosclerotic plaque of the lesion, which have larger necrotic core (NC) are at higher risk of 
plaque rupture and micro-embolisation during PCI and subsequent cardiac enzyme release 
(114, 120). The necrotic core component contains fragile tissues, such as lipid deposition 
with foam cells, intramural bleeding, and/or cholesterol crystals, and these tissues are often 
separated from the vessel lumen by only a thin fibrous cap and, hence, they are thought to be 
easily liberated as small emboli during coronary stenting (120-122).  
 
1.8.2.2.2 Platelet Activation and Thrombosis- leading to Microvascular Plugging of 
Platelets and Neutrophils. 
 
During PCI plaque rupture, the arterial endothelial barrier is denuded, and atherosclerotic 
material, connective tissue elements, and sub-endothelial matrix proteins (collagen, von 
Willebrand factor) are exposed to blood (123). Platelets adhere to collagen and von 
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Willebrand factor via specific cell receptors (glycoprotein [GP] VI, GP Ia/IIa, GP Ib-IX), and 
become activated (124, 125). Activated platelets de-granulate and secrete agonists, 
chemotaxins, clotting factors, and vasoconstrictors that promote platelet aggregation, 
thrombin generation, and vasospasm. 
Increased platelet aggregation during PTCA was shown in 1993 by Gasperitti et al. (126), in 
the blood drawn of coronary sinus during angioplasty. In a recent study by Mahemuti et al. 
(127) a transient significant increase in TF (14%; P = 0.004),  prothrombin fragments 1 and 2 
(40%; P = 0.001), and F-VIIa (31%; P = 0.007) following angioplasty were reported, although 
the levels returned to normal after stents were deployed. Cuisset et al. in 2007 (128), showed 
the higher incidence of PMI in low responders to dual antiplatelet therapy in a non-ST 
elevation acute coronary syndrome (NSTEACS) patient cohort. This was established using 
high post-treatment platelet reactivity (HPPR) (maximal intensity of ADP 10 μM-induced 
platelet aggregation >70%), which identifies low responders to dual antiplatelet therapy 
(aspirin and clopidogrel). PMI occurred significantly more frequently in patients with HPPR 
than in the normal-responders, as evidenced by post-procedure Troponin I release (43% vs. 
24%, p=0.014). Previously, Chen et al. in 2004 (129), had shown that Aspirin-resistance is 
associated with a high incidence of myonecrosis after non-urgent PCI despite clopidogrel 
pre-treatment using rapid platelet function assay-ASA (RPFA-ASA). The incidence of any CK-
MB elevation was 51.7% in Aspirin-resistant patients and 24.6% in Aspirin-sensitive patients 
(p < 0.006). Elevation of cTnI was observed in 65.5% of Aspirin-resistant patients and 38.5% 
of Aspirin-sensitive patients (p < 0.012).  
The release of potent bio-factors like tissue factor (TF) leading to micro-vascular thrombosis 
and no-reflow during in vivo plaque disruption by PTCA was demonstrated by Bonderman et 
al. (130) in 2002.  
Mizuno et al. (131) in 2000, showed increased levels of coagulation factors in coronary 
circulation after PTCA despite adequate administration of intravenous heparin. TF levels in 
coronary sinus blood were elevated 4 hours after PTCA, followed by increased levels of 
thrombin-antithrombin III complex, a specific and sensitive marker for thrombin generation, 
24 hours after PTCA. It was further confirmed by Salloum et al. in 2005 (132), that a 
significant amount of TF is released in situ immediately after PCI in saphenous venous grafts 
(SVGs), measured by aspiration through export catheter.  
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1.8.2.2.3 Neuro-hormonal Activation and Modulation of Vascular and Myocardial 
Function. 
Coronary vasospasm distal to the PTCA site was shown in arteriographic analysis  in 1988 by 
Fischell TA et al. (133). Microcirculatory vasospasm is thought to be an important 
phenomenon, occurring during coronary interventions. Potent vasoconstrictors, like 
serotonin (5-HT) and endothelin, which are released by activated platelets, were shown to be 
significantly increased in the distal coronary bed during SVG PCI (132).  
Microcirculatory vasospasm is thought to play a significant role in the ‘No reflow 
phenomenon’ frequently seen during Primary PCI (134). The neural mechanism of 
vasoconstriction is supported by studies which have shown that alpha-adrenoreceptor 
blockade by drugs like uradipil and yohimbine, attenuates coronary vasoconstriction and 
increases coronary flow reserve (CFR) during coronary angioplasty and rotational 
atherectomy (135-137).  
 
1.8.2.2.4 Oxidative Stress and Inflammation 
 
Angioplasty associated increase in isoprostane -PG(F2)Alfa and ischaemia modified albumin 
(IMA), which are associated with free radical damage through reactive oxygen species (ROS) 
generation, suggests oxidative stress to be an important mechanism of PMI (138, 139). 
However, most of the studies on oxidative stress were carried on primary PCI patients, many 
of whom have completely occluded arteries, suggesting that oxidative stress in these 
conditions owes more to reperfusion injury. 
Rises in inflammatory markers interleukin-6 and C-reactive protein (CRP) levels post 
angioplasty and PCI have been shown in clinical studies (140, 141). Bonz et al. in 2003(142), 
showed that the inflammatory markers were higher in patients who had significant Troponin 
release post PTCA, as compared to patients who had no Troponin release post-procedure, 
suggesting inflammation as one of the mechanisms of PMI. Gach et al. (143) in 2005, showed 
early increased release of neutrophil markers (myeloperoxidase, lactoferrin) in patients 
undergoing stents, which did not increase with diagnostic angiography.  
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1.8.3 Factors Influencing PMI 
 
The key factors which influence the incidence and magnitude of PMI can be broadly classified 
into patient factors, angiographic or lesion related factors, and procedural factors. 
Assessment of these factors prior to the intervention allows risk stratification for PMI. 
 
1.8.3.1 Patient Factors 
Patient factors implicated for higher incidence of PMI include: older age (144), multi-vessel 
CAD (106), diffuse CAD (145), systemic atherosclerosis (145), pre-existing renal impairment 
(146), presence of anaemia (147), pre-procedural C reactive protein (CRP) elevation (148), 
and pre-procedural white blood cell count >9.5 x 106/L (149). Also, patients with evolving 
MIs with elevated cardiac enzymes before the procedure are at increased risk of PMI. This 
was shown in a sub-analysis from the IMPACT-II trial (89). In the setting of unstable angina 
and acute coronary syndromes, Troponin T elevation is associated with more complex 
coronary stenoses and an increased likelihood of multi-vessel CAD (150-152). The plaque 
seen in coronary arteries of acute coronary syndromes (ACS) have large lipid cores and a thin 
capsule, the so called ‘vulnerable plaque’, compared to coronary arteries in patients with 
stable angina, which appear to have a thick capsule (153). The unstable plaque in the setting 
of an ACS is more likely to denude during revascularisation procedures. In the non-ST 
elevation acute coronary syndrome (NSTEACS), this increased PMI with early intervention 
was shown in a recent trial of 1200 Troponin positive patients; ICTUS (Invasive Versus 
Conservative Treatment in Unstable Coronary Syndromes Investigators). The incidence of 
PMI was significantly higher in the early invasive strategy group than the selective invasive 
group (11.3 percent vs. 5.4 percent, P=0.001) (154).  
In the case of Primary PCI, myocardial injury also occurs due to reperfusion injury with a 
mechanism distinct from that associated with peri-procedural injury (8). As both 
Reperfusion Injury and PMI are associated with cardiac enzyme rise, it is difficult to separate 
the relative contributions towards myocardial injury by these two processes. The cardiac 
enzyme released due to the infarction itself further complicates interpretation. 
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1.8.3.2 Angiographic or Lesion related Factors 
Complexity of the arteriosclerotic lesions and coronary anatomy influence the amount of 
PMI, presumably due to prolonged and aggressive catheter manipulation. The plaque burden, 
number of lesions, presence of bifurcation lesions, tortuosity and calcification are all likely to 
influence myocardial injury during PCI. A recent study investigating the ability of four 
angiographic classification schemes to predict peri-procedural myocardial injury in patients 
undergoing PCI for stable angina, found the Syntax scoring system to be reliable in predicting 
PMI (155).  
In addition, coronary embolisation of atherothrombotic debris, resulting in elevated cardiac 
enzymes and an ST-elevation or non-ST elevation MI during catheter intervention, is a more 
common problem after PCI in saphenous vein grafts (SVGs) rather than in native coronary 
arteries (156, 157). A possible explanation is that atherosclerotic plaques in vein grafts are 
softer, more friable, and are more commonly associated with thrombus and platelet 
activation compared to plaques in native coronary arteries, all these features making SVG 
lesions prone to fragmentation and distal embolisation during PCI (158, 159).  
 
1.8.3.3 Procedural Factors 
The incidence of PMI with elevation of cardiac enzymes is significantly higher in Directional 
Coronary atherectomy (DCA) compared to PTCA. (16% versus 6%; P<.0001)(160-162). Also, 
suboptimal stenting has been shown to be associated with increases in the peri-procedural 
incidence of non-ST elevation MI (NSTEMI); 8.7 versus 4.2 percent, p =0.003).  In a recent 
study, Hoole et al. (163) also implicate longer stent length for increased myocardial enzyme 
release. 
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1.9 Peri-operative Myocardial Injury During CABG   
Coronary artery bypass graft (CABG) surgery, which is the surgical way of myocardial 
revascularisation of the diseased coronary arteries, predates the percutaneous 
revascularisation. In fact, the development of coronary artery bypass technology in the 1950s 
spurred surgeons to develop coronary artery bypass grafting. Cardiac surgery developed 
later than other surgical specialties, largely due to technical difficulties of operating on the 
heart. This procedure has also seen tremendous advancement, both in the surgical aspects, 
choice of conduits and in the myocardial protection from peri-operative effects which will be 
discussed in detail here. Although PCI was devised 20 years later in 1970s, it has surpassed 
CABG in the number procedures performed annually. However, CABG still remains the most 
common cardiac surgery performed in the world. 
Although, a lot of early operations attempted to operate on the surface of the heart, they 
were limited by the technology of their time. Most were very ingenious, and in many ways 
ahead of their time. These operations to treat CHD included methods to increase non 
coronary blood flow to the heart by creating pericardial adhesions (164, 165). Some also 
studied the effects of coronary sinus ligation in an attempt to impede venous outflow and 
thereby improve myocardial perfusion.  However, in the final analysis they all required the 
ability to support the circulation to make the breakthrough that they were seeking. The 
crucial technology of artificial circulatory support was developed, principally by the 
perseverance of Dr John Gibbon (166). The ‘‘heart lung machine’’ of Gibbon could support 
circulation, and was a major breakthrough in the field of cardiac surgery. Also, in 1950 
Bigelow had found that in experimental models the total body oxygen consumption was 
decreased with temperature, and this included myocardial metabolism (167). With the initial 
heart lung machines, there was need for high flow rates to provide for the body’s oxygen 
demands. But this need was circumvented when investigators reassessed Bigelow’s previous 
findings, and found that by adding hypothermia, the total body oxygen requirements were 
greatly reduced in patients.  
The surgeons in 1960s reviewing complications of cardiac surgery did not initially consider 
the possibility of myocardial injury, due to surgery itself. It was in 1967, when Taber’s group 
first reported that there was myocardial necrosis following cardiac surgery, and showed that 
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patchy necrosis up to 30% of the myocardium occurred post cardiac surgery (168). Cooley et 
al.  (169) in 1972 reported the phenomenon of ‘stone’ heart, when the heart goes into a state 
of ischaemic contracture during double valve surgery, especially when the ischaemic time 
was prolonged. With many researchers finding similar peri-operative myocardial injury, the 
question of whether the protection of myocardium during cardiac surgery is adequate 
became serious, and improving protective techniques were explored. 
 
1.9.1 Cardioplegia Use for Myocardial Preservation 
 
The first use of ‘elective cardiac arrest’ was by Melrose in 1955, who also coined the term 
‘’cardioplegia’‘ for the technique (170). Melrose used a solution containing potassium citrate 
to remove trans-membrane electrical potential, and to stop cardiac impulse and arrest the 
heart in diastole, by injecting the solution into aortic root. There was initial wide interest in 
cardioplegia however with experience there were evidences of late myocardial necroses 
following use of Melrose solution. This was shown to be due to extremely high 
concentrations of potassium and high osmolarity of Melrose solution (171). Cardioplegia, 
thus fell into disrepute until there was a better understanding of the components necessary 
for safely inducing electromechanical arrest, and preserving cell structure and function 
during ischaemia (172). The use of hypothermia with continuous coronary perfusion 
continued to be the predominant method, and this was supplemented with the use of 
ventricular fibrillation to induce cardiac standstill.  
The resurgence in the interest in cardioplegia in 1970s could be attributable for pioneering 
work by Gay and Ebert who used crystalloid solution for cardioplegia which contained much 
lower concentrations of KCL (173). Hearse and his group’s further work on potassium 
solutions led to the development of St Thomas’s solution which was first used clinically in 
1976 (174). Since then, there has been a lot of work done to enhance the substrate of 
cardioplegic solution by many researchers. The essential clinical prerequisites for 
cardioplegia include a solution that is safe in ischaemic models, the distribution of flow to all 
cardiac regions, periodic replenishment to counteract non-coronary collateral washout and 
strategies for protection in various clinical conditions (175). The likely composition of 
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current pharmacological cardioplegic solutions and principles are summarised in the table 
below. 
Table 1 
PRINCIPLE METHOD 
Immediate arrest K+,Mg2+,procaine 
Hypothermia 10°C-20°C 
Substrate Oxygen, glucose, glutamate, aspartate 
Appropriate pH (buffer) Tris-hydroxymethyl aminomethane(THAM) 
solution, bicarb, phosphate 
Membrane stabilization Ca2+, steroids, procaine, calcium channel 
blockers, magnesium, O2 radical scavenger 
 Reproduced from Allen BS, Buckberg GD Myocardial management of arterial Revascularization, 2006.(175) 
 
Blood as a cardioplegic vehicle was first introduced by Dr Gerald Buckberg’s group in 1978, 
after their vast experimental work (176). Blood cardioplegia has become most popular 
method of cardioplegia in the current era. Very few surgeons however continue to use 
crystalloid cardioplegia and other methods of myocardial protection, like fibrillatory arrest. 
Blood cardioplegia is the preferred choice, as this physiological source of oxygen is available 
readily in the extracorporeal circuit, and its use limits the haemodilution when large 
amounts of cardioplegia are needed. Also blood proteins like histidine aid in buffering 
capacity required for cardioplegia. Furthermore the rhelogic advantage on microvasculature 
afforded by the erythrocytes enhance papillary muscle perfusion compared to oxygenated 
crystalloid cardioplegia and reduce coronary vascular resistance and oedema formation 
(175). The erythrocytes in blood also contain many endogenous oxygen free radical 
scavengers (superoxide dismutase, catalase and glutathione) (175). The current practice in 
most surgical centres of the world is usage of cold blood cardioplegia. The cardioplegia is also 
used retrogradely through coronary sinus in many centres. Surgeons differ in their opinion in 
preferred cardioplegic route and some advocate a combination of antegrade and retrograde 
cardioplegia in during surgery. Antegrade cardioplegia is thought to not provide adequate 
perfusion to distal areas of complete coronary occlusions, where retrograde perfusion is of 
value, however retrograde cardioplegia is criticised for its inadequacy of right ventricular 
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perfusion. Consequently, in many centres a combination of the two, adapted to particular 
surgery and patient is usually practiced (177).  
The other cardioprotective strategy that few surgeons use other than cardioplegic arrest, is 
by inducing electrical ventricular fibrillatory arrest. The argument for this strategy is that, 
the perfusion to myocardium remains intact until aortic cross clamp is applied and hence 
myocardium is exposed to lesser ischaemic burden. In this method, the proximal 
anastomosis to the aorta is created without the need of cross-clamping, and aortic cross 
clamp is applied intermittently when distal anastomoses are created. This, hence, reduces 
ischaemic time that the myocardium experiences significantly. However, it also means that 
the cardioplegic protection with oxygen and substrates provided by cardioplegia solution is 
deprived in this method. Potentially, hence, myocardium could experience more injury for 
given ischaemic time when compared to cardioplegia, although the conundrum is that the 
ischaemic time itself is reduced.   
In the United Kingdom, a survey in 2004 indicated that among surgeons performing on-
pump CABG, 85% used cardioplegia, mostly antegrade cold cardioplegia and 15% used cross 
clamp ventricular fibrillation as cardioprotection (178).  
 
1.9.2 Need for Further Myocardial Protection. 
Although considerable progress has been made in surgical techniques and other 
perioperative myocardial protective strategies, allowing for the majority of patients to 
undergo cardiac surgery without significant mortality, a significant proportion of patients 
may still experience substantial morbidity related to adverse cardiovascular events.  These 
include prolonged contractile dysfunction (stunning), myocardial infarction, low-output 
syndromes, and overt ventricular failure, all resulting in prolonged intensive care unit stay 
and reduced functional capacity and ultimately contribute to overall mortality. Although the 
predominant mechanism for this myocardial injury still is ischaemia-reperfusion injury, 
there are other causes, which can affect myocardial injury sustained during cardiac surgery. 
These include the inflammatory response to extraneous substances in the cardiopulmonary 
bypass circuit, athero-embolism, over distension and direct myocardial injury due to 
retraction and handling of the heart (179). Generally, these latter influences are well 
understood and are minimised by intra-operative cardiac decompression, appropriate care 
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in handling and retracting the heart and aorta, as well as careful monitoring and 
manipulation of heart rate, filling pressure, and systemic vascular resistance (179). Also, 
delivery of cardioplegia solution at high infusion pressure can be deleterious to myocardium 
especially to ischaemic tissue (175). This is especially in cases of anterograde cardioplegia 
where perfusion pressure in the coronary arteries is not usually monitored. 
 
1.9.3 Biomarker Elevation after CABG 
It is not surprising that elevation of cardiac biomarkers occurs in most of the patients 
undergoing elective CABG. Cardiac Troponins (cTn I or cTn T) and CKMB are used for 
diagnosis of myocardial necrosis. The diagnostic accuracy of these biomarkers is reduced 
after CABG due to their release as a routine sequelae of the procedure (180, 181). The 
incidence of elevated CKMB above ULN has been noted in 62-90% of the patients undergoing 
CABG (180, 181). However, patients with substantial elevation of cardiac enzymes are known 
to have worse prognosis.  In a review of 2918 patients, the six month mortality associated 
with elevations of CK-MB <5, ≥5 to ≤10, ≥10 to ≤20, and >20 times above the upper limit of 
normal was 3.4, 5.8, 7.8, and 20.2 percent, respectively; this relationship remained significant 
after adjusting for other risk factors (182). Also, in a series of 3812 patients, serum CK-MB 
was significantly predictive of increased mortality, only with values more than 10 times the 
upper limit of normal (180). This increase in mortality persisted at an average follow-up of 
three years. Likewise, the increase of Troponin levels after CABG indicates necrosis of 
myocardial cells, which predicts a poor outcome in particular when elevated to the highest 
quartile or quintile of the measurements (183, 184). The Joint ESC/ACCF/AHA/WHF Task 
Force for the Redefinition of Myocardial Infarction has classified myocardial infarction 
associated with CABG surgery as ‘Type 5 myocardial infarction’. Unlike the prognosis, scant 
literature exists concerning the use of biomarkers for defining myocardial infarction in the 
setting of CABG. Therefore by arbitrary convention, biomarker values more than five times 
the 99th percentile of the normal reference range during the first 72 h following CABG, 
when associated with the appearance of new pathological Q-waves or new LBBB, or 
angiographically documented new graft or native coronary artery occlusion, or imaging 
evidence of new loss of viable myocardium, is considered as diagnostic of a CABG related 
myocardial infarction (type 5 myocardial infarction) (97).  
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1.9.4 Cardiac Imaging in Diagnosis of Perioperative Myocardial Injury 
 
Apart from cardiac enzymes and ECG changes, imaging modalities can also be used to 
determine the occurrence of myocardial injury and also can localise the injured myocardium. 
Myocardial SPECT and cardiac MRI are the two imaging methods, which have been used to 
assess perioperative myocardial injury. Using contrast enhanced magnetic resonance 
imaging; Steuer et al. (185) in their study of patients undergoing CABG have demonstrated 
the visualisation and the quantification of myocardial necrosis post CABG. They also showed 
strong correlation with the Troponin T release and CKMB release, and MRI findings of 
myocardial necrosis. There was strong inter-observer agreement in quantification of infarct 
mass through MRI in this study. The perioperative myocardial injury using SPECT scan was 
demonstrated as early as 1989 by Burns et al. (186). The correlation of SPECT imaging 
infarct size with enzymatic and other modalities of quantification of infarction is also well 
established (187). Direct comparison between the two modalities on detection and 
reproducibility of the infarct size have shown that cardiac MRI is more sensitive and better 
reproducible technique than SPECT sestamibi and also more sensitive in diagnosing 
subendocardial infarctions (188-190).  
 
 
 1.9.5 Factors Influencing Perioperative Cardiac Enzyme Release 
 
There are many factors involving the surgical setting of CABG surgery, which can influence 
the myocardial injury and consequent enzyme release. Some of the known factors are 
discussed below. 
 
a. Cardioplegia vs Cross Clamp Fibrillation 
 
The type myocardial protective strategy that is used in CABG is likely to influence myocardial 
injury during CABG.  The ‘Cardioplegia’ and ‘cross clamp fibrillation’ methods are the two 
commonly employed myocardial protection strategies. As discussed in the previous section, 
intermittent cross clamp fibrillation is likely to decrease the ischaemic time that the surgery 
requires, as the myocardial perfusion remains intact until the aortic clamps are applied. 
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However, it also means that the cardioplegic protection with oxygen and substrates provided 
by cardioplegia solution is deprived in this method. Therefore, potentially myocardium could 
experience more injury for given ischaemic time when compared to cardioplegia. A 
prospective randomized study by Musumeci et al. (191) involving 91 patients undergoing 
CABG, showed that intermittent cross clamp fibrillation (ICCF) was better in reducing 
perioperative cardiac enzyme release compared to cold blood cardioplegia method. The 
ischaemic time in the ICCF group was significantly lower so this could have influenced the 
results.  A meta-analysis by Scarci et al. (192) involving 13 studies showed no difference in 
cardiac enzyme release between these two methods. No study to-date has evaluated the 
enzyme release by these methods as a ratio of ischaemic time. Majority of the surgeons 
across the world use cardioplegic method as their choice. In the United Kingdom, a survey in 
2004 indicated that among surgeons performing on-pump CABG 85% use cardioplegia, 
mostly antegrade cold cardioplegia and 15% use cross clamp ventricular fibrillation as 
cardioprotection (193).  
 
b. Blood Cardioplegia vs Crystalloid Cardioplegia  
Being a physiological buffer with oxygen carrying capacity, blood cardioplegia is now the 
preferred choice of cardioplegia and the advantages of using blood cardioplegia were 
discussed in an earlier section. In terms of myocardial enzyme release, two meta-analyses 
evaluating a total of 52 randomised trials have concluded that blood cardioplegia results in 
significantly less myocardial enzyme release compared to crystalloid cardioplegia (194, 195). 
However, there are still many surgeons across the world committed to crystalloid 
cardioplegia. The likely advantages of crystalloid cardioplegia are it is cheaper and quicker to 
administrate and gives a better view when performing distal coronary artery anastomoses 
(194).  
 
c. On Pump vs Off Pump CABG  
In the last decade, less invasive cardiac operative techniques have emerged and off-pump 
CABG (OPCAB) is currently most widely practiced minimally invasive surgery. This involves 
bypass grafting on a beating heart and avoids usage of cardiopulmonary bypass. The 
ischaemia to heart during the operation is only regional, as compared to global ischaemia in 
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conventional CABG, as individual coronary arteries are clamped separately during individual 
vessel grafting. It is logical to imagine that this would reduce myocardial injury and 
outcomes, however large randomised studies and meta-analysis have shown no benefit in 
mortality, morbidity or incidence of peri-operative MI (196, 197). Although the ischaemia is 
regional, the relative hypoxic injury in OPCAB myocardium is likely to be more than that in 
conventional CABG where the heart is cardioplegic and hence with lesser oxygen demand 
during ischaemic period. 
 
d. Ischaemic Times and Cardiopulmonary Bypass Times (CPB)- 
The ischaemic time refers to the duration of time the myocardium is deprived of vascular 
perfusion during CABG. This corresponds to aortic cross clamp time during on pump cardiac 
surgeries, and in OPCAB surgeries, it corresponds to the total coronary artery clamping 
times. It is very logical to expect that, higher the myocardial ischaemia duration, 
correspondingly more myocardial injury to be expected as many areas of myocardium enter 
from reversible into irreversible injury phase. A cross clamp time of more than 90 minutes is 
shown to be an independent predictor of significant perioperative myocardial injury (198). 
Prolonged cross clamp times and CPB time often denoted technical difficulties, in executing 
the planned operation. This could be due to unfavorable anatomy, unexpected intra-
operative complications, or difficulties in weaning the patient from bypass, may be due to 
residual ischaemia or post-CPB myocardial stunning, all of which are factors responsible for 
cardiac enzyme elevation. A CPB time of more than 120 minutes is shown to be independent 
predictor of significant perioperative myocardial injury (199). One study has shown that the 
cardiac enzyme release at the end of the procedure correlates to both aortic cross clamp 
times and CPB times (200).  
1.10 Current and Emerging Therapeutic Strategies to Reduce Revascularisation Associated 
Myocardial Injury 
 
Both peri-procedural myocardial injury during PCI, and peri-operative myocardial injury 
during CABG carry well known prognostic implications in terms of both mortality and 
morbidity, as already discussed in their relevant sections. The search for preventing and 
reducing these forms of ischaemia-reperfusion injury, therefore, has a very important place 
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in the clinical field. Consequently, various therapeutic strategies have been explored over 
years with significant success in reduction of these forms of injuries. We shall now explore 
these strategies, in the individual settings of PCI and CABG separately, as the pharmacological 
strategies are different in these two settings although many therapies overlap. 
 
1.10.1 Therapeutic Strategies to Protect from Peri-procedural Myocardial Injury 
 
The therapeutic strategies being pursued to combat PMI can largely be divided into three 
subgroups. 
A.   Strategies to prevent side-branch occlusion 
B. Strategies to prevent distal embolisation and microvascular coagulation. 
C. Strategies of protecting the myocardium itself against PMI (Cardioprotection). 
 
1.10.1.1 Strategies to Prevent Side-branch Occlusion. 
Bifurcation lesions are always difficult to treat. Although strategies of stenting both main 
vessel and side-branch using drug eluting stents (DES) using different techniques like ‘crush’ 
and ‘culotte’ are evaluated, no long term benefits have been found in RCTs (201-203). In fact, 
in BBC-ONE trial there was a higher MI incidence including PMI in ‘complex stent strategy’ 
(203). A ‘simple strategy’ of main vessel PCI with an option of side-branch stenting or 
balloon, only if warranted appears to be the current preferred practice. 
 
1.10.1.1 Strategies to Prevent Distal Embolisation and Microvascular Coagulation. 
 
Antiplatelet and Anti-thrombotic Drugs. 
Platelet activation plays a cardinal role in the pathophysiology of PMI. Anti-platelets and anti-
thrombotics are used as first line preventative drugs to counteract the pro-coagulant milieu 
created during coronary interventions and hence to minimise myocardial damage.  
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Aspirin 
 Aspirin has been known to be protective against peri-procedural Q wave MI, for more than 
20 years. However the initial trials involved very large doses of aspirin (e.g. 990mg) or 
aspirin combined with Dypiridamole or Ticlopidine. Protection against immediate PTCA 
complications when compared to placebo were shown by these trials (204, 205). There have 
been no randomised trials to determine optimum loading dose of Aspirin prior to PCI, but the 
guidelines suggest dosages of 75-325mg in patients already on long term low dose Aspirin, 
and 300 to 325mg Aspirin before PCI if not previously treated with Aspirin (206). The need 
for additional anti-platelet treatment in PCI is due to Aspirin being a comparatively weak 
inhibitor of platelet function. Other agonists such as ADP, collagen, or thrombin can still 
activate platelets, as measured by ex vivo tests in patients taking Aspirin (207). There also is 
an approximate 24% prevalence of Aspirin resistance in the community (208).  
 
Thienopyridines 
Thienopyridine drugs include the anti-platelet agents Clopidogrel, Ticlopidine and Prasugrel. 
The metabolites of these drugs irreversibly bind to ADP (P2Y12) receptors on the platelet, 
thus attenuating ADP-mediated GP IIb/IIIa receptor activation and platelet aggregation.(209) 
Clopidogrel has been adopted as the drug of choice over ticlopidine in view of enhanced 
safety and tolerance. However Clopidogrel resistance is common in the population. Following 
a 300-mg oral clopidogrel loading dose and 75 mg administered daily thereafter, ‘resistance’ 
was observed in 31% and in 15% of patients at 5 and at 30 days post-PCI, respectively (210). 
A higher loading dose of 600 mg clopidogrel was associated with a lower incidence of early 
resistance (8%) compared with a 300 mg load (25%)(211). The results from the ARMYDA 2 
trial suggested that a 600-mg loading dose of clopidogrel safely and more effectively reduced 
the occurrence of peri-procedural infarctions than did a 300-mg loading dose (212). 
Multivariable analysis showed that pre-treatment with the 600-mg clopidogrel loading 
regimen was associated with an approximately 50% risk reduction of peri-procedural 
myocardial infarction (Odds ratio 0.48, P = 0.044). Prasugrel, a new thienopyridine has been 
found to have much less variability in response compared to clopidogrel and appears not to 
have non responders, however its role in PMI reduction is not yet established (213).  
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GPIIb/IIIa inhibitors 
Platelets adhere to collagen and von-Willebrand factor via specific surface membrane 
glycoprotein cell receptors and become activated. The platelet GP IIb/IIIa receptor is of 
particular interest because of its central role in platelet aggregation. Three intravenous GP 
IIb/IIIa inhibitors are currently available for clinical use: abciximab, tirofiban and 
eptifibatide. Abciximab is a monoclonal antibody directed against the receptor, while 
tirofiban and eptifibatide are high affinity non-antibody receptor inhibitors. There are 
numerous trials, which have evaluated the potential merits of GPIIb/IIIa inhibitors during 
PCI comparing to placebo. A recent meta-analysis evaluating 21 randomised controlled trials 
which included 23,941 patients comparing GPIIb/IIIa inhibitors and placebo inferred a 
reduced 7 day post-procedure MI incidence in the GPIIIa/IIb treated group (4.31% vs. 6.97%, 
OR 0.59 CI 0.46-0.75) (214).  
The relative clinical efficacy of abciximab, tirofiban, and eptifibatide at currently 
recommended doses has been uncertain for patients undergoing PCI. One meta-analysis in 
2001 compared relative efficacy of individual GPIIbIIa inhibitors analysing 8 RCTs with 
14644 patients. Abciximab resulted in a significant reduction of post-procedure MI from 
8.5% to 4.3% (OR 0.49; 95% CI 0.40 to 0.59); compared to tirofiban and eptifibatide both of 
which showed non-significant reduction in MI from 6.9% to 5.9% (OR 0.85; 95% CI 0.69 to 
1.04) (215). In the TARGET RCT (216) which directly compared tirofiban and abciximab 
involving 4809 patients during PCI, Abciximab significantly reduced the peri-procedural MI 
compared to tirofiban – an absolute 1·5% reduction of early myocardial infarction (6·9% vs. 
5·4%, p=0·041). It was also recognised in this trial that patients with ACS undergoing PCI had 
the greatest benefit from abciximab. 
 
Anti-thrombotics 
Unfractionated heparin, which was the predominant anti-thrombotic treatment when PTCA 
was the only intervention, continues to be used in most PCI procedures. The other anti-
thrombotics that have been evaluated in recent years include low molecular weight heparin 
and the direct thrombin inhibitors Bivalirudin and Fondaparinux. However, there have been 
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no randomised trials showing reduction in peri-procedural MI in elective PCI with any of the 
above anti-thrombotics.  
 
Distal protection devices 
Two types of embolic protection devices are in current usage, filters and aspiration 
(thrombectomy) catheters. Distal protection using filters appear to be of benefit in 
saphenous venous graft interventions but are not routinely used in PCI of native coronary 
arteries. In the SAFER trial (217) use of the embolic protection device in SVG interventions, 
with or without the concomitant administration of a glycoprotein IIb/IIIa inhibitor, 
significantly reduced the incidence of myocardial infarction (8.6% versus 14.7 %) and the 
‘no-reflow’ phenomenon (3% versus 9%). 
 
Direct Stenting 
Direct stenting of the coronary lesion without pre-dilatation was found to reduce post-
procedural Troponin I levels over 24 hours in a randomised controlled trial involving 311 
patients by Nageh et al. (218). In a recent study by Cuisset et al. (219), direct stenting in 
stable-angina patients was associated with reduced microvascular dysfunction induced by 
PCI as compared with conventional stenting. It appears that further studies are required to 
establish the usefulness of direct stenting in reduction of peri-procedural myocardial injury. 
One meta-analysis comparing outcomes of direct stenting with conventional stenting found 
no benefit in MACE with non-significant trend towards reduction in early MI and death post-
PCI (220).  Prospective trials will be needed, as the use of direct stenting may select less 
complex lesions in which less PMI might be expected.       
  
Strategies for protecting the myocardium against PMI (Cardioprotection) 
 
Much of the existing medical therapy administered during PCI is to maintain the patency of 
the coronary artery and comprises primarily of anti-platelet and anti-thrombotic therapy. In 
cases of coronary no-reflow, intracoronary adenosine, calcium channel blockers or nitrates 
may be administered with the intention to improve myocardial reperfusion and maintain 
microvascular perfusion. However, an attractive alternative strategy may involve rendering 
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the myocardium resistant to the detrimental effects of PMI by pharmacological or novel 
interventions. 
 
Statins 
In addition to its lipid-lowering effect, some of the beneficial effects elicited by this class of 
drugs may be attributed to a variety of non-lipid lowering pleiotropic effects, including 
improved endothelial function, reduced oxidative stress, less platelet adhesion, and 
increased atherosclerotic plaque stability (221). Nitric oxide has been implicated as a crucial 
signalling molecule in cardioprotection and is involved in the other pleiotropic effects of 
statin therapy (221).  
Although previous observational prospective and retrospective studies had shown reduction 
of peri-procedural myocardial damage in patients on pre-procedural statin (222, 223),  it was 
in 2004 when ARMYDA trial (224) established that a significant reduction in post-procedure 
cardiac enzymes occurred in patients  randomised to 40mg Atorvastatin for 7 days prior to 
the elective PCI compared to statin-naive patients. The recent NAPLES II trial (2009)(225) 
randomised 668 patients undergoing elective PCI studied the effect of a single 80mg loading 
dose of Atorvastatin within 24 hours before stent deployment compared to a control statin 
naive group. A significant reduction in peri-procedural MI was shown in the Atorvastatin 
group (9.5% vs. 15.8% OR: 0.56; 95% confidence interval: 0.35 to 0.89; p = 0.014). ARMYDA-
ACS trial (226) which involved non-ST elevation myocardial infarction patients showed that 
the post-procedural elevation of CK-MB and Troponin-I was significantly lower in patients 
randomised to a loading dose of 80mg atorvastatin 12 hours before PCI and further 40mg 
pre-PCI compared to control group (7% vs. 27%, p = 0.001 and 41% vs. 58%, p = 0.039, 
respectively). Yun et al. (227), in their recent study on ACS patients, showed reduction in PMI 
in patients with single high-dose Rosuvastatin loading when compared to control group 
(11.4% versus 5.8%, p=0.035).  
  The ARMYDA-RECAPTURE trial (228) studied Atorvastatin reload in patients on chronic 
statin therapy undergoing percutaneous coronary intervention. They randomised 383 
patients with both stable angina (53%) and non-ST-segment elevation acute coronary 
syndromes (47%) who were on previous statin therapy to have 80 mg loading of 
atorvastatin 12 hours before PCI and further dose of 40mg atorvastatin pre PCI versus a non 
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loading control group. This study inferred a lower incidence of post-procedural CK-MB and 
Troponin-I elevation > ULN in the atorvastatin arm (13% vs. 24%, p = 0.017, and 37% vs. 
49%, p = 0.021, respectively). Of note, the stable angina patients who had PCI did not benefit 
from atorvastatin reload. A meta-analysis in 2007 by Merla et al.(229) evaluating 9 trials 
with 4751 patients, which assessed the impact of statin pre-treatment on peri-procedural 
myonecrosis, found 9% incidence in the statin-treated group compared 17.5% in the control 
group (OR 0.45, 95% CI: 0.33 to 0.62, p <0.01).  
 
 Beta Blockers 
Intra-coronary propranolol at a dose of 15 µg/kg administered across the stenosis before the 
balloon dilation was shown to reduce peri-procedural incidence of CK-MB and Troponin T 
elevation compared to control patients in 2003 by Wang et al. (230). When intracoronary 
propranolol administered with the GPIIbIIIa inhibitor eptifibatide, the post procedural CK-
MB was significantly reduced compared to placebo, (231) highlighting an additive benefit of 
a  beta blocker with a GPIIbIIIa inhibitor. Post-PCI CK-MB elevation > ULN occurred 
significantly more frequently in the placebo (21.5%) than in the propranolol (12.5%) group 
(RR 0.42; 95% CI 0.09, 0.63; P = 0.016) (231). It has been suggested that reduction in 
myocardial oxygen consumption may have accounted for the observed beneficial effect of 
propranolol. Another mechanism of benefit that has been suggested is an increase in the 
endocardial/epicardial ratio of tissue perfusion in the ischaemic area (232).  
 
Adenosine 
Adenosine is a naturally occurring nucleoside with a half-life in blood of less than 10 seconds. 
Adenosine, administered via the intravenous or intracoronary route, produces a hyperaemic 
effect that is commonly used in the measurement of coronary flow reserve and fractional 
flow reserve during PCI (233). Intra-coronary adenosine infusion, which pharmacologically 
mimics preconditioning, has been shown to significantly decrease peri-procedural cardiac 
enzyme rise in a small randomised study by Desmet et al. (234) in 2002, involving 28 
patients. This study, however, involved infusion of adenosine over 10 minutes followed by 90 
seconds of balloon inflation. A more recent randomised placebo controlled trial involving 62 
patients undergoing non urgent PCI, showed reduction in peri-procedural biomarker 
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elevation in patients randomised to receive a bolus of intracoronary adenosine 50µg before 
‘wiring’ as compared to placebo group (adjusted OR = 0.19, 95% CI:0.05–0.75, P =0.017) 
(235). Larger studies are required to establish adenosine’s benefit and feasibility for routine 
adoption.  
 
Trimetazidine 
Trimetazidine is a piperazine derivative anti-anginal drug with a vasodilatory effect on 
coronary arteries and has been extensively studied due to its additional cardioprotective 
preconditioning properties. The mechanism of cardioprotection by trimetazidine appears to 
be modulation of mitochondrial homeostasis downstream of the preconditioning pathway 
(236). One placebo controlled randomised controlled trial involving 266 patients studied a 
loading dose of 60mg trimetazidine 30 min before re-canalisation; This study showed 
significant reduction in post-procedural Troponin I levels in the Trimetazidine group at all 
time points and also a significant reduction in the total Troponin I area under the curve 
(237).  
 
Other Drugs of Promise 
Cyclosporin-A and Erythropoietin are currently under investigation for usefulness in 
preventing peri-procedural myocardial injury. The cardioprotective effect of Erythropoetin 
appears to be due to activation of pro-survival kinases in the RISK (Reperfusion Injury 
Signalling Kinase) pathway (238) and that of Cyclosporin-A due to direct attenuation of 
mitochondrial permeability transition pore opening (mPTP) and preservation of 
mitochondrial function.(239) Cyclosporine’s role in reducing reperfusion injury in primary 
PCI setting was shown by Ovize et al. (240) but its role in reducing PMI in elective PCI 
settings still needs to be established. Erythropoietin has been evaluated in the settings of 
acute MI patients undergoing primary PCI and the results have been disappointing and in 
fact showing higher adverse event rates (241, 242).  
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Non pharmacological interventions 
 Ischaemic and Remote Ischaemic Preconditioning  
Ischaemic preconditioning and remote ischaemic preconditioning in the context of peri-
procedural myocardial injury and peri-operative myocardial injury will be discussed at the 
end of this section in detail. 
 
1.10.2 Therapeutic strategies to protect from peri-operative myocardial Injury during 
CABG 
The myocardial injury sustained during CABG is dependent on mainly the type of cardiac 
surgery, the duration of surgery in terms of cross clamp time and cardio pulmonary bypass 
time, concomitant valve surgery, the type of electro-mechanical arrest strategy used for 
myocardial preservation (cardioplegia/cross clamp fibrillation/ off pump surgery) and 
substrate enhancement of the cardioplegic solution. Along with these, direct handling of the 
heart and injury due to cardiotomy through myocardium that is performed in valvular 
surgeries are other sources of myocardial enzyme release.  
Consequently the focus in improving the outcomes during CABG has always been, to 
maintain low ischaemic time, improving the cardioplegic substrate enhancement, and 
maintenance of hypothermia. These strategies and their evolvement over the years have 
been discussed in the earlier section. There are, however, other cardioprotective 
interventions, which can modify ischaemia-reperfusion injury and these will be discussed 
here. Broadly these can be summarised as 
1. Preconditioning 
2. Antioxidants 
3. Calcium channel blockers 
4. Phospholipase A2 inhibitors 
5. Na+-H+ echanger inhibitors 
6. Protein phosphatise inhibitors 
7. Phosphodiesterase inhibitor – pentoxifylline 
8. 5 HT receptor antagonists. 
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Preconditioning  
Ischaemic preconditioning, remote ischaemic preconditioning and anaesthetic 
preconditioning in the settings of CABG would be discussed in detail at the end of this 
section.  
Antioxidants 
Reactive oxygen species (ROS) in the form of superoxide anion (O2-), hydrogen peroxide 
(H2O2), hydroxyl radical (OH), reactive nitrites and nitrates are well known to be produced 
during ischaemia reperfusion injury (243). By their nature, ROS can attack virtually all 
cellular targets nonspecifically. In addition to altering membrane integrity and permeability, 
ROS also denature proteins, causing a loss in normal enzyme activity (244). In addition, they 
interfere with the sarcoplasmic reticulum calcium transport and potentiate inflammatory 
responses, by acting as chemotactic agents (244). Therefore exogenous antioxidant 
administration has been studied in ischaemia reperfusion injury settings. N- acetyl cysteine 
(NAC) has been shown in clinical CABG settings, to reduce ROS levels in coronary sinus blood 
but studies looking at post-operative myocardial enzymes are not promising (245, 246). 
Similarly, Allopurinol has been shown to reduce inotropic score and hospital stay, when used 
preoperatively, in patients undergoing valvular heart surgery, but without much effect on 
myocardial enzyme levels (247). In the laboratory settings, superoxide dismutase (SOD), 
Coenzyme Q10, oxypurinol, N-2 mercaptopropionyl glycine, melatonin and desferrioxamine 
have all been shown to be beneficial in ischaemic reperfused hearts (248-251).  
 
 
Calcium Channel Blockers 
Calcium channel blockers are known to protect myocardium in ischaemia reperfusion 
settings through various mechanisms, which include coronary vasodilatation, energy sparing 
effect resulting in lower ATP depletion, slower loss of adenosine precursors, protection of 
sarcolemma, and retardation of early rise in cytosolic Ca2++(252). Diltiazem infusion peri-
operatively has been shown to reduce postoperative myocardial enzyme release in one 
study(253) and intravenous nifedipine in another study on CABG patients has been shown to 
decrease ischaemic burden (254).  
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Phospholipase A2 Inhibitors 
Phospholipase A2 inhibitors, which aid in protecting cell membrane integrity, are known to 
render protection against ischaemia-reperfusion damage. Manoalide, Mepacrine, 
chlorpromazine and MR-256 are known to be beneficial in myocardial ischaemia reperfusion 
settings in animal models; their exact mechanism of protection is still largely unknown, with 
no human clinical studies yet (255-257).  
 
Na+-H+ Exchanger inhibitors 
As discussed previously Na+-H+ Exchanger activation under ischaemic condition with low pH, 
leads to further Na+ retention, which leads to Na-Ca exchanger activation leading to calcium 
entry to cell, which leads to intracellular damage. Therefore Na-H inhibitors are researched 
for their cardioprotective effects. Amiloride and Cariporide are shown in animal heart 
models to reduce infarct size, in myocardial ischaemia reperfusion models (258). Cariporide 
is shown to cardioprotect in clinical setting of CABG with reduction in postoperative MI and 
mortality in the CABG subgroup of the GUARDIAN study (259). However, recently published 
EXPEDITION trial showed slightly higher mortality in Cariporide treated patients, although 
incidence of perioperative MI was significantly reduced in this group (260).  
 
Protein phosphatase inhibitors, phosphodiesterase inhibitor- pentoxifylline and 5-HT 
receptor antagonists are the other agents studied in the settings of ischaemia reperfusion 
injury, however it is yet to be shown if they are cardioprotective in the clinical settings (252).  
1.11 Ischaemic Preconditioning in Myocardial Revascularisation  
 
Myocardial Ischaemic preconditioning, as described in previous section is a powerful 
endogenous cardioprotective phenomenon protecting heart from lethal ischaemic insult, 
when pre-exposed to sub lethal episodes of ischaemia and reperfusion. As myocardial 
revascularisation is a typical example of predictable settings of ischaemia reperfusion injury, 
preconditioning is a very attractive concept in this setting to prevent myocardial injury. 
Consequently, this strategy has been evaluated in both PCI settings and CABG settings. 
Laskey in 1999 (261), in a group of patients with various unstable ischaemic syndromes 
undergoing PTCA, showed that a preconditioning protocol of 90 second balloon inflation of 
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the target artery followed by 5 minute reperfusion, a cycle repeated twice, reduced CK 
enzyme elevation post procedure. However, this study was not strictly evaluating 
‘preconditioning’, as patients in this study included acute MI patients and unstable angina 
patients. In MI patients, the protocol applied cannot be called IPC, rather it is IPostC. During 
PTCA, multiple balloon inflations of each at least 60 seconds were routine, and therefore 90 
seconds inflation as a preconditioning stimulus, was very much plausible. However, with the 
current PCI strategies with stent usage, balloon inflation rarely exceeds 30 seconds and 
multiple balloon inflations are not common. Consequently, a preconditioning stimulus of 2 
cycles of 90 second balloon inflations with 5 minutes of reperfusion in between those 
inflations is not very attractive for most cardiologists, who probably view this as very 
invasive.  In CABG settings, there are many studies, which have evaluated the effect of IPC. 
Our research group in 1993 was the first to demonstrate the beneficial effect of IPC in CABG 
settings. IPC with 2 cycles of 3 minute aortic cross clamping separated by 2 minutes of 
reperfusion, before the more prolonged intermittent cross-clamp fibrillation in these 
patients resulted in higher ATP levels in myocardial biopsies (262). In another study, our 
group showed reduction in myocardial injury as indicated by a significant reduction in 
Troponin –T release in similar CABG settings (263). Since then, there has been multitude of 
studies showing cardioprotective benefits in terms of cardiac enzyme release, improved LV 
function and lower ionotropic scores in patients undergoing IPC in both cardioplegia settings 
and in cross clamp fibrillation settings. These studies are reviewed in detail by Venugopal et 
al. (264). Very few studies have refuted the cardioprotective effect of IPC in CABG settings 
and it appeared that these studies had either different IPC protocols or different cardioplegia 
delivery method (265-267). In spite of these evidences, surgeons do not routinely adopt IPC 
as this intervention could prolong their surgery and due to lack of clarity regarding accurate 
preconditioning protocols.  
 
1.12 Remote Ischaemic Preconditioning in Myocardial Revascularisation 
 
Certainly being less invasive, remote ischaemic preconditioning (RIPC) has become an 
attractive strategy for reduction of revascularisation related myocardial injury. As the 
concept is relatively new, there are many ongoing studies evaluating the effect of RIPC in 
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various clinical cardiac settings. In the elective PCI settings, Hoole et al. (268) have shown 
that remote preconditioning by 3 cycles of 5 minute forearm ischaemia followed by 5 
minutes of reperfusion reduced post procedure cardiac Troponins at 24 hours, as well as 6 
months cardiac and cerebral events rate. A previous smaller study by Ilidromitis et al. (269) 
had failed to demonstrate any improvement in cardiac enzymes in single vessel disease 
patients undergoing elective PCI. As RIPC typically needs to be applied before the onset of 
sustained ischaemia, it cannot be applied in the settings of acute MI as one cannot predict the 
onset. Consequently remote post-conditioning strategies are used in these circumstances. 
This applies during thrombolytic therapy in acute MI as well. The other setting where RIPC 
could be possibly of benefit is in the setting of urgent in-hospital PCI other than ST elevation 
MI presentations. These settings include patients presenting with Non-ST elevation acute 
coronary syndromes (NSTEACS). In these patients, there are unstable plaques in coronary 
arteries; however the vessel is still patent. So, the predominant injury sustained during PCI 
procedures is peri-procedural myocardial injury (PMI) to which RIPC might be of benefit 
similar to the benefit in elective PCI settings. The other settings where RIPC could be of 
potential benefit include rotablation for chronic total occlusions, and in settings of trans-
catheter aortic valve implantation (TAVI). Both these settings are known to release large 
embolic particles, and consequently myocardial injury could be expected. In CABG settings, 
our group was the first to show that RIPC with 3 cycles of 5 minutes fore-arm ischaemia and 
5 minutes of reperfusion using a blood pressure cuff, could reduce postoperative Troponins 
over 72 hours by 43% (79). This study included CABG patients receiving blood cardioplegic 
arrest or cross clamp fibrillation as a surgical cardioprotection strategy. In a separate study, 
involving only patients receiving blood cardioplegia, we have shown that similar trend 
persisted with 42% reduction in postoperative mean Troponin levels (270). Diabetic patients 
were excluded in this study. A recent study by Thielman et al. (271) has shown that in 
patients receiving crystalloid cardioplegia during CABG procedures for 3 vessel disease, RIPC 
reduced postoperative Troponins over 72 hours by 44.5%. The two latter studies described 
included a non-diabetic population only. However, two recent studies have failed to 
demonstrate any clinical or biochemical superiority of RIPC in the settings of elective CABG. 
These include a large double blind randomised study involving 162 patients undergoing 
elective CABG with standard blood –cardioplegia by Bonser et al. (272) and another smaller 
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study involving 54 patients undergoing elective CABG with either cardioplegia or cross –
clamp fibrillation as myocardial preservation strategy by Kunst et al. (273).  
 
1.13 Anaesthetic Preconditioning 
 
Pharmacological mimics of ischaemic preconditioning have always interested researchers. 
Interestingly, few volatile anaesthetics, which are routinely used in major surgical 
procedures have been identified to possess inherent ability to induce preconditioning in 
myocardium. Kersten et al. (274) in 1997, first showed that isoflurane mimics ischaemic 
preconditioning via activation of KATP channels in canine hearts. This finding also triggered 
more research into the mechanisms involved in anaesthetic preconditioning. Subsequently, 
the involvement of protein kinase C, mitogen-activated protein kinases, adenosine type 1 
(A1) receptors, reactive oxygen species, and endothelial nitric oxide synthase have been 
shown to mediate volatile aneasthetics mediated preconditioning (275-280). It was initially 
thought that IPC and anaesthetic preconditioning shared the same signal pathway. However, 
in 2004, Sergeev et al. (281) demonstrated that anaesthetic induced preconditioning was 
associated with a more homogenous and predictable cardioprotective phenotype at a 
transcriptional level compared with IPC. Using a proteomic approach, it was shown that 
volatile anaesthetics induce long lasting changes in the expression profile of 106 proteins, 
which are related to their cardioprotective effect (282). Recently, involvement of pro-
survival kinases such as PI3/Akt(283) and the transcription factor HIF-1(284) has also been 
shown with volatile anaesthetic preconditioning. Isoflurane, enflurane, halothane and 
recently sevoflurane are the volatile anesthetic agents mostly studied so far. 
It is important to note that β-blockers may adversely affect anaesthetic preconditioning. 
Several studies have shown that anaesthetic mediated cardioprotection is abolished by 
propranolol and esmolol during anaesthetic induced preconditioning (285-287). This is 
particularly relevant in patients undergoing cardiac surgeries as most of the patients are on 
β-blockers as anti-anginal medication and/or as cardiac failure medication. Another 
important context where anesthetic preconditioning is shown to have less effect is in 
patients with diabetes and in the context of hyperglycemia (288). Diabetic hearts are less 
susceptible to anaesthetic preconditioning, possibly due to sharing similar pathways of 
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ischaemic preconditioning. Diabetes and preconditioning will be discussed in slightly more 
detail in the next section.   
  
1.14 Myocardial Revascularisation in Diabetic Patients  
 
The incidence of diabetes mellitus (DM) - a metabolic disease is increasing in an alarming 
rate throughout the world. Globally, the estimated diabetes prevalence for 2010 is 285 
million and is expected to affect 438 million people by 2030 (289). In the UK, there are 2.6 
million people who have been diagnosed with diabetes in the UK (2009) which is 4.1 % 
average prevalence and is estimated that 4 million people would be diabetic by 2025 (290). 
90% of the people who have diabetes are Type 2 diabetic (291). The remarkable rate at 
which this particular disease has progressed confirms that diabetes is one of the biggest 
health challenges facing the UK today. Both Type 1 and Type 2 diabetic patients are at risk of 
cardiovascular complications. In the UKPDS Study (the largest prospective study of diabetes 
patients), macro-vascular disease (coronary artery disease, stroke and peripheral vascular 
disease) occurred in 20% of Type 2 DM, and macro-vascular disease was responsible for 
59% of death in these patients (292). The impact of coronary artery disease in these patients 
has immense implications with increased MI incidence compared to non-diabetics. The 
Framingham heart study estimated that ischaemic heart disease accounts for more than 50% 
of death in diabetic patients (293). Type 2 diabetics without a prior infarction are at the same 
risk for MI and coronary mortality as non diabetics with a prior MI (294). It is now well 
known that diabetic patients also have worse prognosis after an acute myocardial infarct 
compared to non diabetics in terms of mortality, re-infarction rates and heart failure rates 
(295-297). Consequently, both primary and secondary care of a diabetic population who are 
at risk, and who present with ischaemic heart disease assumes a significant place in health 
care provision. Diabetic patients also have a higher incidence of multi-vessel disease 
compared to non-diabetic patients. In the TAMI trial 66% of the diabetic patients had multi-
vessel disease (295).  
The extent of coronary disease and its diffuse nature in a diabetic population poses unique 
challenges during revascularisation procedures. The prognosis after cardiac 
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revascularisation procedures is also worse in a diabetic population compared to non-
diabetics. In patients undergoing PCI, diabetics have higher re-stenosis rates and lower event 
free survival compared to non diabetics (298, 299). This trend also applies to surgical 
revascularisation procedures.  In patients undergoing CABG, both short term (30 days) and 
long term mortality (5yr and 10 yr) are higher among a diabetic population compared to 
non-diabetics (300, 301). It appears, therefore, that diabetic patients being more vulnerable 
to peri-operative risks should be better cardioprotected during cardiac surgeries. 
  
1.14.1 Ischaemia Reperfusion Injury in Diabetic Heart 
 
The diabetic heart response to ischaemic injury has been a matter of debate over many years. 
There exists controversy, as to whether the diabetic heart is more or less sensitive to 
ischaemic injury. Also, type 1 diabetic heart experiments and type 2 diabetic models have 
yielded different results, and this has further compounded the generalisation of ischaemic 
response in diabetic hearts. Among the animal models available, those developed in rodents 
have been studied most thoroughly, for reasons such as short generation time, inherited 
hyperglycaemia and/or obesity in certain strains, and economic considerations (302). Type 1 
diabetes in rats is induced my injection of either Streptozocin or Alloxan, which are toxic 
glucose analogues, that preferentially accumulate in pancreatic beta cells via the GLUT2 
glucose transporter. They are lethal to these cells and hence are diabetogenic. Type 2 diabetic 
rats are inbred rats and these spontaneously diabetic rodent models include OLETF rats, 
Goto Kakizaki (GK) rats, db/db mice, Zucker diabetic Fatty (ZDF) rats, and ob/ob mice. While 
the GK rats appear to be a suitable model for non-obese diabetes, ZDF rats are generally 
applied to studies of diabetes with obesity and cardiovascular complications due to the 
dyslipidaemia background (302).  
In type 1 diabetic canine models, some studies have shown an increased susceptibility to 
ischaemia in the myocardium resulting in larger infarct size and more severe rhythm 
disturbances (303, 304). However, few studies involving rat models have shown that type 1 
diabetic myocardium is paradoxically more resistant to ischaemia, resulting in limitation of 
infarct size (305). Similar findings were also shown in a rabbit diabetes model by Hadour et 
al. (306). In a recent in vivo study, Galagudza et al. (307) have shown that alloxan induced 
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diabetic rats of more than 6 weeks duration, had significantly less infarct size compared to 
controls for 30 minute ischaemia followed by 60 minute reperfusion, and ischaemic 
preconditioning has no further protective effect on diabetic hearts. Compared to in-vivo 
studies, most of in-vitro models have been consistent in demonstrating more resistance in 
diabetic hearts for severe ischaemia (305, 308). The possible explanations for these 
discrepancies are reviewed by Feuvray et al. (309). and Paulson et al. (310). In summary, the 
sensitivity of the diabetic heart to ischaemic injury depends upon the experimental 
conditions. With only a few exceptions, most studies showing lesser sensitivity to 
ischaemic injury in diabetes model used animal models with short duration of diabetes, 
employed zero flow ischaemia and had glucose as the only metabolic substrate. Most of the 
studies with longer duration of diabetes, if fatty acids were present and/or a model of low-
flow ischaemia were used; the diabetic heart was more sensitive to ischaemic injury than 
non-diabetic hearts.  The degree of flow reduction during ischaemia is thought to play an 
important role in determining the ability of diabetic hearts to recover from a period of 
ischaemia and reperfusion. During zero-flow ischaemia, glycolysis and subsequent acidosis 
may be detrimental to the cell. In these settings, the altered glucose metabolism in diabetic 
heart with decreased glycolytic flux is believed to be beneficial, as it attenuates production 
of glycolytic products –lactate and H+ load. In addition, the diabetic heart exhibits a 
decrease in the activity of Na+/H+ and Na+/Ca2+ exchangers, and in conjunction with lower 
glycolytic rates during ischaemia this may result in reduced accumulations of Na+, and 
consequently during reperfusion, there is lesser gradient for reverse mode of 
Na+/Ca2+exchanger. This results in reduced Ca2+ influx limiting the injury in the diabetic 
heart. In contrast, during low flow ischaemia, the degree of intracellular lactate is less due to 
washout. Under these conditions, glycolysis may be beneficial, particularly to the diabetic 
heart that already has reduced rate of glycolysis. Many of the studies showing increased 
sensitivity to ischaemic injury had employed low flow ischaemia in their models (311-314).  
 
The duration of the diabetes induction has also been an important factor in determining 
the sensitivity of ischaemia in diabetic myocardium. Two stages of experimental diabetes 
mellitus are identified- acute (1-3 weeks) and chronic (6-9 weeks) (315). Diabetes 
induction for more than 6 weeks in rat models, have mostly yielded results showing 
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increased sensitivity to ischaemia.  Tosaki et al. (316) clearly demonstrated that even in the 
zero-flow ischaemic conditions, the duration of a diabetic state influences the ischaemia 
reperfusion injury. In their isolated heart models, 2 week old diabetic hearts demonstrated 
reduced incidence of ventricular arrhythmias and improved contractile function, relative to 
age matched control hearts following 30 minute global ischaemia followed by reperfusion. 
This protection was lost in 4-week and 6-week diabetic hearts, and 8-week old diabetic 
hearts exhibited depressed recovery after global zero-flow ischaemia compared to the 
control rats. 
In isolated heart models of type 1 diabetes, lesser susceptibility to reperfusion arrhythmias 
in the initial 2 weeks of diabetes induction has been shown and this protection appears to be 
lost with progressive diabetes (4,6 and 8 weeks) (316).  
 
Lastly, presence of exogenous fatty acids in the perfusion medium does influence the 
ischaemia reperfusion injury in diabetic heart models. This is particularly relevant in 
diabetes hearts, as hyperlipidaemia and diabetes are commonly coexistent. In DM1 rat 
models perfused under diabetic substrate conditions (elevated glucose and fattyacids) 
diabetic hearts recovered less contractile function compared to non-diabetic hearts even in 
presence of zero flow ischaemia (317). The exact mechanisms of the detrimental effect of 
fatty acids on IR injury specifically to DM hearts  are still unclear. 
Most of the studies on diabetic rat models have been on type 1 DM. There are limited studies 
evaluating type 2 DM (inbred) rat models for the response to ischaemia and reperfusion. The 
results of few studies, which have evaluated type 2 DM rats, have been interesting. 
In type 2 diabetic inbred rat models, both Zucker fatty rats and Goto Kakizaki rats were 
shown to be more resistant to ischaemic insult compared to non-diabetic rats, in a 
Langendorff perfused model for a 50 minute ischaemia followed by 120 minutes of 
reperfusion (318). These rats were studied when they were 16 weeks old. In another study 
by Anzawa et al (319), who evaluated ischaemic response in another inbred type 2 diabetic 
male Otsuka Long-Evans Tokushima Fatty (OLETF) rats at 16 and 32 weeks of age, it was 
shown that compared to control age matched non diabetic hearts, 32 weeks OLETF rats had 
exacerbated acidosis in their coronary effluent indicating greater propensity of ischaemic 
insult. This study, however did not find significant differences in acidosis of coronary 
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effluent, between 16 weeks OLETF rat hearts compared to their age matched non- diabetic 
rat hearts. In an in vivo study by Yue et al. (320), ZDF rats (12 to 14 weeks old) were shown 
to have bigger infarct size compared to Zucker lean rats (Non diabetes rats) for 30 minutes 
of LAD occlusion followed by 24 hours of reperfusion. Similar findings were reported in a 
prior in vivo IR model in db/db type 2 DM rats by Jones et al (321). Therefore, type 2 DM 
animal models have also revealed contradictory findings on the susceptibility to injury 
during ischaemia and reperfusion. It is a well-known phenomenon that type 2 diabetes is 
dominated by hyperinsulinaemia, hyperglycaemia, and dyslipidaemia, while Type 1 diabetes 
is characterised by insulinopenia, hyperglycaemia, and a largely unaffected lipid profile 
(318).  
 
1.14.2 Preconditioning the Diabetic Myocardium 
 
Although the susceptibility to ischaemia reperfusion injury in experimental and in vivo 
animal diabetic models has always been unequivocal, most studies evaluating whether 
ischaemic preconditioning would reduce IR injury in diabetic models have consistently 
shown inability in reducing IR injury. There was however, one study by Tatsumi T et al. (322) 
that observed reduction in IR injury when type 1 DM rats were preconditioned with 2 cycles 
of 5 min ischaemia and 10 min reperfusion before the rat hearts were subjected to a 30 min 
sustained ischaemia, in a isolated perfused model. These were Male Sprague-Dawley rats 
after 4 weeks of Streptozozin induced DM1. Ravingerova T et al. (323), in their Langendorff-
perfused model of Streptozocin-induced DM1 rats, observed that rats in their early phase of 
diabetes (1 week) were much resistant to IR injury related ventricular arrhythmia, and 
preconditioning with 1 cycle of 5 min ischaemia followed by 10 min reperfusion had no 
further benefit in subsiding V arrhythmia. However, older DM1 rats (9 weeks) had increased 
V arrhythmia comparable to non-diabetic hearts, and preconditioning significantly reduced V 
arrhythmias in this older diabetic group. Interestingly, a recent in vivo experiment by 
Galagudza et al. (307), which used 6 week old Alloxan-induced DM1 male Wistar rats, 
showed very different results from those of  Ravingerova T et al. (307). In this study, DM1 
rats had significantly less infarct size than control rats for 30 min sustained ischaemia, and 
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also had significantly less V arrhythmia. IPC with one episode of 5 minute ischaemia and 
reperfusion in DM rats, did not have any effect on infarct size reduction, and had only subtle 
beneficial effect on V arrhythmia (307).  
 
 
In type 2 diabetic inbred rat models, both Zucker fatty rats and Goto Kakizaki (GK) rats were 
shown to be more resistant to ischaemic insult compared to non-diabetic rats, and also 
preconditioning with 4 cycles of 2 min ischaemia and 3 min reperfusion had no beneficial 
effect in limiting infarct size in either of the diabetic rats (318). In our laboratory, we showed 
that in GK rats, a prolonged preconditioning protocol with 3 cycles of 5minute ischaemia and 
10 minute reperfusion can reduce the infarct size, however, with lesser preconditioning 
stimulus, the protection is not seen (324). The control group in this experiment was non-
diabetic Wistar rats. The diabetic GK hearts did show reduced infarct size to the index IR 
injury, compared to controls. It was also shown that this increased threshold was likely due 
to a defect in the PI3 Kinase- Akt pathway, resulting in lesser Akt phosphorylation in GK rats 
(324). This was the first study, which demonstrated that diabetic myocardium could be 
preconditioned, albeit with a higher threshold. The total Akt levels were the same in both 
diabetic rats and control rats, but it appears that phosporylation of Akt is deficient in diabetic 
rats. In a human atrial trabeculae model from our lab, Sivaraman et al. (325) showed that 
prolonged hypoxia preconditioning of 7 minutes followed by 16 minute reperfusion was 
cardioprotective in contractility recovery after sustained ischaemia in diabetic patients, 
whereas the standard protocol with 4 minute hypoxia could not caardioprotective. In 
contrast, control non-diabetic patients’ trabeculae had a cardioprotective effect even with the 
standard preconditioning protocol. Basal levels of Akt phosphorylation were less in 
trabeculae from diabetic patients.  In another GK rat model, from our lab, it was shown that 
levels of Phosphatase and Tensin homologue on chromosome 10 (PTEN), a recently 
discovered enzyme responsible for negatively regulating PI3 kinase pathway, is elevated in 
diabetic rat hearts (326). A recent study by Hassouna et al. (327) has  implicated 
mitochondrial dysfunction to the impairment of IPC in diabetic myocardium, raising 
possibility of dysfunctional mitochondrial KATP channels.  
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In summary, it appears that the diabetic hearts from animal models in particular 
circumstances, are more resistant to ischaemic injury, and although further reduction of this 
IR injury is possible through preconditioning, it requires an increased preconditioning 
stimulus.  
 
66 
 
2. AIMS AND OBJECTIVES  
In spite of significant advances in both surgical and percutaneous myocardial 
revascularisation procedures, significant peri-operative and peri-procedural myocardial 
injury still occurs, leading to worse outcomes after revascularisation procedures. Some 
groups of patients are at a higher risk of sustaining myocardial injury during 
revascularisation, and these subgroups would need better cardio-protection during these 
procedures so that the myocardium could resist and cope with the ischaemia-reperfusion 
injury sustained. As discussed in the previous chapter, patients with non-ST elevation acute 
coronary syndrome (NSTEACS) undergoing urgent in-hospital PCI are at an increased risk of 
peri-procedural myocardial injury. Similarly, in the setting of CABG, type 2 diabetic patients 
sustain increased peri-operative myocardial injury, and have increased morbidity and 
mortality. 
 
We evaluated the cardio-protective intervention (Remote Ischaemic Preconditioning) in 
these two high risk subgroups of patients, who are known to be susceptible for increased 
myocardial injury during revascularisation procedures i.e. a) patients who have had 
NSTEACS undergoing urgent in-hospital PCI procedures, and b) Type 2 diabetic patients 
undergoing cardiac bypass surgery. 
 
2.1 Overall Hypothesis 
 
Remote ischaemic preconditioning reduces myocardial injury in the myocardial 
revascularisation settings of coronary angioplasty and coronary artery bypass graft surgery. 
Hypothesis 1 
Remote Ischaemic preconditioning reduces myocardial injury in non-ST elevation acute 
coronary syndrome (NSTEACS) patients, undergoing urgent in-patient coronary angioplasty. 
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Hypothesis 2 
Remote Ischaemic preconditioning reduces myocardial injury in Type 2 diabetic patients, 
undergoing elective coronary artery bypass surgery. 
2.2 Overall Aim 
 
To study the effect of remote ischaemic preconditioning on the myocardial injury in 
NSTEACS patients undergoing coronary angioplasty, and to study the effect of remote 
ischaemic preconditioning on the myocardial injury in Type 2 diabetic patients undergoing 
elective coronary artery bypass surgery. 
2.3 Objectives 
 
a) To study the effect of remote ischaemic preconditioning on myocardial injury in 
consecutive patients admitted with NSTEACS (Unstable angina or Non-ST elevation 
myocardial infarction-NSTEMI), undergoing urgent in-hospital coronary angioplasty. 
b) To study the effect of remote ischaemic preconditioning on myocardial injury in Non-
ST elevation myocardial infarction (NSTEMI) subgroup of NSTEACS patients, 
undergoing urgent in-hospital coronary angioplasty. 
c) To study the effect of remote ischaemic preconditioning on myocardial injury in 
consecutive Type 2 diabetic patients, undergoing elective coronary artery bypass 
graft surgery with or without aortic valve surgery, irrespective of surgical myocardial 
preservation technique. 
d) To study the effect of remote ischaemic preconditioning on myocardial injury in Type 
2 diabetic patients, undergoing elective coronary artery bypass graft surgery, with or 
without aortic valve replacement using cardioplegia as the technique of myocardial 
preservation. 
e)  To study the effect of remote ischaemic preconditioning on short term outcomes after 
elective coronary artery bypass surgery in Type 2 diabetic patients. The short-term 
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outcomes selected in this study are based on those measured in other clinical studies 
on IPC and RIPC:  
1. Duration of ventilation support. 
2. Duration of intensive care unit stay. 
3. Inotrope score. 
4. Acute kidney injury over first three postoperative days. 
5. Incidence of cardiac arrhythmias. 
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3. REMOTE ISCHAEMIC PRECONDITIONING IN NON-ST ELEVATION ACUTE 
CORONARY SYNDROME (NSTEACS) PATIENTS UNDERGOING PERCUTANEOUS 
CORONARY INTERVENTIONS. 
Remote ischaemic preconditioning in the form of transient limb ischaemia is a simple, non-
invasive intervention, which is easily applicable to clinical settings. As discussed previously, 
the protocol was first standardised by Kharbanda et al. (67) in normal human volunteers 
with transient upper limb ischaemia as remote preconditioning stimulus in a study 
demonstrating endothelial protection. The same group subsequently showed that this 
remote preconditioning effect has both early and delayed phases, both of which were 
dependent on the neuronal mechanism that could be blocked by administration of ganglion 
blocker trimetaphan (69). In a later study, they also showed that the protective endothelial 
effects through contralateral limb ischaemia can be reproduced by administering the 
protocol after the index limb ischaemic episode – remote ischaemic postconditioning, and 
that both RIPC and RIPostC were dependent on the opening of the mito-KATP channel (328).  
The first clinical study utilising this remote preconditioning protocol was performed by 
Cheung et al. (329), who demonstrated reduced Troponin I in children undergoing corrective 
surgery for congenital cardiac defects. In the settings of coronary angioplasty, Hoole et al. 
demonstrated reduced Troponin elevation at 24 hours post procedure in patients 
undergoing elective PCI, who were randomised to remote preconditioning (268). Our current 
study hypothesises, that remote ischaemic preconditioning (RIPC) induced by transient limb 
ischaemia and reperfusion, would reduce myocardial injury in adult patients admitted with 
non-ST elevation acute coronary syndrome (NSTEMI and Unstable angina) undergoing 
inpatient coronary angioplasty. 
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3.1 METHODS 
3.1.1 Overview 
 
We conducted a two Centre, open label randomised controlled study of the effect of RIPC 
induced by transient limb ischaemia on myocardial injury during urgent inpatient coronary 
angioplasty, among consecutive patients admitted with non-ST elevation acute coronary 
syndromes. 
3.1.2 Ethical Approval and Informed Consent   
 
The protocol for this study was written in accordance with the International Conference on 
Harmonisation - Good Clinical Practice (ICH-GCP) guidance, and the study was subject to 
approval by the joint University College London (UCL)/University College London Hospitals 
(UCLH) committees for the ethics of human research. Approval for the study was sought on 
the standard application form initially provided by the NHS COREC (Central office for the 
Research Ethics Committees), and subsequently integrated with the National Research Ethics 
Service (NRES), affiliated to the National Patient Safety Agency (NPSA). In addition to the 
study protocol, the patient information sheet, consent form, and letter to the patient’s 
general practitioner, were also approved by the ethical committee. 
Once ethical approval was obtained, a separate application was made to the research and 
development (R&D) department UCLH, who also acted as sponsors of the study. Any 
amendments to the protocol were classed as major or minor, as per advice from the ethical 
committee. I made the amendments and submitted the documents, annotated with 
appropriate dates and version numbers for approval for each amendment. A separate site-
specific information (SSI) form was submitted to Surrey Research Ethics Committee, 
Guildford for including a second recruitment centre, East Surrey Hospital. 
 Any serious adverse event or reaction during the course of the study had to be reported to 
the R&D department as per guidelines. No serious adverse events or reactions occurred 
during the course of this study. 
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Patients admitted with NSTEMI and unstable angina awaiting urgent inpatient coronary 
angiography, were approached after a decision for the coronary angiography was made. 
Informed consent was obtained using the current version of the patient information sheets, 
and consent forms, and patients’ signatures obtained. A copy of the signed consent form and 
the patient information sheet were given to the patient, and the original forms filed in the 
hospital notes. An additional copy of the signed consent form was filed at the Hatter 
Cardiovascular Institute, for patients recruited at the Heart Hospital, and at East Surrey 
Hospital for patients recruited at Surrey and Sussex NHS Trust. 
3.1.3 Patient Recruitment 
 
Consecutive patients admitted with NSTEACS, between September 2008 and September 
2010, were screened for recruitment into the study. At the East Surrey Hospital site, the 
patient recruitment for this study was started from February 2009. 
3.1.4 Inclusion Criteria 
 
• Age > 18 years. 
Consecutive patients admitted with NSTEACS (NSTEMI and Unstable angina) undergoing in-
hospital coronary angioplasty. NSTEMI is defined as Troponin positive chest pain among 
admitted patients. Unstable angina is defined as cardiac sounding chest pain, with ECG 
changes of myocardial ischaemia among admitted patients. 
3.1.5 Exclusion criteria 
 
• Renal failure (EGFR <35 ml/min/1.73m2) 
• Patients with Troponins levels, which are not stable and increasing, in bloods taken at 
least 6 hours apart before the coronary angiography. 
• Peripheral vascular disease affecting upper limbs 
• Cardiac arrest in the present hospital admission 
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• Patients on drugs Nicorandil or Glbenclamide. 
3.1.6 Randomisation and Transient Limb Ischaemia Protocol 
 
Patients were randomised to either the control group or the RIPC group, using electronic 
randomisation methods of random sequence generation for the two treatments. A simple 
randomisation method was used to allocate patients to receive either RIPC or a placebo. 
http://www.random.org/sequences/ 
RIPC was induced by transient limb ischaemia in patients randomised to receive the 
intervention. This was achieved by inflating a standard 9 inch blood pressure cuff to 200 
mmHg on the upper arm for five minutes, for three cycles each separated by a reperfusion 
period of five minutes, during which time the cuff was kept deflated. A similar protocol was 
first used by Kharbanda et al. (67), to induce remote endothelial preconditioning in the 
contra-lateral limb in normal human volunteers.  
The protocol was applied to the right arm whenever possible, but if a continuous intravenous 
fluid/drug infusion was already established in right arm, the RIPC protocol was applied on 
the left arm. The protocol was commenced on the day of the angiography procedure and was 
timed around an hour before the coronary angiography procedure. If the angiography was 
delayed more than three hours after RIPC, the patient was excluded from the study. 
Loukogeorgakis et al. (69), in their characterisation model of remote preconditioning in 
human volunteers, have shown that the endothelial protection conferred by RIPC disappears 
after 4 hours of preconditioning stimulus.  
3.1.7 Percutaneous Intervention (PCI) Procedure 
 
Twelve lead ECG traces were recorded before the procedure, and the findings were recorded 
in all recruited patients. The consultant performing the coronary angiography decided the 
choice of arterial access. Once the arterial sheath was inserted (femoral/radial/brachial), a 
blood sample from the arterial sheath was taken to determine the baseline (Zero hour) 
Troponin T and CKMB levels. The coronary angiography was done in all patients before a 
decision of proceeding to PCI was made. The interventional consultant responsible for the 
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coronary angiography determined if the patients were to proceed to PCI, based on the 
clinical and angiographic assessment. 
If the patients did not proceed to PCI, they were excluded from taking further blood samples. 
The patients, who were proceeded to PCI were monitored throughout the procedure, and 
procedural details were clearly recorded. The interventional consultant performing the 
procedure determined the choice and sizes of catheters and stents. Detailed interventional 
events and parameters were recorded during the procedure. Any complications during the 
procedure were also recorded. 
Post PCI procedure, all patients were transferred to either the recovery unit or coronary care 
unit, and any post procedure events until their discharge from the hospital were recorded. 
The interventional consultant determined if the patients were required to have GP3a2b 
inhibitor post procedure, and this was recorded.  
 
3.1.8 Serum TroponinT and CK-MB Measurement 
 
Blood samples were taken for cTnT and CK-MB levels at the time of arterial sheath insertion 
(0 hour), and at 6 hours, 12 hours, and 24 hours post PCI procedure. In both recruiting 
Centres, cTnT was measured quantitatively by a one-step enzyme immunoassay based on 
electrochemiluminescence technology (Elecsys 2010; Roche). The lower detection limit of 
this assay (99th percentile URL) is 0.01 µg/L, with a co-efficient of variation of 10%, and 
recommended diagnostic range of 0.03-0.09 µg/L indicating possible myocardial injury and a 
threshold of > 0.1µg/L indicating myocardial injury suggestive of myocardial infarction. 
CK-MB mass assay in both the recruitment centres were measured using Elecsys 2010 CK-
MB STAT assay (Roche Diagnostics). The lower detection limit of this assay (99th percentile 
URL) is 4 µg/L and coefficient of variation < 10% with a recommended diagnostic level of > 4 
µg/L indicating myocardial injury. 
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Enzyme level parameters were compared with respect to mean increase at individual time 
points, proportional increase from baseline levels, and area under the curve (AUC) of enzyme 
levels over 24 hours. 
 
3.1.9 Statistical Analysis 
 
Standard statistical methods were used for analysis. Histograms with normal plots were 
performed to check normal distribution in the two groups. Differences between the groups 
for continuous variables were tested using the analysis of variance (ANOVA) test, and for 
categorical variables using Chi-square test. The general linear multivariate model was used 
to test for multivariate analysis. Area under the Curve (AUC) analysis was performed using 
the trapezoid rule. Significance was interpreted at the 95% confidence interval, having 
corrected for any inequality of variance between the groups. The data analysis was based on 
intention to treat. Data were analysed using SPSS statistical software version 16. 
3.1.9.1 Sample Size Calculation 
 
In a recent large prospective study, the incidence of cTnT elevation >0.03µg/L after PCI 
procedures was reported to be 46% in patients with normal baseline cTnT levels, and 80% in 
patients who have already raised Troponins at baseline (330). As our patient cohort involved 
patients with unstable angina (normal baseline cTnT levels), and patients with NSTEMI 
(elevated baseline cTnT levels), we assumed an incidence of 60% for cTnT elevation 
>0.03µg/L, above the baseline level in our patient cohort undergoing PCI. Therefore, for a 
reduction of 20% absolute incidence from 60% to 40% we needed 95 patients in each group 
at 5% significance and 80% power. 
3.2 RESULTS 
A total of 293 patients were screened for inclusion into the study.  10 patients refused to take 
part in the study; 3 patients had baseline renal dysfunction (EGFR <35mls/min/1.73m2); 3 
patients were unable to consent due to dementia. Therefore, 277 patients were randomised. 
There were134 patients in control group, and 143 patients in RIPC group. All 277 patients 
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underwent coronary angiography. 158 patients did not proceed for PCI. 51 patients had 
normal coronary arteries, 58 patients were referred to coronary artery bypass surgery 
(CABG), and 39 patients were suitable for medical management only.  
Among 119 patients who completed full study, 9 patients had their baseline Troponin levels 
(0 hour Troponin level) higher than the admission Troponin levels and therefore, excluded 
from further analysis. In total 110 patient’s data were included in the final analysis. 58 
patients were in control group, and 52 patients in RIPC group. 66 (60%) patients had 
NSTEMI with Troponin increase during admission, and 44 (40%) patients had unstable 
angina, with ECG changes of myocardial ischaemia at rest.  
Fig 1.  
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Fig 2 
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            293 
Patients randomised 
            277 
Control gp 
134 
RIPC gp 
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64 Patients  55 Patients 
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proceeded for 
PCI 
88 Not 
proceeded for 
PCI 
6 patients 
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troponins 
were 
increasing at 
0 hour 
3 patients 
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troponins were 
increasing at 0 
hour 
 
58 Patients 
(CONTROL) 
52 Patients 
(RIPC) 
16 patients excluded 
(Refused, unable to consent 
or eGFR <35) 
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3.2.1 Baseline Characteristics- Patient Profile 
The baseline characteristics of the entire cohort randomized and baseline characteristics of 
the patients who completed the study are depicted in the tables below separately I tables 
3.01 and tables 3.1. 
Table 3.01 
Demographics Control (n=134) RIPC (n=143) 
Age (years) 64.5 62.1 
Male 
Female 
81 
53 
96 
47 
Previous Angina 68 (50.8%) 54 (37.7%) 
Diabetes 40 (29.8%) 37 (25.8%) 
Hypertension 63 (47%) 72 (50.3%) 
Dyslipidaemia 48 (35.8%) 66 (46.1%) 
Pulmonary disease 7 (5%) 12 (8%) 
Mild Renal impairment 2 (1.4%) 2 (1.3%) 
Previous MI 23 (17.1%) 27 (18.8%) 
Current smoker 43 (32%) 54 (37.7%) 
Last Chest pain (before 
PCI) (hours) 
77 69 
Time to Intervention 
from first presentation 
(days) 
 
3.76 3.9 
Baseline 
Creatinine level 
76 81 
Mean Troponin-T levels 
at admission 
0.28 (SEM=0.06) 0.34 (SEM 0.06) 
Mean Troponin-T  levels 
at the time of PCI (0 hour 
level) 
0.15 (SEM=0.04) 0.28 (SEM = 0.04)) 
Mean CKMB level at the 
time of PCI (0 hour level) 
4.2 (SEM= 0.7) 5.32(SEM= 1.2) 
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Table 3.0.2 
Drugs Control RIPC 
Aspirin 120 (89.5%) 126 (88.1%) 
Statin 90 (67.1%) 93 (65%) 
Nitrate 14 (10.4%) 20 (13.9%) 
Beta blocker 52 (38.8%) 49 (34.2%) 
Ca2+ channel blocker 19 (14.1%)  27 (18.8%) 
Sulphonylurea 12 (8.9%) 9 (6.2%) 
ACE inhibitor 90 (67.1%)  86 (60.1%) 
 
In patients who completed the study, there were no significant differences between the 
control and RIPC groups, with respect to most of the baseline characteristics. The control 
group, however, had more patients with previous history of angina (44% vs. 25%; p = 0.04). 
The other characteristics, which were tending towards statistically significant difference, 
were: a) Diabetes, and b) Smoking history. A higher proportion of patients in the control 
group had diabetes (20.7% vs. 7.7% p =0.06). RIPC group had more smokers compared to 
the control group (42% vs. 24% p =0.06).  
The procedural delay from the time of admission to PCI was not different in the two groups 
(3.98 days vs. 3.78 days, p = 0.62). The procedural time delay from the time of the last chest 
pain was also not different between each group (79.1 hours vs. 67.3 hours, p = 0.23). 
Table 3.1 
Demographics Control (n=58) RIPC (n=52) 
Age (years) 62.05 60.9 
Male 
Female 
45 (77.6%) 
13 (22.4%) 
43 (82.7%) 
9 (17.3%) 
Previous Angina 26 (44.8%) 13 (25%) 
Diabetes 12 (20.7%) 4 (7.7%) 
Hypertension 25 (43.1%) 30 (57.7%) 
Dyslipidaemia 20 (34.5%) 22 (42.3%) 
Pulmonary disease 2 (3.4%) 4 (7.7%) 
Mild Renal impairment 0 (0%) 1 (1.9%) 
Previous MI 10 (17.2%) 11 (21.2%) 
Current smoker 14 (24%) 22 (42%) 
Last Chest pain (before 
PCI) (hours) 
79.1 67.3 
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Time to Intervention 
from first presentation 
(days) 
 
3.98 3.75 
Baseline 
Creatinine level 
82.21 82.92 
Mean Troponin-T levels 
at admission 
0.30 (SEM= .06) 0.35 (SEM=.07) 
Mean Troponin-T  levels 
at the time of PCI (0 hour 
level) 
0.17 (SEM=0.04) 0.29 (SEM = 0.05) 
Mean CKMB level at the 
time of PCI (0 hour level) 
3.91 (SEM= 0.3) 5.86 (SEM= 1.4) 
 
 
Table 3.1.1 
Drugs Control RIPC 
Aspirin 54 (93.1%) 50 (96.2%) 
Statin 47 (81%) 44 (84.6%) 
Nitrate 5 (8.6%) 7 (13.5%) 
Beta blocker 22 (37.9%) 28 (53.8%) 
Ca2+ channel blocker 9 (15.5%) 8 (15.4%) 
Sulphonylurea 3 (5.2%) 1 (1.9%) 
ACE inhibitor 25 (43.1%) 24 (46.2%) 
 
 
3.2.2 Pre-procedure Drug Profile 
There were no significant differences in the drug profile between both groups prior to the 
procedure. The drug profile of both groups is summarised in table 3.2. 
3.2.3 Baseline Characteristics : Peri-procedural Variables 
The peri-procedural variables in the two groups are summarised in table 3.3. All patients 
undergoing PCI had at least one stent deployed. Around 85% of patients in both groups had 
single vessel intervention. Most patients had drug eluting stents in both groups (90%). RIPC 
group had more patients receiving GPIIbIIIa inhibitors compared to control group, which 
was nearly statistically significant (13.7% vs. 3.5%, p = 0.08). There were no differences in 
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the number of balloon inflations, mean stent length or mean stent diameter between the two 
groups.  
 
3.2 Peri-Procedure Variables 
 
Variable Control RIPC 
GPIIbIIIa inhibitors 2 (3.5%) 7 (13.7%) 
No of vessels intervened 
(Mean) 
1.16 (SEM= 
0.048) 
1.15 (SEM= 0.05) 
No of balloon inflations 
(mean) 
6.93 (SEM= 0.60) 6.45 (SEM= 0.59) 
LAD intervention 25 (43.1%) 15(28.8%) 
Multiple vessel 
intervention 
9 (15.5%) 8 (15.4%) 
Pre-dilation 55 (94.8%) 49 (94.6%) 
Drug Eluting Stents 51 (87.9%) 47 (90.4%) 
No of Stents (Mean) 1.57 1.56 
Mean Stent length (mm) 33.06 30.96 
Mean Stent diameter 
(mm) 
3.04 3.22 
 
 
3.2.4 Serum CTnT Release 
 
Cardiac TnT levels were measured pre-procedurally (during access site puncture: 0 hour 
cTnT) and at 6 hours, 12 hours and 24 hours post procedure. The mean (+SD) cTnT levels at 
these time points are shown in table 3.3. 
 
Table 3.3 
 
Time (Hours) Control RIPC Mean 
difference 
Confidence 
interval 
P Value 
0 0.17 +0.36 0.29 +0.39 -0.113 +0.07 -0.25 - 0.03 0.12 
6 0.24+0.46 0.41+0.61 -0.17 +0.10 -0.37 - 0.03 0.10 
12 0.29+0.52 0.42+0.69 -0.13+0.11 -0.36 - 0.10 0.27 
24 0.27+0.44 0.37+0.57 -0.09+0.10 -0.30 - 0.10 0.34 
Values present mean + SD (in µg/L) 
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Percentage rise in 
troponins from base 
line 
6hrs 12hrs 24hrs 
Control 41.1% 70.5% 58.8% 
RIPC 41.3% 44.8% 27.5% 
 
 
 
 
There was no statistical difference in the cTnT levels in the blood samples at any time 
intervals post procedure. The mean baseline Troponin levels (0 hour troponins) of the RIPC 
group was higher than that of control group, [Mean (SD) of RIPC group 0.29(+0.39) µg/L vs. 
0.17(+0.36) µg/L in control group]. This baseline inequality leads to the appearance in the 
above graph, that  higher Troponin level are released at individual time points in RIPC group. 
However, the Troponin area under the curve (AUC) over 24 hours adjusted to the baseline 
Troponin levels, showed no statistical difference between the two groups (Mean +SD of 
Troponin AUC in RIPC group 9.45+13.8 vs. 8.97+10.7 in the control group, p =0.83). 
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3.2.5 Periprocedural Myocardial Infarction incidence (PMI) 
 
The incidence of PMI was calculated and compared between the two groups, and the results 
are summarised in the table 3.5. The new ‘universal definition of myocardial infarction’, 
defines peri-procedural myocardial infarction during PCI as an increase in cardiac enzymes 
more than 3 times ULN. In patients with already increased baseline Troponins, further 
increases in Troponin levels should be more than 20% of the baseline Troponin levels. An 
increase in cardiac enzyme level > 1 x ULN will still constitute periprocedural myocardial 
injury, however 3 x ULN increase will constitute periprocedural myocardial infarction. 
 
In our cohort of patients with NSTEACS, 55% of the patients undergoing in-hospital PCI had 
PMI according to the new universal definition of MI. There was, however, no difference in the 
incidence of PMI between the two groups for occurrence of PMI. These results are 
summarised below. 
Table 3.3.1 
PMI definition Control RIPC P value 
 
>0.03µg/L increase in the cTnT level from 
baseline (0 hour) level 
 
31 (53.4%) 
 
29 (55.8%) 
 
0.85 
>20% increase in cTnT level from baseline (0 
hour) level 
 
34 (58.6%) 
 
33 (63.5%) 
 
0.69 
>0.03µg/L increase and >20% increase in cTnT 
level from baseline (0 hour) level 
 
30 (51.7%) 
 
26 (50%) 
 
1.0 
CKMB mass increase >12µg/L (>3x ULN) from 
baseline level 
 
5 (8.6%) 
 
8 (15.4%) 
 
0.37 
Troponin increase > 1 x ULN (>0.01 µg/L) from 
baseline level 
 
34 (58.6%) 
 
33 (63.5%) 
 
0.69 
CKMB mass increase > 1 x ULN (>4.9 µg/L) 
from baseline level 
 
18 (31%) 
 
18 (34.6%) 
 
0.83 
 
 
3.3 Sub-group Analysis of Results in NSTEMI Cohort of Patients. 
 
Our patient cohort consisted of both NSTEMI and Unstable angina patients needing urgent 
in-patient PCI. 60% of this cohort (66 patients) had NSTEMI, and 40% constituted UA. We 
sub-analysed the NSTEMI cohort for the PMI incidence applying the universal definition of 
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MI and compared between the two groups. The baseline characteristics and the results will 
be discussed below. 
 
3.3.1 Baseline Patient Characteristics (NSTEMI COHORT) 
 
The baseline characteristics in both groups are well matched, with respect to most of the 
variables. However, the control group had significantly more patients with pre-existing 
angina (35.5% vs. 8.6%, p = 0.01). In addition, the control group had a higher number of 
diabetic patients, which nearly reached statistical significant (25.8% vs. 8.6%, p = 0.10). 
Table 3.4 
Demographics Control (n=31) RIPC (n=35) 
Age (years) 61.6 58.2 
Male 
Female 
25 (80.6%) 
6 (19.4%) 
29 (82.9%) 
6 (17.1%) 
Previous Angina 11 (35.5%) 3 (8.6%) 
Diabetes 8 (25.8%) 3 (8.6%) 
Hypertension 16 (51.6%) 18 (51.4%) 
Dyslipidaemia 11 (35.5%) 12 (34.3%) 
Pulmonary disease 0 (0%) 2 (5.7%) 
Previous MI 5 (16.1%) 6 (17.1%) 
Current smoker 11 (35.5%) 18 (51.4%) 
Last Chest pain (before 
PCI) (hours) 
72.8 65.2 
Time to Intervention 
from first presentation 
(days) 
 
3.7 3.5 
Baseline 
Creatinine level 
80.1 80.3 
Mean Troponin-T levels 
at admission 
0.56 0.51 
Mean Troponin-T  levels 
at the time of PCI (0 hour 
level) 
0.32 0.42 
Mean CKMB level at the 
time of PCI (0 hour level) 
4.5 7.2 
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3.3.2 Pre-procedure Drug Profile 
There were no significant differences in the drug profile between both groups prior to the 
procedure. The drug profile of both groups has been summarised in table 3.4. 
Table 3.4.1 
Drugs Control (n=31) RIPC (n=35) 
Aspirin 30 (96.8%) 35 (100%) 
Statin 26 9(83.9%) 31 (88.6%) 
Nitrate 1 (3.2%) 4 (11.4%) 
Beta blocker 13 (41.9%) 20 (57.1%) 
Ca2+ channel blocker 7 (22.6%) 4 (11.4%) 
Sulphonylurea 1 (3.2%) 0 (0%) 
ACE inhibitor 15 (48.4%) 16 (45.7%) 
 
3.3.3 Baseline Characteristics: Peri-procedural Variables 
The peri-procedural variables in the two groups are summarised in table 3.5. All patients 
undergoing PCI had at least one stent deployed. Around 85% of patients in both groups had 
single vessel intervention. There were no differences in the number of balloon inflations, 
mean stent length, or mean stent diameter between the two groups. The peri-procedural 
variables and their comparison between the two groups are listed in the table 3.5. 
3.5 Peri-Procedure Variables 
Table 3.5 
Variable Control (n=31) RIPC (n=35) P value 
GPIIbIIIa inhibitors 2 (6.5%) 5 (14.3%) 0.43 
No of vessels intervened 
(Mean) 
1.16 1.17 0.91 
No of balloon inflations 
(mean) 
6.58 6.86 0.79 
LAD intervention 12 (38.7%) 7 (20%) 0.11 
Multiple vessel 
intervention 
5 (16.1%) 6 (17.1%) 1 
Pre-dilation 29 (93.5%) 33 (94.3%) 1 
Drug Eluting Stents 27 (87.1%) 33 (94.3%) 0.40 
No of Stents (Mean) 1.39 1.60 0.25 
Mean Stent length (mm) 29.3 32.5 0.45 
Mn Stent diameter (mm) 2.99 2.92 0.52 
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3.3.4 Serum Troponin T Release 
Troponin T levels were measured pre-procedurally (during access site puncture: 0 hour 
cTnT), and at 6 hours, 12 hours, and 24 hours post procedure. The mean (+SD) cTnT levels at 
these time points are shown in table 3.6. 
Table 3.6 
Time (Hours) Control RIPC Mean 
difference 
Confidence 
interval 
P Value 
0 0.32 +0.46 0.42 +0.42 -0.10 +0.10 -0.32 - 0.11 0.34 
6 0.41+0.59 0.59+0.67 -0.18 +0.15 -0.50 - 0.11 0.24 
12 0.44+0.61 0.61+0.78 -0.16+0.17 -0.51 - 0.18 0.34 
24 0.36+0.49 0.51+0.63 -0.15+0.14 -0.43 - 0.13 0.29 
Values present mean + SD (in µg/L) 
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There was no statistical difference in the cTnT levels, at any time intervals post procedure 
between the two groups. The mean baseline troponin levels (0 hour troponins) of RIPC group 
was higher than that of the control group ( 0.42(+0.42) in RIPC group vs. 0.32(+0.46) in 
control group). This baseline inequality leads to the appearance, in the above graph, as 
higher Troponin release at individual time points in the RIPC group. However, the  Troponin 
area under the curve (AUC) over 24 hours adjusted to the baseline Troponin levels, showed 
no statistical difference between the two groups (Mean +SD of Troponin AUC in RIPC group 
13.5+15.2  vs. 11.96+13.05 in control group, p =0.64). 
 
3.3.5 Periprocedural Myocardial Infarction Incidence (PMI) 
 
The incidence of PMI was calculated and compared between the two groups, and the results 
are summarised in the table 3.7. The new Universal definition of myocardial infarction, 
defines peri-procedural myocardial infarction during PCI as an increase in cardiac enzymes 
more than 3 times ULN. In patients with already increased baseline troponins, further raise 
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in Troponins should be more than 20% of the baseline troponin levels. Therefore, in this 
NSTEMI cohort an increase in baseline Troponins more than 3 x ULN (> 0.03µg/L) and 
greater than 20% of the baseline (0 hour Troponins) were taken as PMI. 
 
Table 3.7 
PMI definition Control 
(n=31) 
RIPC 
(n=35) 
P value 
 
>0.03µg/L increase and >20% increase in cTnT 
level from baseline (0 hour) level 
 
16 (51.6%) 
 
20 (57.1%) 
 
0.65 
CKMB mass increase >12µg/L (>3x ULN) from 
baseline level and >20% increase from the 
baseline level 
 
2 (6.5%) 
 
8 (22.9%) 
 
0.09 
 
There was no statistically significant difference in PMI incidence between the two 
groupswhen the increase in Troponin levels  was compared according to the new universal 
definition of MI (51.6% in control group vs. 57.1% in RIPC group, p = 0.65). However, when 
the same criteria of PMI definition was applied to CKMB marker (> in 3x ULN plus 20% 
increase in the enzyme levels from baseline levels), a higher number of patients in the RIPC 
group had PMI, which was nearly statistically significant (6.5% in control group vs. 22.9% in 
the RIPC group). 
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3.4. DISCUSSION 
 
In this prospective, two-Centre open label randomized controlled trial, RIPC did not 
demonstrate a statistically significant benefit in the reduction of peri-procedural myocardial 
injury, determined by serial myocardial enzymes post percutaneous coronary interventions, 
in high risk patients. RIPC did not demonstrate reductions in the incidence of peri-procedural 
myocardial infarction either. In elective PCI settings, Hoole et al.(268) have demonstrated a 
significant peri-procedural myocardial enzyme reduction in their randomised controlled trial 
with similar RIPC protocol. A previous smaller study by Ilidromitis et al. (269), had failed to 
demonstrate any improvement in cardiac enzymes in single vessel disease patients 
undergoing elective PCI. There are several reasons, why our study with RIPC intervention 
fails to demonstrate significant benefit in myocardial enzyme release, compared to placebo. 
These issues will be further elaborated in this section. 
 
Firstly, our study is underpowered for the primary end point of 20% absolute reduction in 
the incidence of PMI, with 80% power and significance of 0.05. While calculating power, it 
was estimated that 93 patients in each group would be needed to reach the 80% power for 
the study. We estimated 1/3 of the patients undergoing urgent in-patient coronary 
angiography would not proceed for PCI, and therefore, estimated that a total patient cohort 
of 290 would be sufficient to reach the necessary power. However, in our study, 2/3 of the 
enrolled patients (n=153) did not proceed to PCI, with only 101 patients completing the 
study. Therefore, although pre-specified total number of patients based on intention to treat 
analysis (n=293) was achieved, the number of patients completing the study were 
insufficient to reach a negative conclusion from this intervention. In a positive clinical study, 
even if the study is underpowered, it is generally accepted to conclude in favor or against the 
hypothesis. However, in a negative study, reaching the pre-specified power is very important 
to conclude that the intervention is not different from the control group, with respect to a 
primary end point. Consequently, to reach the pre-specified power in our study, we have 
calculated that a further 250 patients would need to be recruited, to achieve a total of 186 
patients, who will have completed the study after exclusions. To this end, we have obtained 
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further amendments from the joint UCLH/UCL ethics committee, and are continuing to 
recruit patients in order to reach the pre-specified power.  
 
Secondly, the patient groups we studied are the patients presenting acutely with NSTEACS. A 
very valid possibility in these patients is that, the episode of NSTEMI/UA itself can provide a 
strong preconditioning stimulus, directly on the heart. There are however, no studies 
demonstrating this effect, as predicting an ACS event is any population is impossible.   The 
unstable thrombus in the denuded plaque is a source of recurrent ischaemia in these 
patients, which theoretically should precondition the heart directly. Consequently, the RIPC 
stimulus prior to the PCI procedure, may not have contributed further to the already 
preconditioned hearts in this group of patients.  
The mean duration from the last chest pain to PCI was around 3 days in both groups. Even if 
the direct myocardial preconditioning effect from the initial ischaemic event has 
disappeared, the myocardium should be ideally in the phase of second window of 
preconditioning during this period (3 days)(19). Therefore, RIPC stimulus is unlikely to have 
had a further protective effect in our cohort of patients. In elective PCI settings, the 
myocardium would not have had any recent ischaemic episode contributing for inherent 
preconditioning, and consequently neither any effect of second window of protection. 
Therefore, RIPC in this group of patients could be cardioprotective, and consequently 
decrease the peri-procedural myocardial injury. This probably explains why, in our study, we 
failed to demonstrate even a trend towards the benefit of enzyme reduction in the 
intervention group, whereas other investigators who studied RIPC in elective angioplasty 
settings, could show significant protection(163).  
 
Thirdly, although most of the pre-procedure variables were comparable between the two 
groups, a significantly higher proportion of patients in the control group had pre-existing 
diagnosis of angina prior to enrolment (45% in control gp vs. 25% in RIPC gp, p= 0.045). As 
angina is a known clinical ischaemic preconditioning stimulus by itself (331, 332), it is 
possible that these patients with angina in the control group are already in a cardioprotected 
state. This certainly could have contributed to the diminished protective effect in the 
intervention group, by decreasing the myocardial injury in the control group. A one way 
90 
 
between-subjects ANOVA test to determine the relationship between Troponin release (AUC) 
and angina as the independent factor, showed near significant results (mean Tr-AUC 6.57 in 
patients with angina vs. 10.64 in patients without angina, p= 0.09), prompting the theory that 
previous angina could be a strong cardioprotective confounder. However, even after 
adjusting this confounding effect in general linear univariate model (GLM) to our study, RIPC 
still did not have any significant reducing effect on Tr-AUC. (Mean Tr-AUC control = 8.84 vs. 
7.4 in RIPC, p= 0.68).  
 
Fourth, in our study, the average number of balloon inflations during PCI in both groups is 
around 7 inflations. Balloon inflations contribute to brief ischaemia until the balloon is 
deflated. 7 balloon inflations appear to be much higher than the average number of inflations 
found in typical PCI. This, high number of balloon inflations in our study groups may have 
contributed to some preconditioning effect in the control group too, which could have, 
therefore, lowered enzyme release in the control group, masking the true beneficial effect of 
remote preconditioning. The balloon inflations were, however, typically less than 30 seconds, 
and the preconditioning effect of these inflations might not be significant. 
Finally, in our study we did not assess the myocardium at risk though any angiographic 
methods or scores. There are various scoring systems (e.g. jeopardy score) based on vessel to 
be intervened and presence of collaterals through which relative myocardium risk could be 
estimated. Because, in our study we have not estimated this, any difference in myocardium 
risk between control and RIPC groups remains unknown, and potentially there could be an 
undetermined confounder. However, there were no differences in other angiographic 
variables between the two groups, including type of vessel intervention, stent length, stent 
diameter etc. 
Therefore, our study has several limitations, which could explain lack of benefit from RIPC in 
the PCI settings. These limitations are likely to prevail in most of the proof of concept studies 
with limited number of patients. A large multicentre randomised controlled trial, with hard 
clinical end points is the best way to determine if RIPC is beneficial in urgent PCI settings. A 
large RCT is needed, incorporating both elective and urgent PCIs, especially due to clear 
benefits seen in the CRISP study (268) in elective PCI settings, and absence of any trend 
towards benefit in our study. The similar findings in a large multicentre study could validate 
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some of the important reasons for lack of benefit in urgent PCI settings, that we discussed 
above.   
  
 
One very interesting observation from our study is that, although the cardiac biomarkers 
cTnT and CK-MB release post-PCI do show a strong correlation, as one would expect, the 
relative proportional increases are not similar. Therefore, the incidence of PMI when one 
biomarker is used appears significantly different in the same group when the other 
biomarker is used to define PMI. In our cohort, cTnT increase >1 ULN occurred in 61% of the 
patients, >3 ULN occurred in 55% of the patients. However, CKMB increase >1 ULN occurred 
in only 33% of the patients, and >3 ULN occurred in only 11 % of the total cohort. Although 
the Joint ESC/AHA/ACC universal definition of MI advocates the use of either cardiac enzyme 
(Troponins or CKMB) in determining the occurrence of PMI, certainly it appears that the 
incidence in PMI would differ significantly in different studies, based on which cardiac 
biomarker is used to diagnose the PMI. 
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4. REMOTE ISCHAEMIC PRECONDITIONING IN TYPE 2 DIABETIC PATIENTS 
UNDERGOING CORONARY ARTERY BYPASS SURGERY 
Remote Ischaemic Preconditioning has an important application in the field of cardiovascular 
surgical settings. Preconditioning in myocardial ischaemia reperfusion injury is a well 
established cardioprotective intervention, as discussed in chapter 1. During cardiac 
surgeries, cross clamping the aorta for the blood-less field, and releasing the cross clamp 
after surgery mimics a typical myocardial ischaemia reperfusion setting, albeit, the 
myocardial oxygen demand during these procedures are reduced by administration of 
cardioplegic solution and other techniques, which have been elaborately discussed in chapter 
1. In fact, the first ever human study looking at the benefit from remote preconditioning was 
conducted by Cheung et al. (333), in the context of cardiac surgery among a paediatric group 
of patients undergoing corrective surgery for congenital heart defects. Yellon’s group from 
the Hatter Cardiovascular Institute, was the first to show the peri-operative myocardial 
enzyme reduction in adult patients undergoing elective CABG in a group of 56 patients (334). 
This study included both diabetic and non-diabetic patients. They also showed, in a separate 
study of non- diabetic patients undergoing elective CABG and receiving cardioplegic method 
of surgical myocardial protection, that RIPC reduces perioperative myocardial enzyme 
release by 40% (270).  In the animal studies, the diabetic hearts have been shown to have 
varied susceptibility to ischaemic injury and in their preconditioning ability. In summary, it 
appears that the diabetic hearts from animal models in particular circumstances, are more 
resistant to ischaemic injury, and although further reduction of this IR injury is possible 
through preconditioning, it requires an increased preconditioning stimulus. This topic has 
been discussed elaborately in chapter 1 (see sections 1.13.1 and 1.13.2). The aim of this 
study was to specifically study whether RIPC reduces peri-operative myocardial injury in 
type-2 diabetic patients undergoing CABG. 
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METHODS 
4.1.1 Overview 
 
We conducted a two Centre open label randomized controlled study, where we studied the 
effect of remote ischaemic preconditioning induced by transient limb ischaemia on peri-
operative myocardial injury in type 2 diabetic patients undergoing elective CABG with or 
without concomitant aortic valve surgery. 
 4.1.2 Ethical Approval and Informed Consent   
 
The protocol for this study was written in accordance with the international Conference on 
Harmonisation- Good Clinical Practice (ICH-GCP) guidance, and the study was subject to 
approval by the joint University College London (UCL)/University College London Hospitals 
(UCLH) Committees for the ethics of human research. Approval for the study was sought on 
the standard application form, initially provided by NHS COREC (Central office for the 
Research Ethics Committees), and subsequently integrated with the National Research Ethics 
Service (NRES), affiliated to the National Patient Safety Agency. In addition to the study 
protocol, the patient information sheet, consent form, and letter to the patient’s general 
practitioner were also approved by the ethical committee. 
Once ethical approval was obtained, a separate application was made to the research and 
development department UCLH, who also acted as sponsors of the study. Any amendments 
to the protocol were classed as major or minor, as per advice from the ethical committee. I 
made the amendments and submitted the documents, annotated with appropriate dates and 
version numbers, for approval of each amendment. An Integrated Research Application 
System (IRAS) form, and a non-NHS SSI application (no: 26244) were filled and transferred 
out to seek approval from HCA ethics committee to include second recruitment centre -The 
Wellington Hospital.  
 Any serious adverse event or reaction during the course of the study had to be reported to 
the R&D department as per guidelines. No serious adverse events or reactions occurred 
during the course of this study. 
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Type 2 diabetic patients admitted for CABG with or without concomitant aortic valve surgery 
were approached on the day prior to their scheduled surgery date, and were explained about 
the study in detail, and their willingness to participate in the trial was established. Informed 
consent was obtained using the current version of the patient information sheets and 
consent forms, and patients’ signatures obtained. A copy of the signed consent form was 
given to the patient with the information sheet and the originals filed in the hospital notes. 
An additional copy of the signed consent form was filed at the Hatter Cardiovascular Institute 
for patients recruited at the Heart Hospital, and at the Wellington Hospital for patients 
recruited at the Wellington Hospital site. 
4.1.3 Patient Recruitment 
 
Consecutive Type 2 diabetic patients admitted for CABG between April 2008 and September 
2010, were screened for recruitment into the study at the Heart Hospital site. At the 
Wellington Hospital site, the patient recruitment was started from March 2010. The first 8 
patients in this study at the Heart Hospital site, were recruited by Dr Vinod Venugopal, and I 
continued patient recruitment from October 2008. 
4.1.4 Inclusion Criteria 
 
Age > 18 years. 
Consecutive type-2 diabetic patients undergoing elective coronary artery bypass surgery 
with or without concomitant aortic valve repair/replacement. Diabetes was confirmed to be 
diagnosed by GP or a hospital specialist and complied with 2006 WHO criteria of diagnosing 
diabetes. 
WHO criteria for diagnosing diabetes mellitus (2006) 
1. Diabetes symptoms (ie polyuria, polydipsia and unexplained weight loss) plus 
• a random venous plasma glucose concentration > 11.1 mmol/l  
or  
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• a fasting plasma glucose concentration > 7.0 mmol/l (whole blood > 6.1mmol/l)  
or  
• two hour plasma glucose concentration > 11.1 mmol/l two hours after 75g anhydrous 
glucose in an oral glucose tolerance test (OGTT). 
2. With no symptoms diagnosis should not be based on a single glucose determination but 
requires confirmatory plasma venous determination. At least one additional glucose test 
result on another day with a value in the diabetic range is essential, either fasting, from a 
random sample or from the two hour post glucose load. If the fasting or random values are 
not diagnostic the two hour value should be used 
4.1.5 Exclusion Criteria 
 
Renal failure. (EGFR <35 ml/min/1.73m2) 
Peripheral vascular disease, affecting the upper limbs. 
Recent myocardial infarction (STEMI or NSTEMI in the immediate four weeks before CABG). 
Angina within three days before the surgery. 
Patients on Nicorandil or Glibenclamide. 
 
Serum Troponins (cTnT) remain elevated for up to two weeks after a myocardial infarction. 
Moreover, some patients undergo CABG surgery as an urgent procedure following an acute 
myocardial infarction (AMI). We, therefore, excluded patients who had an AMI within four 
weeks immediately prior to the cardiac surgery. Likewise, since the kidneys excrete cTnT, 
the excretion of this marker would be unreliable in renal failure patients, and in these group 
of patients, the baseline levels of cTnT can be elevated. Therefore, these patients were 
excluded from the study. 
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4.2.1 Anaesthetic Procedure 
 
Pre-medication comprising Temazepam 10-20mg orally was administered to each patient 
one hour before surgery. On arrival to the anaesthetic room, a peripheral venous cannula 
was inserted and the patients were sedated with Midazolam given intravenously. An arterial 
cannula was inserted prior to the induction of anaesthesia for invasive monitoring of the 
blood pressure. Continuous arterial pressure monitoring was commenced and an infusion of 
normal saline started. Anaesthesia was induced with Midazolam + Etomidate or Propofol, 
Fentanyl (5-15µg/kg) and either Pancuronium (0.1mg/kg). The trachea was intubated, 
mechanical ventilation commenced with O2+ air, and anaesthesia was maintained by either 
halogenated anaesthetics (Isoflurane or Sevoflurane) or with an infusion of Propofol, 
administered by target controlled infusion to achieve a target plasma concentration of 3-
8µg/ml. Midazolam, Fentanyl, and Pancuronium were given as required. Arterial blood 
pressure, central venous pressure, electrocardiogram and nasopharyngeal temperature were 
recorded continuously.  
4.2.2 Randomisation and Transient Limb Ischaemia Protocol 
 
Patients were randomised to either control group or RIPC group, using an electronic 
randomisation method of random sequence generator for two treatments. A simple 
randomisation method was used to allocate patients to receive either RIPC or the placebo. 
http://www.random.org/sequences/ 
 
RIPC was induced by transient limb ischaemia in patients randomised to receive the 
intervention. This was achieved by inflating a standard 9 inch blood pressure cuff to 200 
mmHg on the upper arm for five minutes for three cycles, each separated by a reperfusion 
period of five minutes during which time the cuff was kept deflated.  
The protocol was applied to the right arm whenever possible, but if the arterial cannula for 
invasive blood pressure monitoring was inserted in the right radial artery, the RIPC protocol 
was applied on the left arm. The protocol was commenced after the patient was 
anaesthetised to avoid any discomfort. 
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4.2.3 Surgical Procedure 
 
After sternotomy, the left internal mammary artery (LIMA) was dissected down from the 
anterior chest wall, while the great saphenous vein was harvested from the leg. Aortic root, 
and the right atrial appendage were inserted with bypass cannulae and a standard non-
pulsatile cardiopulmonary bypass (CPB) was established using the membrane oxygenator. 
The coronary artery bypass grafts (LIMA or saphenous venous grafts) were constructed on 
cardiopulmonary bypass, with each distal anastomosis to the coronary arteries being 
performed during cardiac standstill. This was achieved by cross clamping the aortic root, 
accompanied by either ventricular fibrillation, or by the injection of cardioplegic solution. 
Moderate hypothermia, between 28 and 32°C, was induced by using the cardiopulmonary 
bypass circuit and, if required, an additional ice pack around the heart in the pericardial sac. 
In the technique of cross clamp fibrillation, the aorta was cross clamped and an alternating 
current was applied to the epicardium to induce ventricular fibrillation, afterwhich the distal 
anastomosis was performed. After each distal anastomosis, the aortic clamp was released 
and a direct current shock used to defibrillate the heart. The proximal anastomoses were 
performed after all the distal anastomoses, with the heart still beating. 
In the second technique, a cardioplegic solution comprising of 1 part of St Thomas Hospital 
Cardioplegia solution 1 mixed with 4 parts of cold blood, was injected antegradely into the 
aortic root, and the distal anastomoses were performed during the duration of a single cross-
clamp. An additional bolus of cardioplegia solution was given into the vein graft following 
each distal anastomosis. In cases of completely occluded coronary arteries, the cardioplegic 
solution was injected retrogradely into the coronary sinus. Thus, depending upon the choice 
of the operating surgeon, either the technique of cross-clamp fibrillation or cardioplegia was 
used during the surgery. 
Re-warming was commenced at the time of the last proximal anastomosis, and the 
cardiopulmonary bypass was discontinued. Protamine was used to reverse the effect of 
heparin. 
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 4.3.1 SerumTtroponin-T Measurement 
 
Blood samples for the measurement of serum cTnT were taken pre-operatively, and at 6, 12, 
24, 48, and 72 hours following surgery. cTnT was measured quantitatively by one-step 
enzyme immunoassay based on electrochemiluminescence technology (Elecsys 2010; 
Roche). The lower detection limit of this assay (99th percentile URL) is 0.01 µg/L with a co-
efficient of variation of 10%, and recommended diagnostic range of 0.03-0.09 µg/L, 
indicating possible myocardial injury, and a threshold of > 0.1µg/L, indicating myocardial 
injury suggestive of myocardial infarction. 
The area under the curve indicative of absolute Troponin release over 72 hours was 
calculated using the trapezoid rule, with the formula below; 
AUCt1-t2 = [(cTnT at t1 hours +cTnT at t2 hours)/2] x (t2-t1) 
AUC 72 hours = AUC0-6+AUC6-12+AUC12-24+AUC24-48+AUC48-72 
4.3.2 Assessment of Immediate Clinical Outcomes 
 
During the post-operative period, data were recorded including the details of postoperative 
intensive care unit parameters, such as duration of ventilation, inotrope use, renal function 
and urine output, duration of hospital stay and post-operative arrhythmias. 
 
4.3.3 Statistical Analysis 
 
Standard statistical methods were used for analysis. Histograms with normal plots were 
performed to check that the data in the two groups was normally distributed. Differences 
between the groups for continuous variables were tested using t-test and for categorical 
variables using the Chi-square test. The general linear multivariate model was used to test 
multivariate analysis. Significance was interpreted at the 95% confidence interval having 
corrected for any inequality of variance between groups. Data was analysed using SPSS 
statistical software version 16.  
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4.3.4 Sample Size Calculation 
 
Our Institute’s previous clinical study involving RIPC in CABG settings, which included both 
non-diabetic and diabetic patient cohorts, and which was the first ever proof of concept 
study of RIPC in the clinical settings formed the basis of the sample size in this study (79). 
Based on this study, we determined that we would require a sample size of 23 patients in 
each group (total 46 patients) to detect a reduction in absolute Troponin release (AUC 72 
hours) of 15µg/L, with a standard deviation of 18µg/L, and a power of 80% at the two sided 
5% significance level. 
4.4 RESULTS 
A total of 72 consecutive Type 2 diabetic patients were approached over a two year period, 
who fulfilled the inclusion criteria for this study. Six patients refused to take part in the study, 
4 patients had their baseline pre-operative eGFR < 35mls/min/1.73m2, and had to be 
excluded from further research protocol. One patient underwent off-pump bypass surgery 
and had to be excluded from further analysis. A total of 61 patients, therefore, completed the 
research study over a two year period. Thirty patients were in the RIPC group, and remaining 
31 patients were in the control group. The flow chart below shows the schematics of patient 
screening and recruitment. 
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Fig 5 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.1 Baseline Characteristics- Patient Profile 
The baseline characteristics of the patients are summarised in table 4.2. Both groups 
matched well, and had no significant differences with respect to most of the baseline 
characteristics. The control group had higher mean HbA1C level compared to the RIPC group 
(8.52 vs. 6.75, p = 0.003). 
Patients randomised 
            61 
Control gp 
31 
RIPC gp 
30 
6 patients refused to consent 
Total number of patients 
screened = 72 
4 patients had eGFR < 35 
1 patient had off-pump CABG 
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4.4.2 Pre-Procedure Drug Profile 
The control group had higher proportion of patients on insulin compared to RIPC group 
(38.7% vs. 16.7%, p = 0.05). There were, however no significant differences in other drug 
profile, prior to the procedure between the two groups. The drug profile of both groups has 
been summarised in table 4.3. 
 
Table 4.2 
Demographics Control (n=31) RIPC (n=30) 
Age (years) 67.0 (+7.5) 69.3 (+10.3) 
Male 
Female 
22 (71%) 
9 (29%) 
21 (70%) 
9 (30%) 
Hypertension 28 (90.3%) 25 (83.3%) 
Dyslipidaemia 24 (77.4%) 27 (90%) 
Previous MI 12 (38.7%) 12 (40%) 
Previous CVA 2 (6.5%) 3 (10%) 
Current smoker 
Ex Smoker 
Never smoked 
4 (12.9%) 
15 (48.4%) 
12 (38.7%) 
1 (3.8%) 
10 (38.5%) 
15 (58.7%) 
Family History 10 (33.3%) 5 (16.7%) 
Body surface Area (m2) 1.91 (+0.18) 1.86 (+0.17) 
Body Mass Index (BMI) 29.9 (+6.0) 29.3 (+4.1) 
Hb A1c level 8.52 (+1.8) 6.75 (+0.95) 
 
 
 
Table 4.3 
Drugs Control RIPC 
Aspirin 20 (64.5%) 13 (43.3%) 
Beta Blocker 21 (67.7%) 18 (60%) 
Statin 27 (87.1%) 27 (90%) 
ACE inhibitor 23 (74.2%) 23 (76.2%) 
Ca2+ channel blocker 10 (47.6%) 10 (38.5%) 
Nitrate 9 (29%) 10 (33.3%) 
Insulin 12 (38.7%) 5 (16.7%) 
Suphonylurea 11 (35.5%) 7 (23.3%) 
Metformin 20 (64.5%) 19 (63.3%) 
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4.4.3 Pre-operative Clinical Parameters. 
Both groups matched well with respect to pre-operative LV function, Left main stem 
involvement, EuroSCORE, and Parsonnet scores. EuroSCORE (European System for Cardiac 
Operative Risk Evaluation) and Parsonnet scoring systems are logistic risk assessment 
models, used to predict the early operative mortality among patients undergoing CABG. The 
EuroSCORE in both groups in our cohort was more than 3 and less than 6, which translates 
into a mortality risk of 3% and therefore confirms that our patient cohort comprised of 
moderate-risk patients. 
Table 4.4  
Pre-operative 
clinical parameter 
Control RIPC 
LV ejection Fraction 
Good (>55%) 
Fair (35-55%) 
Poor (<35%) 
 
20 (71.4%) 
8 (28.6%) 
0 
 
19 (73.1%) 
7 (26.9%) 
0 
Left Main Stem (LMS) 
> 50% disease 
3 (10.7%) 3 (11.5%) 
EuroSCORE 4.16 (+2.7) 3.73 (+2.3) 
Parsonnet Score 13.38 (+7.5) 14.23 (+8.5) 
 
 
4.4.4 Intra-operative Parameters 
The intra-operative variables in the two patient groups are summarised in table 4.5. 
Antegrade intermittent cold blood cardioplegia was the predominant method of myocardial 
preservation strategy used during cardiac surgery in this study cohort (81%). Intermittent 
cross clamp fibrillation was used in 19% of the patients as myocardial preservation strategy. 
All intra-operative variables were evenly matched between the two groups. Both groups had 
equal numbers of patients undergoing concomitant aortic valve replacement (4 in each 
group) with CABG.  
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Table 4.5 
Operative parameters 
 
Control RIPC 
Bypass temperature 32.30 (+1.2) 32.50 (+1.3) 
Type of cardioprotection 
 
Cardioplegia 
Cross clamp fibrillation 
 
 
26 (83.9%) 
5 (16.1%) 
 
 
24 (80%) 
6 (20%) 
Concomitant aortic valve 
surgery 
4 (12.9%) 4 (13.3%) 
No of vessels bypassed 
(mean) 
2.74 (+0.89) 2.80 (+0.80) 
Cross clamp time(min) 56.68 (+23.0) 51.67 (+23.3) 
Cardiopulmonary bypass 
time (CPB) (min) 
86.77 (+32.1) 82.47 (+24.1) 
Maintenance anaesthesia 
Isoflurane 
Sevoflurane 
 
23 (74.2%) 
8 (25.8%) 
 
25 (83.3%) 
5 (16.7%) 
No of Grafts 
                 One 
                 Two 
                 Three 
                  More than three 
 
3 (9.7%) 
7 (22.6%) 
17 (54.8%) 
4 (12.9%) 
 
3(10%) 
4 (13.3%) 
19(63.3%) 
4 (13.3%) 
 
4.5.1 Serum Troponin Release  
Cardiac TnT levels were measured pre-operatively at the time of anaesthetic induction, and 
at 6, 12, 24, 48, and 72 hours post cardiac surgery. The mean (+SD) cTnT levels at these time 
points are shown in table 4.6. 
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Table 4.6 
Time 
(Hours) 
Control RIPC Mean 
difference 
Confidence 
interval 
P Value 
6 0.59+0.37 0.54+0.41 0.05 +0.10 -0.15 - 0.25 0.62 
12 0.51+0.23 0.46+0.31 0.042+0.07 -0.10 - 0.18 0.55 
24 0.38+0.21 0.35+0.20 0.029+0.05 -0.07 - 0.13 0.58 
48 0.27+0.16 0.24+0.14 0.035+0.03 -0.04 - 0.11 0.38 
72 0.23+0.17 0.22+0.15 0.014+0.04 -0.07 - 0.09 0.73 
Values present mean + SD (in µg/L) 
 
There were no statistical differences in the mean cTnT levels between the RIPC group and 
control groups at 6, 12, 24, 48 or 72 hours. There was no significant difference in the cTnT 
AUC over 72 hours between the two groups. The mean cTnT AUC in the control group was 
24.55 (+13.13) µg/L.72 hrs vs. 22.38(+13.39) µg/L.72 hrs in RIPC group, p=0.52. There was 
no statistical difference in the maximum Troponin level over 72 hours between the two 
groups, maximum cTnT control group 0.64 (+0.34) µg/L vs. 0.57(+0.40) µg/L in the RIPC 
group, p = 0.51.    
                                                Fig 6: Troponin release post CABG 
Error bars in the figure represents Std Error of the mean
4.5.2 Serum CK-MB Release
Serum CK-MB mass were measured pre
at 6, 12, 24, 48, and 72 hours post cardiac 
time points are shown in table 4.7.
Table 4.7 
Time 
(Hours) 
Control 
0 3.40+0.74 
6 23.95+11.7 
12 20.07+9.4 
24 16.63+9.4 
48 7.32+3.12 
72 5.07+3.4 
Values present mean + SD (in µg/L)
0
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-operatively at the time of anaesthetic induction and 
surgery. The mean (+SD) CK
 
RIPC Mean 
difference 
Confidence 
interval
3.72+2.07 0.27+0.47 -0.12 - 0.68
23.32+9.5 0.62 +3.1 -5.78 - 7.04
17.71+6.8 2.3+2.46 -2.61- 7.33
15.46+6.6 1.17+2.37 -3.61 - 5.96
7.34+3.85 0.025+1.07 -2.19 - 2.14
4.49+1.5 0.57+0.81 -1.06 – 
 
12 24 48 72
Hours post surgery
P=0.55
P=0.58
P=0.38
 
-MB levels at these 
 
P Value 
 0.56 
 0.84 
 0.34 
 0.62 
 0.98 
2.22 0.48 
Control-26
RIPC -24
P=0.73
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There were no significant differences in the CK-MB mass between the two groups at any time 
points postoperatively, i.e. at 6, 12, 24, 48 or 72 hours. In addition, there was no statistical 
difference in the peak CK-MB mass levels over 72 hours between the two groups, peak CK-
MB mass levels in the control group was 24.83 (+12.3) µg/L vs. 23.66 (+9.4) µg/L in the RIPC 
group, p = 0.71. 
 
4. 5.3 Post-operative Ventilation Times 
Post-operative ventilation times did not differ significantly between the two groups. Mean 
ventilation time for the control group was 7.74 (+5.47) hours vs. 7.93 (+3.49) hours in the 
RIPC group, p = 0.87. 
4.5.4 Post-operative ITU Stay and High-care Stay 
There were no significant differences in the duration of ITU stay between the two groups 
post-operatively. In addition, there was no statistical difference in the duration of high-care 
stay between the two groups. Mean ITU stay (number of nights) in the control group was 
2.77 (+4.6) vs. 2.8(+2.4) in the RIPC group, p= 0.98. Mean number of days of high care stay in 
the control group was 3.68 (+4.5) vs. 4.69 (+6.1) days in the RIPC group, p = 0.47. 
4.5.5 Postoperative Inotrope Requirement and Inotrope Score 
Data were obtained regarding the inotrope requirement post-operatively in all patients 
during their ITU stay. Based on the maximum inotrope concentration required, inotrope-
score was calculated using the formula: Inotrope score = Dosages (in μg/kg/min) of 
Dopamine + Dobutamine + [(Adrenaline + Noradrenaline + Isoproterenol) × 100] + 
[Enoximone × 15], adapted from Ko et al.(335).   
Inotrope support was required in 5 (16.1%) of patients in the control group compared to 11 
(36.6%) patients in the RIPC group. This difference, however, was not statistically significant, 
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p= 0.12. The inotrope scores among the patients requiring inotrope support did not differ 
significantly between the two groups. Inotrope score in the control group was 7.40 (+5.2) 
μg/kg/min vs. 9.98 (+8.67) μg/kg/min in the RIPC group, p = 0.55. 
4.5.6 Post-operative Atrial Fibrillation (AF)  
New AF occurred in 6 (19.4%) patients in the control group vs. 4 (13.3%) patients in the 
RIPC group. This was not statistically significant, p= 0.73. 
4. 5.7 Post-operative Acute Kidney Injury (AKI) 
AKI was defined as an abrupt (within 48 hours) reduction in kidney function either with an 
absolute increase in serum creatinine of more than or equal to 0.3 mg/dl (≥ 26.4 μmol/l), a 
percentage increase in serum creatinine of more than or equal to 50% (1.5-fold from 
baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per 
hour for more than six hours) (336). 
AKI was observed in 4 (12.9%) patients in the control group vs. 2 (6.7%) patients in the RIPC 
group. This difference was not statistically significant, p = 0.67. 
 
4.6 Sub-group Analysis of Patients Undergoing Cardiac Surgery with Cardioplegia as 
Myocardial Preservation 
As described in previous chapters, 85% of the cardiac surgeons in the UK use cardioplegia as 
myocardial preservation strategy. Cross clamp fibrillation is an alternative myocardial 
preservation strategy, invariably involving less aortic cross clamp time, however, devoid of 
additional protection from cardioplegic solution. Extensive literature reviews have 
concluded that both these myocardial preservation strategies provide equivalent 
cardioprotection during cardiac bypass surgeries (192). Previous studies evaluating the 
invasive ischaemic preconditioning (IPC), have consistently shown benefit in cardiac surgery 
employing cross clamp fibrillation as myocardial preservation strategy (262, 263). However, 
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in studies involving cardioplegia as myocardial preservation strategy, the beneficial effect of 
IPC has been controversial (265-267). It is, therefore,  important in evaluating RIPC, that we 
also analyse a cohort of our patients employing cardioplegic myocardial preservation. 
 50 patients (82%) of our cohort had cardioplegia as myocardial preservation strategy. These 
patients were further analysed grouping them into controls and the RIPC group, and the 
results are detailed below. 26 patients were in the control group and 24 patients were in the 
RIPC group. 
4.6.1 Baseline Characteristics- Patient Profile 
The baseline characteristics of the patients are summarised in table 4.8. Both groups 
matched well and had no significant differences with respect to most of the baseline 
characteristics. The control group had higher mean HbA1C level compared to the RIPC group 
(8.67 vs. 6.62, p = 0.002). 
4.6.2 Pre-Procedure Drug profile 
The control group had higher proportion of patients on insulin compared to RIPC group 
(38.5% vs. 12.5%, p = 0.05). The control group also had a higher proportion of patients on 
Aspirin pre-operatively compared to the RIPC group (65.4% vs. 37.5% p = 0.05). There were, 
however, no significant differences in other drug profiles prior to the procedure between the 
two groups. The drug profile of both groups has been summarised in table 4.9. 
 
Table 4.8 
Demographics Control (n=26) RIPC (n=24) 
Age (years) 67.4 (+6.9) 68.8 (+10.5) 
Male 
Female 
20 (76.9%) 
6 (23.1%) 
16 (66.7%) 
8 (33.3%) 
Hypertension 23 (88.5%) 20 (83.3%) 
Dyslipidaemia 19 (73.1%) 21 (87.5%) 
Previous MI 10 (38.5%) 7 (29.2%) 
Previous CVA 2 (7.7%) 2 (8.3%) 
Current smoker 
Ex Smoker 
Never smoked 
3 (11.5%) 
13 (50%) 
10 (38.5%) 
1 (4.5%) 
8 (36.4%) 
13 (59.1%) 
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Family History 8 (32%) 4 (16.7%) 
Body surface Area (m2) 1.93 (+0.18) 1.86 (+0.17) 
Body Mass Index (BMI) 30.6 (+6.0) 29.6 (+4.1) 
Hb A1c level 8.67 (+1.8) 6.62 (+0.96) 
 
 
 
Table 4.9 
Drugs Control RIPC 
Aspirin 17 (65.4%) 9 (37.5%) 
Beta Blocker 16 (61.5%) 16 (66.7%) 
Statin 273(88.5%) 21 (87.5%) 
ACE inhibitor 19 (73.1%) 18 (75%) 
Ca2+ channel blocker 8 (47.1%) 8 (40%) 
Nitrate 7 (26.9%) 7 (29.2%) 
Insulin 10 (38.5%) 3 (12.5%) 
Suphlonylurea 9 (34.6%) 5 (20.8%) 
Metformin 17 (65.4%) 13 (54.2%) 
 
4.6.3 Pre-operative Clinical Parameters. 
Both the groups matched well with respect to pre-operative LV function, Left Main Stem 
involvement, EuroSCORE, and Parsonnet scores. The EuroSCORE in both the groups in our 
cohort was more than 3 and less than 6, which translates into mortality risk of 3% and, 
therefore, confirms that our patient cohort comprised of moderate-risk patients. 
Table 4.9.1 
Preoperative 
Clinical parameters 
Control RIPC 
LV ejection Fraction 
Good (>55%) 
Fair (35-55%) 
Poor (<35%) 
 
16 (30.4%) 
7 (69.6%) 
0 
 
15 (28.6 %) 
6 (71.4 %) 
0 
Left Main Stem (LMS) 
> 50% disease 
3 (12.5%) 2 (9.1%) 
EuroSCORE 4.27 (+2.8) 3.79 (+2.5) 
Parsonnet Score 14.08 (+7.7) 14.76 (+8.9) 
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4.6.4 Intra-operative Parameters 
The intra-operative variables in the two patient groups are summarised in table 4.9.2. All 
intra-operative variables were evenly matched between the two groups. Both groups had 
equal number of patients undergoing concomitant aortic valve replacement (4 in each group) 
with CABG.  
Table 4.9.2 
Operative parameters Control RIPC 
Bypass temperature 32.10 (+1.1) 32.20 (+1.2) 
Concomitant Valve 
Surgery 
4 (15.4%) 4 (16.7%) 
No of vessels bypassed 
(mean) 
2.73 (+0.96) 2.79 (+0.88) 
Cross clamp time(min) 61.81 (+21.5) 57.25 (+22.7) 
Cardiopulmonary Bypass 
time (CPB) (min) 
92.6 (+31.6) 86.6 (+24.7) 
Maintenance anaesthesia 
Isoflurane 
Sevoflurane 
 
20 (76.9%) 
8 (25.8%) 
 
19 (79.2%) 
5 (16.7%) 
No of Grafts 
                  One 
                  Two 
                  Three 
                  More than three 
 
3 (11.5%) 
6 (23.1%) 
13 (50%) 
4 (15.4%) 
 
3(12.5%) 
3 (12.5%) 
14(58.3%) 
4 (16.7%) 
 
 
4.7.1 Serum Troponin Release  
Cardiac TnT levels were measured pre-operatively at the time of anaesthetic induction and at 
6, 12, 24, 48, and 72 hours post cardiac surgery. The mean (+SD) cTnT levels at these time 
points is shown in table 4.9.3 
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Table 4.9.3 
Time 
(Hours) 
Control RIPC Mean 
difference 
Confidence 
interval 
P Value 
6 0.61+0.40 0.58+0.45 0.03 +0.12 -0.21 - 0.27 0.80 
12 0.52+0.25 0.50+0.34 0.022+0.08 -0.14 - 0.19 0.79 
24 0.41+0.22 0.38+0.22 0.025+0.06 -0.07 - 0.13 0.69 
48 0.29+0.17 0.26+0.15 0.030+0.04 -0.10 - 0.15 0.51 
72 0.26+0.18 0.24+0.16 0.016+0.04 -0.08 - 0.11 0.73 
Values present mean + SD (in µg/L) 
 
There were no statistical differences in the cTnT levels between the RIPC group and the 
control group at 6, 12, 24, 48 or 72 hours. There was no significant difference in the cTnT 
AUC over 72 hours between two groups, mean cTnT AUC Conrol group 25.97 (+13.89) 
µg/L.72 hrs vs. 24.18(+14.44) µg/L.72 hrs in the RIPC group, p=0.65. There was no statistical 
difference in the maximum Troponin level over 72 hours between the two groups, maximum 
cTnT control group 0.66 (+0.37) µg/L vs. 0.62(+0.44) µg/L in the RIPC group, p = 0.70.    
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                                                Fig 7: Troponin release post cardiac surgery 
 
4.7.2 Serum CK-MB Release 
Serum CK-MB mass were measured pre-operatively at the time of anaesthetic induction and 
at 6, 12, 24, 48, and 72 hours post cardiac surgery. The mean (+SD) CK-MB levels at these 
time points is shown in table 4.9.4. 
Table 4.9.4 
Time 
(Hours) 
Control RIPC Mean 
difference 
Confidence 
interval 
P Value 
0 3.54+0.72 3.87+2.3 -0.30+0.59 -0.15 - 0.89 0.61 
6 25.37+12.8 23.77+10.1 1.60 +3.88 -6.30 – 9.51 0.68 
12 20.68+10.3 18.23+7.3 2.44+2.96 -3.58- 8.47 0.41 
24 17.83+10.1 15.31+6.9 2.52+2.86 -3.29 – 8.34 0.38 
48 7.44+3.24 7.55+4.22 -0.11+1.30 -2.76 - 2.54 0.93 
72 5.20+3.66 4.80+1.44 0.40+0.96 -1.56 – 2.36 0.68 
Values present mean + SD (in µg/L) 
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There were no significant differences in the CK-MB mass between the two groups at any time 
points postoperatively, i.e. at 0, 6, 12, 24, 48 or 72 hours. In addition, there was no statistical 
difference in the peak CK-MB mass levels over 72 hours between the two groups, peak CK-
MB mass levels in control group 26.20 (+13.3) µg/L vs. 23.90 (+10.1) µg/L in RIPC group, p = 
0.56. 
4.7.3 Post-operative Ventilation Times 
Post-operative ventilation times did not differ significantly between the two groups. Mean 
ventilation time for the control group was 7.74 (+5.80) hours vs. 8.32 (+3.84) hours in the 
RIPC group, p = 0.71. 
4.7.4 Post-operative ITU Stay and High-care Stay 
There were no significant differences in the duration of ITU stay between the two groups 
post-operatively. There was also no statistical difference in the duration of high-care stay 
between the two groups. Mean ITU stay (number of nights) in the control group 3.12 (+5.0) 
vs. 2.35(+1.4) in the RIPC group, p= 0.51. Mean number of days of high care stay in the 
control group was 3.96 (+4.9) vs. 4.62 (+6.6) days in the RIPC group, p = 0.69. 
4.7.5 Postoperative Inotrope Requirement and Inotrope Score 
Data were obtained regarding the inotrope requirement post-operatively in all patients 
during their ITU stay. Based on the maximum inotrope concentration required, Inotrope-
score was calculated using the formula: Inotrope score = Dosages (in μg/kg/min) of 
Dopamine + Dobutamine + [(Adrenaline + Noradrenaline + Isoproterenol) × 100] + 
[Enoximone × 15], adapted from Ko et al. (337).   
Inotrope support was required in 5 (26.3%) of patients in the control group compared to 7 
(35.0%) patients in the RIPC group. This difference was not statistically significant, p= 0.55. 
The inotrope scores among the patients requiring inotrope support did not differ 
significantly between the two groups. Inotrope score in the control group was 7.40 (+5.2) 
μg/kg/min vs. 12.18 (+10.3) μg/kg/min in the RIPC group, p = 0.36. 
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4.7.6 Post-operative Atrial Fibrillation (AF)  
New AF occurred in 6 (23.1%) patients in the control group vs. 2 (8.3%) patients in the RIPC 
group. This was, however, not statistically different, p= 0.25. 
4.7.7 Post-operative Acute Kidney Injury (AKI) 
AKI was defined as an abrupt (within 48 hours) reduction in kidney function either with an 
absolute increase in serum creatinine of more than or equal to 0.3 mg/dl (≥ 26.4 μmol/l), a 
percentage increase in serum creatinine of more than or equal to 50% (1.5-fold from 
baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per 
hour for more than six hours) (336). 
AKI was observed in 4 (15.4%) patients in the control group vs. 2 (8.3%) patients in the RIPC 
group. This difference was not statistically significant, p = 0.66. 
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4.8 DISCUSSION 
In this prospective open labelmrandomised controlled study involving Type 2 diabetic 
patients undergoing cardiac surgery, remote ischaemic preconditioning using 3 cycles of 5 
minute upper limb ischaemia, did not demonstrate a significant reduction in the cardiac 
biomarker release (primary end point) postoperatively. There appeared no significant 
difference in the clinical endpoints of ventilation times, post-operative ITU stay, post-
operative high care stay, post-operative AF incidence or post-operative AKI incidence 
between the two groups. These findings, did not change when a subgroup analysis of 
cardioplegic myocardial preservation cohort was analysed. I shall now discuss the possible 
reasons, why RIPC did not show any significant clinical or biochemical superiority in our 
study. 
4.8.1 Possible Reasons of Lack of Superiority of Primary End Points in the RIPC Group 
in the Diabetic Cohort. 
Three cycles of 5 minutes forearm ischaemia is a proven remote ischaemic stimulus that has 
shown clear reduction in Troponin AUC in non-diabetic patients undergoing CABG (270). The 
threshold of RIPC at which the myocardial protection manifests in the clinical setting is still 
unknown and it is possible that RIPC with two cycles of 5 minutes forearm ischaemia might 
also be protective in non-diabetic patients. Conversely, it might be that 3 cycles of 5 min 
ischaemia is the minimum ischaemic stimulus for any protection in the Troponin reduction 
to manifest. Most of the cardiovascular clinical studies involving RIPC have used 3 cycles of 5 
min remote ischaemic stimulus in their studies(78, 79, 163, 270, 271, 338). In our Institute 
we are currently investigating if lower or higher ischaemic stimuli are as protective as 3 
cycles of RIPC stimulus. 
From the animal studies we do know that, in Type 2 diabetic rats, preconditioning with 
standard ischaemia stimulus fails to demonstrate the reduction in infarction, and that a 
prolonged ischaemic stimulus is needed to precondition diabetic hearts in these animal 
models (318, 324).  Similar observations were shown in the human atrial trabeculae model 
by Sivaraman et al. (325), where a standard preconditioning protocol failed to demonstrate 
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contractile recovery in diabetic human trabeculae subjected to 90 min ischaemia. By 
prolonging the ischaemic preconditioning stimulus, the contractile recovery similar to non 
diabetic myocardium was demonstrated in diabetic human trabeculae. When translating this 
effect clinically and evaluating remote ischaemic stimulus in cardiac surgery, it is not 
surprising that a standard stimulus of 3 cycles of 5 minute forearm ischaemia might not have 
sufficient preconditioning stimulus in diabetic patients, particularly, if 3 cycles of 5 minute 
ischaemia is the threshold stimulus in non-diabetic patients. Certainly, the only way to 
evaluate this hypothesis is by investigating whether a prolonged remote ischaemic 
preconditioning stimulus reduces the perioperative Troponin release in Type 2 diabetic 
patients. In addition, characterisation of RIPC in non-diabetic patients with 2 cycles of 5 
minute ischaemia and reperfusion, and even 1 cycle of 5 minute ischaemia and reperfusion 
will likely establish the threshold remote ischaemic stimulus in clinical patients for reducing 
the myocardial injury during cardiac surgery.    
 
Secondly, in the animal studies, the ischaemic standard stimulus has been at least 90 minutes 
or over, and this is an absolute ischaemia. In clinical studies, the ischaemic stimulus (cross 
clamp time) in most cardiac surgeries has been around 60 minutes. In addition, this is not 
absolute ischaemia as the myocardium itself is perfused with cardioplegia solution, which 
reduces the ischaemic effect significantly. Importantly, if the surgical cardioprotection 
method is cross clamp fibrillation rather than cardioplegic cardioprotection, then this could 
be considered as absolute ischaemia. However, cross clamp fibrillation method will only 
involve maximum period of 20 minutes and, therefore, it never renders the ischaemic burden 
similar to the animal model settings. It is important to recognise that the infarct size seen in 
animal models are never seen in human cardiac surgeries. Consequently, the clinical 
endpoints in most clinical studies are surrogate markers like Troponins. It could, therefore, 
mean that the clinical translation for evaluation of preconditioning is being conducted in 
significantly different conditions of ischaemia-reperfusion settings, i.e. smaller, altered 
settings of myocardial ischaemia, and confounded by the presence of other preconditioning 
agents, which will be discussed later. This is particularly relevant in diabetic patients 
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undergoing cardiac surgery, as we know from the animal models that, in particular 
conditions, diabetic hearts are relatively less susceptible to ischaemic insult than non-
diabetic myocardium. In our study, diabetic patients in the control group had a 72 hour 
Troponin area under the curve of 24.55 µg/L.72hrs. This is much smaller than the control 
group 72 hour Troponin AUC in the previous study from our own Institute, evaluating RIPC 
in the non-diabetic patient group in similar settings, and in the same surgical centre, with a 
value of 31.53 µg/L.72hrs (270) Certainly, this observation strengthens the hypothesis that 
human diabetic myocardium is resistant to index ischaemic insult, translating from the 
similar findings in the animal models.  
The use of inhalational anaesthetics, which do provide preconditioning effect with some of 
the intrinsic mechanisms similar to ischaemic preconditioning, is well known. Anaesthetic 
preconditioning is discussed in detail in the previous chapter (see section 1.13). Most of the 
patients undergoing cardiac surgeries are subjected to these volatile anaesthetics. Most of 
our patients in this study had Isoflurane (75%) or Sevoflurane (25%) as maintenance 
anaesthesia during the cardiac surgery. Certainly, this is an important confounding factor 
seldom experienced in animal models. Exposure to anaesthetic preconditioning could have 
diluted the effect of remote ischaemic preconditioning in our patient cohort, which partly 
explains similar AUC in both the control group and the RIPC group. However, our Institute’s 
previous studies on non-diabetic CABG patients evaluating RIPC, was performed under 
similar settings and similar anaesthetic protocols, and those studies have shown significantly 
improved troponin levels in the RIPC group (79, 270). This suggests that RIPC could provide 
additional protection over and above of that provided by volatile anaesthetics.  However, two 
recent studies have failed to demonstrate any clinical or biochemical superiority of RIPC in 
the settings of elective CABG. These include a large double blind randomised study involving 
162 patients undergoing elective CABG with standard blood –cardioplegia by Bonser et al. 
(272), and another smaller study involving 54 patients undergoing elective CABG with either 
cardioplegia or cross–clamp fibrillation as the myocardial preservation strategy, by Kunst et 
al.(273). Both these studies included a similar RIPC stimulus, and were conducted in patients 
undergoing coronary artery bypass surgery. The study by Bonser et al. (272), excluded 
patients with diabetes mellitus, and all patients had cardioplegia as surgical cardioprotection 
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method. The study by Kunst et al. (273), however, included patients with diabetes mellitus, 
and had patients undergoing surgery with either cardioplegia or intermittent cross clamp 
fibrillation as the surgical cardioprotection method. The findings of both these studies have 
raised doubts if RIPC adds to any further significant cardioprotection over and above that 
provided by inhalational anaesthetics. A recent study by Lucchinetti et al. specifically 
studying the effect of remote preconditioning in Isoflurane anaesthetised patients during 
CABG, showed no added benefit from preconditioning(339). In another recent study, looking 
at remote preconditioning in valvular heart surgery has reported 44% reduction in Troponin 
I area under the curve over 72 hours (340). Maintenance anaesthesia was predominantly 
with sufentanil in these patients, and this cohort included diabetic patients. 
Interestingly, anaesthetic preconditioning effect in diabetic animal models appears to be 
significantly less compared to non-diabetic models (288). This appears to be due to similar 
protective pathways involved in anaesthetic preconditioning and in ischaemic 
preconditioning. For this reason, confounding effect of volatile anaesthetics could be thought 
to be not so important in a diabetic population. In our study, there was no difference in the 
proportion of patients in both the control and RIPC groups receiving volatile aneasthetics as 
maintenance anaesthesia. 
Cardio pulmonary bypass (CPB), itself is thought to provide preconditioning stimulus and, 
therefore, RIPC might not have added further cardioprotection. In a study by Ghosh et al. 
(341), who evaluated classic ischaemic preconditioning in the reduction of post-operative 
troponin levels, found that IPC did not affect Troponin release in patients undergoing CABG 
with either cardioplegia or cross-clamp fibrillation. IPC however reduced Troponin levels 
significantly in patients undergoing CABG on the beating heart (without the use of CPB). 
Although exact mechanisms are unclear, it is thought that systemic inflammatory response 
and altered adrenergic state conferred by CPB, contribute to the  preconditioning effect 
(341).  
Therefore, there appears to be a few reasons why RIPC in our clinical study has failed to 
demonstrate reduction in cardiac enzyme levels, when compared to the control group. 
Patients undergoing CABG are a very heterogenous group. The duration of CPB and cross 
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clamp times, volume of inhalational anaesthetics required, relative myocardium at risk, 
which is exposed to ischaemia during surgery, use of drugs with inherent preconditioning 
effect, and presence of angina prior to CABG are very different in each individual and, clearly, 
cardiac enzyme release do vary significantly among different patients. Smaller studies like 
ours might not be able to definitely answer the research question, whether RIPC is a further 
myocardial protective agent or not in this context, and consequently larger multicentre 
studies are required to answer this important question. ERICCA is a large multi-centre 
randomised trial which is currently underway involving 1610 patients and is powered for 
clinical outcomes(342). This study is likely to answer and clarify the prevailing questions and 
doubts about remote ischaemic preconditioning during CABG. 
 
120 
 
5. SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
Remote Ischaemic Preconditioning is a simple non-invasive effective cardioprotective 
method, which has a role in various clinical contexts. Our two clinical trials involved 
evaluation of RIPC in two specific groups of population i.e. NSTEACS patients undergoing 
urgent in-hospital PCI, and in Type 2 diabetic patients undergoing elective cardiac bypass 
surgery. RIPC in both these trials did not show significant clinical or biochemical superiority 
compared to standard (control) therapy. The possible reasons of this lack of significant 
difference in primary end points have been discussed earlier. Our studies reinforce the need 
for alternative or more intensive cardioprotective strategies in these high risk groups 
undergoing myocardial revascularisation.  
Our studies raise the research question of ‘what is the threshold remote preconditioning 
needed for clinical cardioprotection?’ Consequently further clinical studies evaluating and 
characterising remote preconditioning were proposed by our Institute and with ethical 
approval, these studies are already in progress. In Type 2 diabetic patients, the role of 
increased and prolonged remote preconditioning stimulus has now been investigated in our 
Institute, involving patients undergoing cardiac surgery as a direct result of the current 
findings. In addition, with the improved peri-operative and per-operative surgical 
techniques, reducing cross clamp times, ever improving anaesthetic agents with inherent 
cardioprotective properties, and with concomitant routine use of cardioprotective drugs in 
routine cardiac surgery (e.g. Nitrates, Statins), the role of further cardioprotection through 
interventions like RIPC might need careful selection of patients. This is likely to be beneficial 
in patients who would be predicted to have prolonged cross clamp times during surgery, as 
the ischaemic burden is higher. This is usually the case in patients undergoing surgical 
coronary revascularisation along with valve surgeries/repairs. In these surgical procedures, 
relatively more myocardium would be theoretically salvageable through measures like RIPC 
over and above the standard treatment, as the ischaemic burden is much higher due to 
prolonged cross clamp times. A separate study, involving complex cardiac surgeries with 
prolonged cross clamp times, and evaluating the effect of RIPC has also been currently 
evaluated at our research centre. 
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The results of our studies do not question RIPC as a cardioprotective agent, but only 
emphasise that RIPC may not be significantly beneficial in certain clinical groups and clinical 
situations. It should also be appreciated that most of the previous studies involving RIPC, 
excluded the diabetic population from their studies, particularly as animal models did not 
show protective effect in IR situations. Our RIPC study in diabetic CABG patients translates 
with the similar results in the human clinical situation. Similarly in the PCI settings, patients 
with recent ACS are known to have increased peri-procedural myocardial injury due to 
unstable soft friable plaques. RIPC in this setting, unfortunately, did not show a clear trend in 
reduction of peri-procedural myocardial enzyme release. The possible reasons were 
discussed in the previous chapter. Ironically, the two groups studied in our studies are the 
patients at much higher risk, and who were in most need for further cardioprotection. The 
findings only suggest that a much stronger cardioprotection strategy either on its own or via 
a combination of available cardioprotection strategies (pharmacological and mechanical), 
must be evaluated in these resistant groups of patients who are in most need of such 
cardioprotection. In addition, the role of combination of remote preconditioning and post 
conditioning in these settings is a potential strategy to explore. More importantly, large 
multicentre randomised controlled trials with hard clinical end points would answer and 
clarify many unanswered questions of effective cardioprotection of remote preconditioning 
in clinical practice of cardiac surgery.  
A summary of all the studies which have used remote ischaemic preconditioning in various 
cardiac surgery settings and in other cardiac interventions are summarised below. 
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Table.5.1 
Cardiac Surgery 
Study No of 
Patients 
RIC Stimulus Patient Group Outcomes 
Cheung(78) 37  Lower limb (4 X 5 
min) 
Elective pediatric 
cardiac surgery 
↓cTnI (P ¼ .04) 
↓ Inotrope score (7.0 vs 10.9 
mcg/kg/min) 
↓ Airway resistance (34 vs 49 
cmH2O/mL/s) 
Hausenloy(79) 57 Upper limb 
ischaemia (3 X 5 
min) 
Elective CABG + valve 
surgery(cold blood 
cardioplegia or cross-
clamp fibrillation) 
↓AUC of cTnT (43%) 
Venugopal(270) 45 Upper limb 
ischaemia (3 X 5 
min) 
Elective CABG + valve 
surgery(cold blood 
cardioplegia only)  
↓AUC of cTnT (42.4%) 
Ali (343) 100 Upper limb 
ischaemia (3 X 5 
min) 
Elective CABG CK-MB (mean reduction 3 IU/L) 
Thielmann (271) 53 Upper limb 
ischaemia (3 X 5 
min) 
Elective CABG (Cold 
crystalloid 
cardioplegia) 
↓AUC of cTnI (44.5%) 
Hong (344) 130 Upper limb 
ischaemia (4 X 5 
min) 
Elective CABG (off-
pump) 
Nonsignificant 26% reduction in 
cTnI release 
Rahman (272) 162 Upper limb 
ischaemia (3 X 5 
min) 
Elective and urgent 
CABG 
No difference in cTnT, ECG changes, 
inotrope score, renal and lung injury 
Li (345) 81 Lower limb 
ischaemia (3 X 4 
min ) 
Elective valve 
replacement 
↓cTnI peak level (40%) but no 
difference in total AUC in the 
perconditioning group compared to 
control 
Zhou (346) 60 Lower limb 
ischaemia (3 X 5 
min) 
Elective pediatric 
cardiac surgery 
↓Inotrope score (12.0 vs 15.87 
mcg/kg/min at 4 hours; 8.63 vs 
10.67 at 12 hours) 
↓LDH/CK-MB/cTnI 
↓Lung injury 
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Lucchinetti (339) 55 Lower limb 
ischaemia (4 x 5 
min) 
Elective CABG 
surgery with 
Isoflurane as 
maintenance 
anaesthesia 
No difference in hs-troponin T 
release compared to placebo. 
Xie JJ (340) 83 Upper limb 
ischaemia ( 3 X 5 
min) 
Elective heart valve 
surgery 
↓AUC of cTnT (43.2%) 
 
Non Cardiac surgery 
Ali (80) 82 Lower limb ischemia 
(2 X10 min) 
Elective AAA Repair ↓ AUC of cTnI (27%) 
↓ Perioperative MI (22%) 
Preserved renal function 
Walsh(347) 40 Sequential lower 
limb ischemia (1 X 10 
min on each limb) 
Elective EVAR 
 
No difference in rates of renal 
outcome indices and cardiac events 
Walsh (348) 40 Sequential lower 
limb ischemia (1 X 10 
min on each limb) 
Elective open 
infrarenal AAA repair 
No difference in rates of renal 
outcome indices 
Walsh (349) 70 Sequential lower 
limb ischemia (1 X 10 
min on each limb) 
Elective carotid 
endarterectomy 
No difference in cardiac and 
neurological outcomes 
 
Elective PCI 
Iliodromitis (269) 41 Bilateral upper limb 
ischemia (3 X 5 min) 
Elective PCI ↓ CRP levels at 49 h (1.7 mg/L 
difference) 
↓ CK-MB (62% AUC) 
↓ cTnI (16% AUC) 
Hoole (268) 202 Upper limb ischemia 
(3 X 5 min) 
Elective PCI ↓ Median cTnI concentration at 24 h 
(0.06 vs 0.16 ng/mL) 
↓ MACCE (HR 28%) 
↓ CP/ST changes 
Hoole (350) 54 Upper limb ischemia 
(3 X 5 min) or TV 
Elective PCI No difference in microvascular 
resistance or coronary flow velocity 
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balloon occlusion 
Hoole (351) 42 Upper limb ischemia 
(3 X 5 min) 
Elective PCI No improvement of ischemic LV 
dysfunction and stunning 
Prasad (352) 95 Upper limb ischemia 
(3 X 5 min) 
Elective and Unstable 
angina PCI 
No difference in the incidence of 
periprocedural myocardial necrosis 
 
Primary PCI 
Rentoukas (353) 96 Upper limb ischemia 
(4 X 4 min, 20 mmHg 
above SBP) 
Primary PCI (STEMI) Improved ST segment resolution 
(82% RIC +Morphine, 73% RIC, 
53% control) 
↓ Peak cTnI (RIC + Morphine: 103.3 
ng/mL, morphine alone RIC: 166 
ng/mL, control: 255.5) 
Botker(338)  Upper limb ischemia 
(4 X 5 min) 
Primary PCI (STEMI) ↓ Myocardial salvage at 1 month 
(median difference of median 
salvage index 0.12 and mean 
difference of mean salvage index 
0.12) 
No difference in cTnT release 
No difference in MACCE 
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